

CGT Exome v5.4.5

| Patient Information | | Sample Information | | Clinic Information | |
|------------------------|-------------------|--------------------------|------------|--------------------|---------------------|
| Unique pat id.: | 0248477 | Sample type: | Blood | Clinic: | WeFIV |
| Patient name: | | Date of draw: | 02/07/2024 | Doctor: | FERNANDO NEUSPILLER |
| Patient DOB: | | Date of receipt: | 03/07/2024 | | |
| Ethnic group: | Caucasian | Report date/time: | 01/08/2024 | | 11:03 |
| Indication: | No family history | | | | |

TEST RESULTS

POSITIVE

The individual is carrier of:

Polydactyly, postaxial, type A7

| | | | |
|--------------------------------|-------------------------------------------|------------------------|--------|
| Gene : | IQCE | Allele: | Het |
| DNA Change: | NM_001287499.1:c.895_904delCG GAGTGTCC | Inheritance: | AR |
| Protein change: | p.Val301fs | OMIM phenotype: | 617642 |
| Variant classification: | Pathogenic | | |

Retinitis pigmentosa, type 7, digenic

| | | | |
|--------------------------------|-----------------------|------------------------|--------|
| Gene : | ROM1 | Allele: | Het |
| DNA Change: | NM_000327.3:c.712delC | Inheritance: | AR |
| Protein change: | p.Leu238fs | OMIM phenotype: | 608133 |
| Variant classification: | Pathogenic | | |

Short-chain acyl-CoA dehydrogenase deficiency

| | | | |
|--------------------------------|----------------------|------------------------|--------|
| Gene : | ACADS | Allele: | Het |
| DNA Change: | NM_000017.3:c.319C>T | Inheritance: | AR |
| Protein change: | p.Arg107Cys | OMIM phenotype: | 201470 |
| Variant classification: | Pathogenic | | |

INTERPRETATION OF TEST RESULTS

En general, este resultado positivo no supone implicaciones clínicas para la persona portadora, ya que existe otra copia normal de los genes recesivos indicados en la tabla que aporta información suficiente para una correcta función biológica. De cara a la descendencia, la probabilidad de transmisión de esta/s variante/s es del 50% de forma independiente para cada una de ellas. Para reducir el riesgo de tener descendencia afectada, la pareja o donante de gametos debe ser negativa para los genes incluidos en la tabla. Esta información podría ser clínicamente relevante para sus familiares directos y para su descendencia.

Si un paciente y su pareja reproductiva son portadores de una mutación en el mismo gen asociado a herencia recesiva, existe un 25% de riesgo de descendencia afectada. Si una paciente es portadora de una variante en un gen con herencia ligada al X, existe un riesgo del 50% de que la descendencia sea portadora de la misma. Los descendientes varones portadores de la variante podrían presentar síntomas de la enfermedad mientras que la descendencia femenina portadora, a priori, no presentará sintomatología o en caso de hacerlo se esperaría leve.

El riesgo de tener hijos afectados por enfermedades causadas por aquellos genes analizados en el test y en los que no se ha identificado mutación disminuye de forma significativa respecto al de la población general, incluso aunque la pareja, o donante de gametos, sea portador/a de mutaciones en dichos genes. No obstante, debido a las limitaciones asociadas a cualquier prueba genética el riesgo no es cero (ver apartado de limitaciones del presente informe y del consentimiento informado).

TEST DESCRIPTION

The Carrier Genetic Test (CGT) is a preconception DNA screening test that aims to identify individuals and couples at increased risk of conceiving children affected by a monogenic disease. Knowledge of this risk may influence a couple's decision to conceive or encourage the couple to adopt preventive measures, including preimplantation genetic testing for the at risk disease (PGT-M) prenatal genetic testing, or to use donated gametes. The multigene CGT interrogates thousands of DNA variants using a high-throughput technology (Next Generation Sequencing, NGS).

COMMENTS

None

TEST METHODOLOGY

DNA is isolated from the sample, usually blood or saliva, and analyzed by whole exome sequencing by NGS., including capture and sequence of all human exons and other gene regions of interest where known disease-causing variants are located. Sequencing raw data is then analyzed using bioinformatics (bioinformatic pipeline v3.0). Briefly, sequence alignment against the GRCh37 human genome reference, variant calling, annotation, and real-time interpretation of variants. QC parameters include, among other, that all reported samples will have a minimum of 7Gb of data, with minimal mean coverage greater than 75x, and a specific depth analysis for more than 68,000 DNA positions where known pathogenic variants are located. In addition, complementary tests (non-NGS techniques) were performed for the following genes, if included, SMN1 gene exon 7-deletion; CYP21A2 gene frequent mutations; HBA1 and HBA2 genes frequent deletions; FXN gene GAA repeat sizing; FMR1 gene CGG repeat sizing (females only); DMD gene frequent deletions/duplications; F8 gene intron 22 inversion (females only). Based on our validations studies, reported samples will have analytical detection rate for SNV variants as per the control sample NA12878 (Control positive); PASS value: NA12878 Sensitivity SNV $\geq 0,97000$.

TEST LIMITATIONS

In the general population, there is a 3-5% risk for birth defects caused by genetic and/or non-genetic factors not detected by this type of test.

Analytically, the CGT test does not cover all known monogenic diseases nor all disease-causing variants for each tested gene. The test does not include the analysis of conditions associated with mitochondrial DNA nor multifactorial nor digenic inheritance. The test does not detect large rearrangements (inversions, deletions and duplications more than 15 nucleotides), variants located in regulatory regions or intronic regions outside the +/-3bp cut off (except if otherwise indicated), or in low sequence coverage areas (<7x). DNA changes caused by trinucleotide repeat expansions are not detected, except those indicated in the methodology section. For copy number variation analysis, when a normal result is obtained (2 copies detected), it is not possible to confirm that one copy is present in each of the two alleles (non-carrier) or if both copies are present in cis on the same allele, with no copies in the other allele (silent carrier). Clinical sensitivity varies among conditions. In particular, the sensitivity for SMN1 is approximately 96% because it is not possible to identify silent carriers among patients with 2 SMN1 copies detected and because point mutations or small indels are not analyzed. For the HEXB gene, the common 16 kb deletion that causes disease in 30% of affected patients is not included in CGT analysis.

Then, a negative CGT result significantly reduces but does not completely exclude the possibility of being a carrier of a variant associated with single gene disorders (see residual risk table). The presence of pseudogenes and/or rare polymorphisms and/or homopolymers may lead to false negative or false positive results. In addition, a negative result for the CGT variants does not exclude the possibility of a de novo variant occurring in the offspring. Germline mosaicism or low-level somatic mosaicism cannot be detected. As with any laboratory test, there is a small chance that this result may be inaccurate for a procedural reason such as an error during sample collection, labelling, processing, data collection or interpretation. Please note that the clinical classification of variants can change over time. To check whether there have been any changes to the classification of reported variants, please contact IGENOMIX.

LEGAL/QUALITY

This test was developed, and its performance characteristics determined by Igenomix Group. It has not been cleared or approved by the US Food and Drug Administration. The test is used as a laboratory developed test for clinical purposes. *IGENOMIX SPAIN holds CLIA Certificate of Compliance: #99D2146167. Part of this test has been outsourced to a referral laboratory whose QMS is based on high Quality Standards, periodically monitored by Igenomix SPAIN and audited by independent external parties.

EXEMPTION CLAUSE OF DIAGNOSTIC LIABILITY

The genetic diagnosis services carried out by IGENOMIX ARGENTINA S.A are exclusively intended to be interpreted by qualified/certified health professionals.

The result obtained by this test and the information that could be derived from it, cannot be considered in any case as substitute of genetic counselling or medical treatment by a trained professional neither represent itself a medical enquiry. We recommend that you consult your physician for genetic testing & counselling upon reception of your results.

Any result should be interpreted in the context of all available clinical findings, within the general context of a medical investigation, which must be conducted by clinically trained professionals. IGENOMIX ARGENTINA S.A is not responsible for any decisions made or actions undertaken by the contracting party based on the results provided by IGENOMIX ARGENTINA S.A or otherwise., nor the harmful temporary consequences diverted by its use, making specific discretion of taking appropriate legal measures assuming an improper use of those mentioned studies and analysis.

SIGNED



Camila Ayala Lira da Cruz
CRBIO 113163
Bióloga

COUNTERSIGNED



Arantxa Hervas PhD
3025-CV
Biotechnologist

This test or part of this test has been outsourced to a referral Laboratory. Lab CLIA No.: 99D2146167

Polydactyly, postaxial, type A7

What is Polydactyly, postaxial, type A7?

Postaxial polydactyly type A7 (PAPA7) is an autosomal recessive disorder caused by homozygous or compound heterozygous mutation in the IQCE gene (617631) on chromosome 7p22. PAPA7 is characterized by postaxial polydactyly and brachydactyly of the hands and/or feet. Other reported features present in some patients include syndactyly of the second and third digits of the feet, learning disabilities, and increased body weight (Umair et al., 2017; Estrada-Cuzcano et al., 2020).

What is the next step if I am a carrier of Polydactyly, postaxial, type A7?

If you are a carrier of Polydactyly, postaxial, type A7 it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

What if my partner isn't a carrier?


If your partner tests negative for Polydactyly, postaxial, type A7, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

What if both parents are carriers of Polydactyly, postaxial, type A7?

When both parents are carriers of Polydactyly, postaxial, type A7, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



If both are carriers of the disease contact your doctor or genetic counselor for information on genetic options for family planning.



Retinitis pigmentosa, type 7, digenic

What is Retinitis pigmentosa, type 7, digenic?

Retinitis pigmentosa, type 7 (RP7) is a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

What is the next step if I am a carrier of Retinitis pigmentosa, type 7, digenic?

If you are a carrier of Retinitis pigmentosa, type 7, digenic it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

What if my partner isn't a carrier?


If your partner tests negative for Retinitis pigmentosa, type 7, digenic, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

What if both parents are carriers of Retinitis pigmentosa, type 7, digenic?

When both parents are carriers of Retinitis pigmentosa, type 7, digenic, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



If both are carriers of the disease contact your doctor or genetic counselor for information on genetic options for family planning.



Short-chain acyl-CoA dehydrogenase deficiency

What is Short-chain acyl-CoA dehydrogenase deficiency?

Short-chain acyl-CoA dehydrogenase deficiency follows an autosomal recessive pattern of inheritance and is caused by pathogenic variants in the ACADS gene located on chromosomal region 12q24.31. The age of onset is infantile. This disease is characterized by seizures, developmental delay, failure to grow with poor feeding, and usually muscle weakness and hypotonia. The prevalence is <1:50,000.

What is the next step if I am a carrier of Short-chain acyl-CoA dehydrogenase deficiency?

If you are a carrier of Short-chain acyl-CoA dehydrogenase deficiency it is important that your partner (or gamete donor) is tested to determine if she/he is also a carrier of this condition.

What if my partner isn't a carrier?


If your partner tests negative for Short-chain acyl-CoA dehydrogenase deficiency, the possibility of having an affected child is very low, significantly lower than the incidence of disease in the general population. However, there is not a test capable of detecting all existing pathogenic variants. Therefore, a residual risk remains of having unknown or undetectable pathogenic variants using current technology.

What if both parents are carriers of Short-chain acyl-CoA dehydrogenase deficiency?


When both parents are carriers of Short-chain acyl-CoA dehydrogenase deficiency, the probability of having a child with the disease is 25% in each pregnancy. (See graph)

What if I am going to use gamete donation?

In this case it is advisable to use the same assay (CGT) to test candidate donors and choose one that is negative for the same condition.



If both are carriers of the disease contact your doctor or genetic counselor for information on genetic options for family planning.



GLOSSARY

TYPES OF INHERITANCE:

- **AR: Autosomal recessive**
Inherited conditions that require two pathogenic variants (one from each parent) in a given gene to display symptoms.
- **XR: X-linked recessive**
The gene is located on the X chromosome. Men with a pathogenic variant have the disease. Women with a pathogenic variant are carriers and generally asymptomatic or may mild symptoms.
- **Digenic inheritance**
In some diseases, the symptoms could be explained by the coexistence of pathogenic variants in two different genes related with the disease instead of two pathogenic variants in the same gene.

ALLELES:

Pathogenic variants present in the two copies of a gene.

- **Homozygous pathogenic variant (Hom.):**
Each copy of the gene has the same pathogenic variant. Generally, this is associated with clinical symptoms.
- **Compound heterozygous (Het.):**
Each copy of the gene has a different pathogenic variant. Generally, this is associated with clinical symptoms. This situation is referred as having variants "in trans".

Pathogenic variant present in one copy of a gene.

- **Heterozygous pathogenic variant (Het.):**
Only one copy of a gene has a pathogenic variant. There is another normal gene copy.

Note: Sometimes an individual has two pathogenic variants in the same gene copy. This situation is referred as having variants in cis and it is considered as a single pathogenic variant.

CNV:

Refers to copy number variation (deletion or duplication), i.e., the number of copies of a particular gene (or gene region) is different from the usual two copies.

LARGE GENE CONVERSION:

Refers to pathogenic variants caused by gene sequence exchange or replacement between a normal functional gene and a quasi-identical non-functional gene (pseudogene).

X-linked conditions

| Chrom | Gene | Disease/Condition | Carrier Rate | Residual Risk |
|-------|----------|-------------------------------------------------------------------------------------------------------|----------------|-----------------|
| X | ABCD1 | Adrenoleukodystrophy | 1 in 3750 | 1 in 37500 |
| X | AP1S2 | Mental retardation, X-linked, syndromic, type 5 (Pettigrew syndrome) | < 1 in 100 000 | Reduced |
| X | AR | Androgen insensitivity syndrome | 1 in 6250 | 1 in 10417 |
| X | ARSL | Chondrodysplasia punctata, brachytelephalangic | < 1 in 100 000 | Reduced |
| X | ARX | Epileptic encephalopathy, early infantile, type 1; ARX-related developmental disorders | 1 in 25 000 | 1 in 100000 |
| X | ATP7A | Menkes disease; Occipital horn syndrome | 1 in 25000 | 1 in 100000 |
| X | ATRX | Mental retardation-hypotonic facies syndrome, X-linked; Alpha-thalassemia/mental retardation syndrome | < 1 in 100 000 | Reduced |
| X | BRWD3 | Mental retardation, X-linked, type 93 | 1 in 10000 | 1 in 50000 |
| X | BTK | Agammaglobulinemia X-linked, type 1 | 1 in 50,000 | 1 in 333333 |
| X | CD40LG | Hyper-IgM syndrome, type 1 (immunodeficiency, X-linked, with hyper-IgM, type 1) | < 1 in 100 000 | Reduced |
| X | CHM | Choroideremia | 1 in 18750 | 1 in 66964 |
| X | COL4A5 | Alport syndrome, X-linked | 1 in 10000 | 1 in 50000 |
| X | CUL4B | Mental retardation, X-linked, syndromic, type 15 (Cabezas type) | < 1 in 100 000 | Reduced |
| X | CYBB | Chronic granulomatous disease, X-linked | 1 in 300 | 1 in 1500 |
| X | DCX | Lissencephaly, X-linked, type 1 | 1 in 2500 | 1 in 50000 |
| X | DKC1 | Dyskeratosis congenita, X-linked | 1 in 62500 | 1 in 1250000 |
| X | DLG3 | Mental retardation, X-linked, type 90 | 1 in 45000 | 1 in 300000 |
| X | DMD | DMD-related conditions | 1 in 1374 | 1 in 27480 |
| X | EDA | Ectodermal dysplasia, type 1, hypohidrotic, X-linked | 1 in 2500 | 1 in 16667 |
| X | EMD | Emery-Dreifuss muscular dystrophy, type 1, X-linked | < 1 in 100 000 | Reduced |
| X | F8 | Hemophilia A | 1 in 1250 | 1 in 31250 |
| X | F9 | Hemophilia B | 1 in 6250 | 1 in 62500 |
| X | FGD1 | Aarskog-Scott syndrome; Mental retardation, X-linked syndromic, type 16 | 1 in 10000 | 1 in 125000 |
| X | FMR1 | FMR1-related conditions | 1 in 400 | 1 in 40000 |
| X | FTSJ1 | Mental retardation, X-linked 44 | 1 in 45000 | 1 in 300000 |
| X | G6PD | G6PD deficiency | 1 in 25 | 1 in 250 |
| X | GJB1 | Charcot-Marie-Tooth neuropathy, X-linked dominant, type 1 | 1 in 9803 | 1 in 196060 |
| X | GLA | Fabry disease | 1 in 18750 | 1 in 187500 |
| X | GPR143 | Ocular albinism, type 1 (Nettleship-Falls type) | 1 in 15000 | 1 in 18750 |
| X | HCFC1 | Mental retardation, X-linked 3 (methylmalonic acidemia and homocysteinemia, cbIX type) | < 1 in 100 000 | Reduced |
| X | HPRT1 | Lesch-Nyhan syndrome | 1 in 95000 | 1 in 380000 |
| X | HSD17B10 | HSD10 mitochondrial disease | < 1 in 100 000 | Reduced |
| X | IDS | Mucopolysaccharidosis, type 2 | 1 in 25000 | 1 in 125000 |
| X | IL1RAPL1 | Mental retardation, X-linked, type 21/34 | 1 in 25000 | 1 in 357143 |
| X | IL2RG | Severe combined immunodeficiency, X-linked | 1 in 25000 | 1 in 500000 |
| X | KDMS5C | Mental retardation, X-linked, syndromic, Claes-Jensen type | 1 in 4000 | 1 in 57143 |
| X | L1CAM | L1 Syndrome | 1 in 7500 | 1 in 150000 |
| X | MECP2 | Encephalopathy, neonatal severe; Rett syndrome | 1 in 37500 | 1 in 250000 |
| X | MID1 | Opitz GBBB syndrome, type 1 | 1 in 18750 | 1 in 125000 |
| X | MTM1 | Myotubular myopathy, X-linked | 1 in 12500 | 1 in 83333 |
| X | NDP | Norrie disease | 1 in 50,000 | <1 in 1,000,000 |
| X | NROB1 | Adrenal hypoplasia, congenital | 1 in 17500 | 1 in 58333 |
| X | OCRL | Lowe Syndrome; Dent disease type 2 | < 1 in 100 000 | Reduced |
| X | OPHN1 | Mental retardation, X-linked, with cerebellar hypoplasia and distinctive facial appearance | < 1 in 500 | Reduced |
| X | OTC | Ornithine transcarbamylase deficiency | 1 in 50000 | 1 in 166667 |
| X | PAK3 | Mental retardation, X-linked, type 30 | 1 in 40000 | 1 in 800000 |
| X | PDHA1 | Pyruvate dehydrogenase E1-alpha deficiency | < 1 in 100 000 | Reduced |
| X | PGK1 | Phosphoglycerate kinase 1 deficiency | < 1 in 100 000 | Reduced |
| X | PHF8 | Mental retardation syndrome, X-linked, Siderius type | < 1 in 100 000 | Reduced |
| X | PLP1 | Pelizaeus-Merzbacher disease | 1 in 353 | 1 in 441 |
| X | POU3F4 | Deafness, X-linked, type 2 | 1 in 556,112 | <1 in 1,000,000 |
| X | PQBP1 | Renpenning syndrome | < 1 in 100 000 | Reduced |
| X | PRPS1 | PRPS1-related disorders | < 1 in 100 000 | Reduced |
| X | RP2 | Retinitis pigmentosa, type 2, X-linked | 1 in 5000 | 1 in 62500 |
| X | RPGR | Retinitis pigmentosa, type 3, X-linked; Cone-rod dystrophy, X-linked, 1 | 1 in 20000 | 1 in 28571 |
| X | RS1 | Retinoschisis | 1 in 15000 | 1 in 100000 |
| X | SH2D1A | Lymphoproliferative syndrome, X-linked, type 1 | < 1 in 100 000 | Reduced |
| X | SLC16A2 | Allan-Herndon-Dudley syndrome | < 1 in 100 000 | Reduced |
| X | SLC6A8 | Cerebral creatine deficiency syndrome, type 1 | < 1 in 100 000 | Reduced |
| X | SYN1 | Epilepsy, X-linked, with variable learning disabilities and behavior disorders | 1 in 30000 | 1 in 150000 |
| X | THOC2 | Mental retardation, X-linked 12 | < 1 in 100 000 | Reduced |
| X | UPF3B | Mental retardation, X-linked, syndromic, type 14 | 1 in 15000 | 1 in 75000 |
| X | WAS | Wiskott-Aldrich syndrome; Thrombocytopenia, X-linked | < 1 in 100 000 | Reduced |
| X | ZDHHC9 | Mental retardation, X-linked syndromic, Raymond type | 1 in 45000 | 1 in 450000 |
| X | ZNF711 | Mental retardation, X-linked, type 97 | 1 in 45000 | 1 in 225000 |

Autosomal recessive conditions

| Chrom | Gene | Disease/Condition | Carrier Rate | Residual Risk |
|-------|----------|-----------------------------------------------------------------------------------------------------------------|--------------|---------------|
| 12 | AAAS | Triple-A syndrome (achalasia-addisonianism-alacrimia) | 1 in 436 | 1 in 8,266 |
| 16 | AARS1 | Epileptic encephalopathy, early infantile, type 29 | N/A | N/A |
| 6 | AARS2 | Combined oxidative phosphorylation deficiency 8; Leukoencephalopathy, progressive, with ovarian failure | N/A | N/A |
| 7 | AASS | Hyperlysinemia, type 1 and type 2 | N/A | N/A |
| 16 | ABAT | GABA-transaminase deficiency | < 1 in 500 | Reduced |
| 9 | ABCA1 | Tangier disease | N/A | N/A |
| 2 | ABCA12 | Ichthyosis, congenital, autosomal recessive, type 4A; ICAR, type 4B (harlequin) | 1 in 194 | 1 in 715 |
| 16 | ABCA3 | Surfactant metabolism dysfunction, pulmonary, type 3 | 1 in 500 | 1 in 7,143 |
| 1 | ABCA4 | Stargardt disease 1; Retinitis pigmentosa 19; Cone-rod dystrophy 3 | 1 in 62 | 1 in 119 |
| 2 | ABCB11 | Cholestasis, benign recurrent intrahepatic, type 2; Cholestasis, progressive familial intrahepatic, type 2 | 1 in 276 | 1 in 3450 |
| 7 | ABCB4 | Cholestasis, progressive familial intrahepatic, type 3 | N/A | N/A |
| 10 | ABCC2 | Dubin-Johnson syndrome | N/A | N/A |
| 16 | ABCC6 | Pseudoxanthoma elasticum; Generalized arterial calcification of infancy, type 2 | < 1 in 500 | Reduced |
| 11 | ABCC8 | Hyperinsulinemic hypoglycemia, type 1 (congenital hyperinsulinism); Permanent neonatal diabetes mellitus (PNDM) | 1 in 192 | 1 in 1920 |
| 14 | ABCD4 | Methylmalonic aciduria and homocystinuria, cblJ type | 1 in 496 | 1 in 49,501 |
| 2 | ABCG5 | Sitosterolemia 2 | N/A | N/A |
| 2 | ABCG8 | Sitosterolemia 1 | N/A | N/A |
| 20 | ABHD12 | PHARC syndrome (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract) | N/A | N/A |
| 3 | ABHD5 | Chanarin-Dorfman syndrome | < 1 in 500 | Reduced |
| 11 | ACAD8 | Isobutyryl-CoA dehydrogenase deficiency | < 1 in 500 | Reduced |
| 3 | ACAD9 | Acyl-CoA dehydrogenase 9 deficiency (mitochondrial complex I deficiency, nuclear, type 20) | 1 in 309 | 1 in 3090 |
| 1 | ACADM | Medium-chain acyl-CoA dehydrogenase deficiency | 1 in 60 | 1 in 600 |
| 12 | ACADS | Short-chain acyl-CoA dehydrogenase deficiency | 1 in 94 | 1 in 1880 |
| 10 | ACADSB | Short/branched-chain acyl-CoA dehydrogenase deficiency | 1 in 500 | 1 in 1,125 |
| 17 | ACADVL | Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency | 1 in 112 | 1 in 1120 |
| 11 | ACAT1 | Alpha-methylacetoacetic aciduria (3-ketothiolase deficiency) | 1 in 300 | 1 in 3750 |
| 17 | ACE | Renal tubular dysgenesis | < 1 in 500 | Reduced |
| 22 | ACO2 | Infantile cerebellar-retinal degeneration | N/A | N/A |
| 17 | ACOX1 | Peroxisomal acyl-CoA oxidase deficiency | < 1 in 500 | Reduced |
| 3 | ACOX2 | Bile acid synthesis defect, congenital, type 6 | N/A | N/A |
| 19 | ACP5 | Spondyloenchondrodysplasia with immune dysregulation | < 1 in 500 | Reduced |
| 16 | ACSF3 | Combined malonic and methylmalonic aciduria | 1 in 90 | 1 in 900 |
| 1 | ACTA1 | Nemaline myopathy 3; Congenital fiber-type disproportion myopathy 1 | < 1 in 500 | Reduced |
| 3 | ACY1 | Aminoacylase 1 deficiency | N/A | N/A |
| 20 | ADA | Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA) | 1 in 390 | 1 in 2600 |
| 22 | ADA2 | Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome; Sneddon syndrome | N/A | N/A |
| 8 | ADAM9 | Cone-rod dystrophy 9 | < 1 in 500 | Reduced |
| 19 | ADAMTS10 | Weill-Marchesani syndrome, type 1, recessive | N/A | N/A |
| 9 | ADAMTS13 | Thrombotic thrombocytopenic purpura, familial (Schulman-Upshaw syndrome) | N/A | N/A |
| 15 | ADAMTS17 | Weill-Marchesani syndrome, type 4, recessive | < 1 in 500 | Reduced |
| 16 | ADAMTS18 | Microcornea, myopic chorioretinal atrophy, and telecanthus | N/A | N/A |
| 5 | ADAMTS2 | Ehlers-Danlos syndrome, dermatosparaxis type | < 1 in 500 | Reduced |
| 9 | ADAMTSL2 | Geleophysic dysplasia type 1 | < 1 in 500 | Reduced |
| 1 | ADAMTSL4 | Ectopia lentis et pupillae; Ectopia lentis, isolated, type 2 | N/A | N/A |
| 1 | ADAR | Aicardi-Goutieres syndrome, type 6 | N/A | N/A |
| 19 | ADAT3 | Mental retardation, autosomal recessive 36 | < 1 in 500 | Reduced |
| 16 | ADGRG1 | Polymicrogyria, bilateral frontoparietal | < 1 in 500 | Reduced |
| 6 | ADGRG6 | Lethal congenital contracture syndrome 9 | < 1 in 500 | Reduced |
| 5 | ADGRV1 | Usher syndrome, type 2C | 1 in 80 | 1 in 147 |
| 10 | ADK | Hypermethioninemia due to adenosine kinase deficiency | 1 in 500 | 1 in 1,498 |
| 22 | ADSL | Adenylosuccinase deficiency | N/A | N/A |
| 14 | ADSS1 | Myopathy, distal, 5 | N/A | N/A |
| 18 | AFG3L2 | Spastic ataxia, type 5, autosomal recessive | N/A | N/A |
| 4 | AFP | Alpha-fetoprotein deficiency | < 1 in 500 | Reduced |
| 4 | AGA | Aspartylglucosaminuria (glycosylasparaginase deficiency) | < 1 in 500 | Reduced |
| 2 | AGBL5 | Retinitis pigmentosa 75 | N/A | N/A |
| 7 | AGK | Cataract 38; Sengers syndrome | < 1 in 500 | Reduced |
| 1 | AGL | Glycogen storage disease, type 3 | 1 in 200 | 1 in 2000 |
| 9 | AGPAT2 | Congenital generalized lipodystrophy (Berardinelli-Seip syndrome) | < 1 in 500 | Reduced |
| 9 | AGPS | Rhizomelic chondrodysplasia punctata, type 3 | < 1 in 500 | Reduced |
| 1 | AGRN | Myasthenic syndrome, congenital, type 8 | N/A | N/A |
| 1 | AGT | Renal tubular dysgenesis | < 1 in 500 | Reduced |
| 3 | AGTR1 | Renal tubular dysgenesis | < 1 in 500 | Reduced |
| 2 | AGXT | Hyperoxaluria, primary, type 1 | 1 in 174 | 1 in 2486 |
| 20 | AHCY | Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase | < 1 in 500 | Reduced |
| 6 | AHI1 | Joubert syndrome, type 3 | 1 in 334 | 1 in 706 |

| | | | | |
|----|----------|------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| 12 | AICDA | Immunodeficiency with hyper-IgM, type 2 | < 1 in 500 | Reduced |
| 4 | AIMP1 | Leukodystrophy, hypomyelinating, type 3 | < 1 in 500 | Reduced |
| 7 | AIMP2 | Leukodystrophy, hypomyelinating, type 17 | < 1 in 500 | Reduced |
| 17 | AIPL1 | Leber congenital amaurosis, type 4 | 1 in 400 | 1 in 571 |
| 21 | AIRE | Autoimmune polyendocrinopathy syndrome, type 1 | 1 in 310 | 1 in 4429 |
| 9 | AK1 | Hemolytic anemia due to adenylate kinase deficiency | N/A | N/A |
| 1 | AK2 | Reticular dysgenesis | < 1 in 500 | Reduced |
| 10 | AKR1C2 | 46,XY disorder of sex development due to testicular 17,20-desmolase deficiency | N/A | N/A |
| 7 | AKR1D1 | Bile acid synthesis defect, congenital, type 2 | < 1 in 500 | Reduced |
| 9 | ALAD | Porphyria, acute hepatic | < 1 in 500 | Reduced |
| 4 | ALB | Analbuminemia | < 1 in 500 | Reduced |
| 10 | ALDH18A1 | Spastic paraplegia, type 9B, autosomal recessive; Cutis laxa, type 3A (De Barsy syndrome) | N/A | N/A |
| 15 | ALDH1A3 | Microphthalmia, isolated 8 | < 1 in 500 | Reduced |
| 17 | ALDH3A2 | Sjogren-Larsson syndrome | < 1 in 500 | Reduced |
| 1 | ALDH4A1 | Hyperprolinemia, type 2 | 1 in 500 | 1 in 49,951 |
| 6 | ALDH5A1 | Succinic semialdehyde dehydrogenase deficiency | N/A | N/A |
| 14 | ALDH6A1 | Methylmalonate semialdehyde dehydrogenase deficiency | N/A | N/A |
| 5 | ALDH7A1 | Epilepsy, pyridoxine-dependent | N/A | N/A |
| 16 | ALDOA | Glycogen storage disease type 12 | < 1 in 500 | Reduced |
| 9 | ALDOB | Fructose intolerance, hereditary | 1 in 80 | 1 in 400 |
| 16 | ALG1 | Congenital disorder of glycosylation, type 1K | 1 in 87 | 1 in 130 |
| 13 | ALG11 | Congenital disorder of glycosylation, type 1P | < 1 in 500 | Reduced |
| 22 | ALG12 | Congenital disorder of glycosylation, type 1G | N/A | N/A |
| 9 | ALG2 | Myasthenic syndrome, congenital, type 14, with tubular aggregates | N/A | N/A |
| 3 | ALG3 | Congenital disorder of glycosylation, type 1D | N/A | N/A |
| 1 | ALG6 | Congenital disorder of glycosylation, type 1C | 1 in 500 | 1 in 5000 |
| 11 | ALG8 | Congenital disorder of glycosylation, type 1H | N/A | N/A |
| 11 | ALG9 | Congenital disorder of glycosylation, type 1L; Gillissen-Kaesbach-Nishimura syndrome | < 1 in 500 | Reduced |
| 2 | ALMS1 | Alström syndrome | 1 in 250 | 1 in 1667 |
| 17 | ALOX12B | Ichthyosis, congenital, autosomal recessive, type 2 | N/A | N/A |
| 17 | ALOXE3 | Ichthyosis, congenital, autosomal recessive, type 3 | N/A | N/A |
| 15 | ALPK3 | Cardiomyopathy, familial hypertrophic, type 27 | N/A | N/A |
| 1 | ALPL | ALPL-related conditions | 1 in 274 | 1 in 2740 |
| 2 | ALS2 | Amyotrophic lateral sclerosis, type 2, juvenile; Primary lateral sclerosis, juvenile; Spastic paralysis, infantile onset ascending | N/A | N/A |
| 12 | ALX1 | Frontonasal dysplasia, type 3 | < 1 in 500 | Reduced |
| 1 | ALX3 | Frontonasal dysplasia, type 1 | < 1 in 500 | Reduced |
| 11 | ALX4 | Frontonasal dysplasia, type 2 | < 1 in 500 | Reduced |
| 5 | AMACR | Bile acid synthesis defect, congenital, type 4; Alpha-methylacyl-CoA racemase deficiency | N/A | N/A |
| 4 | AMBN | Amelogenesis imperfecta, type IF | < 1 in 500 | Reduced |
| 19 | AMH | Persistent Mullerian duct syndrome, type 1 | N/A | N/A |
| 12 | AMHR2 | Persistent Mullerian duct syndrome, type II | N/A | N/A |
| 14 | AMN | Megaloblastic anemia 1 (Imerslund-Grasbeck syndrome) | N/A | N/A |
| 1 | AMPD1 | Myopathy due to myoadenylate deaminase deficiency | N/A | N/A |
| 1 | AMPD2 | Pontocerebellar hypoplasia, type 9 | < 1 in 500 | Reduced |
| 3 | AMT | Glycine encephalopathy | 1 in 310 | 1 in 6200 |
| 1 | ANGPTL3 | Hypobetalipoproteinemia, familial, type 2 | N/A | N/A |
| 9 | ANKS6 | Nephronophthisis 16 | N/A | N/A |
| 3 | ANO10 | Spinocerebellar ataxia, autosomal recessive, type 10 | 1 in 224 | 1 in 2,236 |
| 11 | ANOS | Limb-girdle muscular dystrophy, type 12 (LGMD R12) | < 1 in 500 | Reduced |
| 2 | ANTXR1 | GAPO syndrome | N/A | N/A |
| 4 | ANTXR2 | Hyaline fibromatosis syndrome | N/A | N/A |
| 7 | AP1S1 | MEDNIK syndrome | < 1 in 500 | Reduced |
| 5 | AP3B1 | Hermansky-Pudlak syndrome, type 2 | N/A | N/A |
| 15 | AP3B2 | Epileptic encephalopathy, early infantile, type 48 | < 1 in 500 | Reduced |
| 19 | AP3D1 | Hermansky-Pudlak syndrome, type 10 | N/A | N/A |
| 1 | AP4B1 | Spastic paraplegia, type 47, autosomal recessive | N/A | N/A |
| 15 | AP4E1 | Spastic paraplegia, type 51, autosomal recessive | < 1 in 500 | Reduced |
| 7 | AP4M1 | Spastic paraplegia, type 50, autosomal recessive | N/A | N/A |
| 14 | AP4S1 | Spastic paraplegia, type 52, autosomal recessive | N/A | N/A |
| 7 | APSZ1 | Spastic paraplegia, type 48, autosomal recessive | N/A | N/A |
| 19 | APOC2 | Hyperlipoproteinemia, type 1B | < 1 in 500 | Reduced |
| 19 | APOE | Sea-blue histiocyte disease | N/A | N/A |
| 16 | APRT | Adenine phosphoribosyltransferase deficiency | N/A | N/A |
| 9 | APTX | Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia | < 1 in 500 | Reduced |
| 12 | AQP2 | Diabetes insipidus, nephrogenic, type 2 | < 1 in 500 | Reduced |
| 20 | ARFGEF2 | Periventricular heterotopia with microcephaly | < 1 in 500 | Reduced |
| 6 | ARG1 | Argininemia (arginase deficiency) | 1 in 418 | 1 in 13933 |
| 17 | ARHGDI1A | Nephrotic syndrome, type 8 | N/A | N/A |

| | | | | |
|----|----------|----------------------------------------------------------------------------------------------------------------|------------|--------------|
| 19 | ARHGEF18 | Retinitis pigmentosa 78 | N/A | N/A |
| 3 | ARL13B | Joubert syndrome type 8 | 1 in 72 | 1 in 119 |
| 16 | ARL2BP | Retinitis pigmentosa with or without situs inversus | < 1 in 500 | Reduced |
| 3 | ARL6 | Bardet-Biedl syndrome, type 3 | < 1 in 500 | Reduced |
| 2 | ARMC9 | Joubert syndrome 30 | N/A | N/A |
| 7 | ARPC1B | Immunodeficiency, type 71, with inflammatory disease and congenital thrombocytopenia | < 1 in 500 | Reduced |
| 22 | ARSA | Metachromatic leukodystrophy | 1 in 192 | 1 in 1920 |
| 5 | ARSB | Mucopolysaccharidosis, type 6 (Maroteaux-Lamy syndrome) | 1 in 314 | 1 in 3925 |
| 1 | ARV1 | Epileptic encephalopathy, early infantile, 38 | N/A | N/A |
| 8 | ASAH1 | Farber lipogranulomatosis; Spinal muscular atrophy with progressive myoclonic epilepsy | N/A | N/A |
| 7 | ASL | Argininosuccinic aciduria | 1 in 133 | 1 in 665 |
| 7 | ASNS | Asparagine synthetase deficiency | < 1 in 500 | Reduced |
| 17 | ASPA | Canavan disease | 1 in 416 | 1 in 13867 |
| 8 | ASPH | Traboulsi syndrome | N/A | N/A |
| 1 | ASPM | Primary microcephaly type 5, autosomal recessive | < 1 in 500 | Reduced |
| 9 | ASS1 | Citrullinemia, type 1 | 1 in 300 | 1 in 3750 |
| 10 | ATAD1 | Hyperekplexia 4 | < 1 in 500 | Reduced |
| 1 | ATF6 | Achromatopsia, type 7 | < 1 in 500 | Reduced |
| 2 | ATIC | AICA-ribosiduria due to ATIC deficiency | < 1 in 500 | Reduced |
| 11 | ATM | ATM-related conditions | 1 in 150 | 1 in 1000 |
| 10 | ATOH7 | Persistent hyperplastic primary vitreous, autosomal recessive | < 1 in 500 | Reduced |
| 1 | ATP13A2 | Kufor-Rakeb syndrome; Spastic paraplegia, type 78, autosomal recessive | N/A | N/A |
| 16 | ATP2A1 | Brody myopathy | N/A | N/A |
| 12 | ATP6V0A2 | Cutis laxa, autosomal recessive, type 2A; Wrinkly skin syndrome | < 1 in 500 | Reduced |
| 7 | ATP6V0A4 | Renal tubular acidosis, distal, autosomal recessive | N/A | N/A |
| 3 | ATP6V1A | Cutis laxa, autosomal recessive, type 2D | < 1 in 500 | Reduced |
| 2 | ATP6V1B1 | Renal tubular acidosis with deafness | < 1 in 500 | Reduced |
| 22 | ATP6V1E1 | Cutis laxa, autosomal recessive, type 2C | < 1 in 500 | Reduced |
| 13 | ATP7B | Wilson disease | 1 in 90 | 1 in 450 |
| 18 | ATP8B1 | Cholestasis, progressive familial intrahepatic, type 1; Cholestasis, benign recurrent intrahepatic, type 1 | 1 in 738 | 1 in 1,803 |
| 3 | ATR | Seckel syndrome, type 1 | < 1 in 500 | Reduced |
| 9 | AUH | 3-methylglutaconic aciduria, type 1 | < 1 in 500 | <1 in 938 |
| 19 | AURKC | Spermatogenic failure, type 5 | N/A | N/A |
| 12 | AVIL | Nephrotic syndrome, type 21 | N/A | N/A |
| 15 | B2M | Immunodeficiency, type 43 | < 1 in 500 | Reduced |
| 1 | B3GALNT2 | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11 | N/A | N/A |
| 1 | B3GALT6 | Ehlers-Danlos syndrome, spondylodysplastic type, 2 | N/A | N/A |
| 11 | B3GAT3 | Multiple joint dislocations, short stature, craniofacial dysmorphism, with or without congenital heart defects | N/A | N/A |
| 13 | B3GLCT | Peters-plus syndrome | N/A | N/A |
| 12 | B4GALNT1 | Spastic paraplegia, type 26, autosomal recessive | < 1 in 500 | Reduced |
| 9 | B4GALT1 | Congenital disorder of glycosylation, type 2D | < 1 in 500 | <1 in 50,000 |
| 5 | B4GALT7 | Ehlers-Danlos syndrome, spondylodysplastic, type 1 | N/A | N/A |
| 11 | B4GAT1 | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13 | < 1 in 500 | Reduced |
| 17 | B9D1 | Joubert syndrome, type 27; ?Meckel syndrome 9 | < 1 in 500 | Reduced |
| 19 | B9D2 | Joubert syndrome, type 34; ?Meckel syndrome, type 10 | < 1 in 500 | Reduced |
| 11 | BBS1 | Bardet-Biedl syndrome, type 1 | 1 in 152 | 1 in 1520 |
| 12 | BBS10 | Bardet-Biedl syndrome, type 10 | 1 in 237 | 1 in 4740 |
| 4 | BBS12 | Bardet-Biedl syndrome, type 12 | 1 in 500 | 1 in 10000 |
| 16 | BBS2 | Bardet-Biedl syndrome, type 2 | 1 in 200 | 1 in 4000 |
| 15 | BBS4 | Bardet-Biedl syndrome, type 4 | N/A | N/A |
| 2 | BBS5 | Bardet-Biedl syndrome, type 5 | < 1 in 500 | Reduced |
| 4 | BBS7 | Bardet-Biedl syndrome, type 7 | N/A | N/A |
| 7 | BBS9 | Bardet-Biedl syndrome, type 9 | N/A | N/A |
| 19 | BCAT2 | ?Hypervalinemia or hyperleucine-isoleucinemia | N/A | N/A |
| 3 | BCHE | Butyrylcholinesterase deficiency | 1 in 30 | <1 in 270 |
| 19 | BCKDHA | Maple syrup urine disease, type 1A | 1 in 320 | 1 in 3200 |
| 6 | BCKDHB | Maple syrup urine disease, type 1B | 1 in 365 | 1 in 2808 |
| 16 | BCKDK | Branched-chain ketoacid dehydrogenase kinase deficiency | N/A | N/A |
| 1 | BCL10 | ?Immunodeficiency, type 37 | N/A | N/A |
| 2 | BCS1L | Mitochondrial complex III deficiency nuclear type 1; GRACILE syndrome; Bjornstad syndrome | 1 in 320 | 1 in 2133 |
| 11 | BEST1 | Bestrophinopathy, AR | < 1 in 500 | Reduced |
| 20 | BFSP1 | Cataract 33, multiple types | < 1 in 500 | Reduced |
| 17 | BHLHA9 | Syndactyly, mesoaxial synostotic, with phalangeal reduction | < 1 in 500 | Reduced |
| 2 | BIN1 | Centronuclear myopathy, type 2 | < 1 in 500 | Reduced |
| 15 | BLM | Bloom syndrome | 1 in 320 | 1 in 3200 |
| 10 | BLNK | ?Agammaglobulinemia 4 | N/A | N/A |
| 19 | BLOC1S3 | Hermansky-Pudlak syndrome, type 8 | < 1 in 500 | Reduced |
| 15 | BLOC1S6 | ?Hermansky-Pudlak syndrome, type 9 | N/A | N/A |

| | | | | |
|----|----------|---------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| 4 | BLTP1 | Alkuraya-Kucinkas syndrome | N/A | N/A |
| 7 | BLVRA | Hyperbiliverdinemia | < 1 in 500 | Reduced |
| 8 | BMP1 | Osteogenesis imperfecta, type 13 | N/A | N/A |
| 7 | BMPER | Diaphanospondylodysostosis | < 1 in 500 | Reduced |
| 4 | BMPR1B | Acromesomelic dysplasia, Demirhan type | < 1 in 500 | Reduced |
| 2 | BOLA3 | Multiple mitochondrial dysfunctions syndrome 2 with hyperglycemia | < 1 in 500 | Reduced |
| 7 | BPGM | Erythrocytosis due to bisphosphoglycerate mutase deficiency | < 1 in 500 | Reduced |
| 8 | BPNT2 | Chondrodysplasia with joint dislocations, GPAPP type | < 1 in 500 | Reduced |
| 7 | BRAT1 | Rigidity and multifocal seizure syndrome, lethal neonatal; Neurodevelopmental disorder with cerebellar atrophy and with or without seizures | N/A | N/A |
| 14 | BRF1 | Cerebellofaciodental syndrome | N/A | N/A |
| 17 | BRIP1 | Fanconi anemia, complementation group J | N/A | N/A |
| 11 | BSC2 | Congenital generalized lipodystrophy, type 2; Encephalopathy, progressive, with or without lipodystrophy | < 1 in 500 | Reduced |
| 1 | BSND | Barter syndrome, type 4A | < 1 in 500 | Reduced |
| 3 | BTB | Biotinidase deficiency | 1 in 120 | 1 in 1500 |
| 15 | BUB1B | Mosaic variegated aneuploidy syndrome 1 | < 1 in 500 | Reduced |
| 12 | C12ORF57 | Temtamy syndrome | < 1 in 500 | Reduced |
| 19 | C19ORF12 | Neurodegeneration with brain iron accumulation, type 4 | < 1 in 500 | Reduced |
| 1 | C1QA | C1q deficiency | < 1 in 500 | Reduced |
| 1 | C1QB | C1q deficiency | < 1 in 500 | Reduced |
| 17 | C1QBP | Combined oxidative phosphorylation deficiency 33 | < 1 in 500 | Reduced |
| 1 | C1QC | C1q deficiency | < 1 in 500 | Reduced |
| 12 | C1S | C1s deficiency | N/A | N/A |
| 6 | C2 | C2 deficiency | N/A | N/A |
| 11 | C2CD3 | Orofaciodigital syndrome, type 14 | N/A | N/A |
| 19 | C3 | Complement component 3 deficiency | N/A | N/A |
| 9 | C5 | Complement component 5 deficiency | N/A | N/A |
| 5 | C6 | Complement component 6 deficiency | N/A | N/A |
| 5 | C7 | Complement component 7 deficiency | N/A | N/A |
| 1 | C8B | Complement component 8 deficiency, type 2 | N/A | N/A |
| 15 | CA12 | Hyperchlorhidrosis, isolated | N/A | N/A |
| 8 | CA2 | Osteopetrosis with renal tubular acidosis (osteopetrosis, autosomal recessive, type 3) | < 1 in 500 | <1 in 1,000 |
| 16 | CA5A | Hyperammonemia due to carbonic anhydrase VA deficiency | N/A | N/A |
| 8 | CA8 | Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3 | < 1 in 500 | Reduced |
| 11 | CABP2 | Deafness, autosomal recessive, type 93 | N/A | N/A |
| 11 | CABP4 | Congenital stationary night blindness, type 2B | < 1 in 500 | Reduced |
| 3 | CACNA1D | Sinoatrial node dysfunction and deafness | N/A | N/A |
| 12 | CACNA2D4 | Retinal cone dystrophy 4 | N/A | N/A |
| 2 | CAD | Epileptic encephalopathy, early infantile, 50 | N/A | N/A |
| 2 | CALCRL | ?Lymphatic malformation 8 | N/A | N/A |
| 17 | CANT1 | Desbuquois dysplasia, type 1; Epiphyseal dysplasia, multiple, type 7 | N/A | N/A |
| 11 | CAPN1 | Spastic paraplegia, type 76, autosomal recessive | N/A | N/A |
| 15 | CAPN3 | Limb-girdle muscular dystrophy, type 1 (LGMD R1) | 1 in 103 | 1 in 412 |
| 7 | CARD11 | Immunodeficiency, type 11A | < 1 in 500 | Reduced |
| 9 | CARD9 | Candidiasis, familial, type 2, autosomal recessive | N/A | N/A |
| 13 | CARS2 | Combined oxidative phosphorylation deficiency 27 | N/A | N/A |
| 1 | CASQ2 | Ventricular tachycardia, catecholaminergic polymorphic, type 2 | 1 in 51 | 1 in 98 |
| 3 | CASR | Hyperparathyroidism, neonatal | < 1 in 500 | Reduced |
| 5 | CAST | Peeling skin with leukonychia, acral punctate keratoses, cheilitis, and knuckle pads | N/A | N/A |
| 11 | CAT | Acatlasemia | N/A | N/A |
| 11 | CATSPER1 | Spermatogenic failure, type 7 | N/A | N/A |
| 17 | CAVIN1 | Lipodystrophy, congenital generalized, type 4 | < 1 in 500 | Reduced |
| 11 | CBLIF | Intrinsic factor deficiency | < 1 in 500 | Reduced |
| 21 | CBS | Homocystinuria due to cystathionine beta-synthase | 1 in 274 | 1 in 2740 |
| 19 | CC2D1A | Mental retardation, autosomal recessive, type 3 | < 1 in 500 | Reduced |
| 4 | CC2D2A | Joubert syndrome, type 9; Meckel syndrome, type 6; COACH syndrome, 2 | 1 in 196 | 1 in 2,800 |
| 18 | CCBE1 | Hennekam lymphangiectasia-lymphedema syndrome, type 1 | N/A | N/A |
| 17 | CCDC103 | Ciliary dyskinesia, primary, type 17 | N/A | N/A |
| 2 | CCDC115 | Congenital disorder of glycosylation, type IIo | < 1 in 500 | Reduced |
| 3 | CCDC174 | Hypotonia, infantile, with psychomotor retardation | < 1 in 500 | Reduced |
| 3 | CCDC39 | Ciliary dyskinesia, primary, type 14 | N/A | N/A |
| 17 | CCDC40 | Ciliary dyskinesia, primary, type 15 | N/A | N/A |
| 12 | CCDC65 | Ciliary dyskinesia, primary, type 27 | < 1 in 500 | Reduced |
| 19 | CCDC8 | 3M syndrome 3 | < 1 in 500 | Reduced |
| 14 | CCDC88C | Hydrocephalus, congenital, type 1 | 1 in 500 | 1 in 7,143 |
| 6 | CCN6 | Progressive pseudorheumatoid dysplasia | < 1 in 500 | Reduced |
| 5 | CCNO | Ciliary dyskinesia, primary, type 29 | N/A | N/A |
| 16 | CD19 | Immunodeficiency, common variable, type 3 | < 1 in 500 | Reduced |
| 1 | CD247 | ?Immunodeficiency, type 25 | N/A | N/A |

| | | | | |
|----|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| 12 | CD27 | Lymphoproliferative syndrome 2 | < 1 in 500 | Reduced |
| 6 | CD2AP | Glomerulosclerosis, focal segmental, type 3, susceptibility to | N/A | N/A |
| 19 | CD320 | Methylmalonic aciduria, transient, due to transcobalamin receptor defect | < 1 in 500 | Reduced |
| 7 | CD36 | Platelet glycoprotein 4 deficiency | N/A | N/A |
| 11 | CD3D | Immunodeficiency, type 19 | < 1 in 500 | Reduced |
| 11 | CD3E | Immunodeficiency, type 18 | < 1 in 500 | Reduced |
| 11 | CD3G | Immunodeficiency, type 17, CD3 gamma deficient | < 1 in 500 | Reduced |
| 20 | CD40 | Immunodeficiency with hyper-IgM, type 3 | < 1 in 500 | Reduced |
| 1 | CD55 | Complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) | N/A | N/A |
| 11 | CD59 | CD59 deficiency | < 1 in 500 | Reduced |
| 19 | CD79A | Agammaglobulinemia 3 | < 1 in 500 | Reduced |
| 17 | CD79B | Agammaglobulinemia 6 | < 1 in 500 | Reduced |
| 11 | CD81 | Immunodeficiency, common variable, type 6 | < 1 in 500 | Reduced |
| 2 | CD8A | CD8 deficiency, familial | < 1 in 500 | Reduced |
| 15 | CDAN1 | Dyserythropoietic anemia, congenital, type 1A | N/A | N/A |
| 1 | CDC14A | Deafness, autosomal recessive, type 105 | < 1 in 500 | Reduced |
| 22 | CDC45 | Meier-Gorlin syndrome 7 | N/A | N/A |
| 2 | CDC47 | Immunodeficiency-centromeric instability-facial anomalies syndrome 3 | < 1 in 500 | Reduced |
| 16 | CDH11 | Elsahy-Waters syndrome | < 1 in 500 | Reduced |
| 10 | CDH23 | Deafness, autosomal recessive, type 12; Usher syndrome, type 1D | 1 in 216 | 1 in 1080 |
| 16 | CDH3 | Ectodermal dysplasia, ectrodactyly, and macular dystrophy; Hypotrichosis, congenital, with juvenile macular dystrophy | N/A | N/A |
| 10 | CDHR1 | Cone-rod dystrophy, type 15 | < 1 in 500 | Reduced |
| 15 | CDIN1 | Dyserythropoietic anemia, congenital, type 1b | N/A | N/A |
| 16 | CDK10 | Al Kaissi syndrome | N/A | N/A |
| 9 | CDK5RAP2 | Primary microcephaly type 3, autosomal recessive | N/A | N/A |
| 6 | CDSN | Peeling skin syndrome 1 | < 1 in 500 | Reduced |
| 16 | CDT1 | Meier-Gorlin syndrome, type 4 | N/A | N/A |
| 14 | CEBPE | Specific granule deficiency | < 1 in 500 | Reduced |
| 1 | CENPF | Stromme syndrome | N/A | N/A |
| 13 | CENPJ | Primary microcephaly type 6, autosomal recessive | < 1 in 500 | Reduced |
| 1 | CEP104 | Joubert syndrome 25 | N/A | N/A |
| 5 | CEP120 | Short-rib thoracic dysplasia 13 with or without polydactyly | N/A | N/A |
| 4 | CEP135 | Microcephaly 8, primary, autosomal recessive | N/A | N/A |
| 15 | CEP152 | Primary microcephaly type 9, autosomal recessive | N/A | N/A |
| 11 | CEP164 | Nephronophthisis 15 | N/A | N/A |
| 3 | CEP19 | Morbid obesity and spermatogenic failure | < 1 in 500 | Reduced |
| 12 | CEP290 | Meckel syndrome, type 4; Joubert syndrome, type 5; Leber congenital amaurosis, type 10 | 1 in 150 | 1 in 375 |
| 7 | CEP41 | Joubert syndrome, type 15 | N/A | N/A |
| 10 | CEP55 | Multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly | N/A | N/A |
| 11 | CEP57 | Mosaic variegated aneuploidy syndrome 2 | < 1 in 500 | Reduced |
| 9 | CEP78 | Cone-rod dystrophy and hearing loss | N/A | N/A |
| 12 | CEP83 | Nephronophthisis 18 | N/A | N/A |
| 2 | CERKL | Retinitis pigmentosa, type 26 | 1 in 250 | 1 in 1667 |
| 15 | CERS3 | Ichthyosis, congenital, autosomal recessive 9 | < 1 in 500 | Reduced |
| 8 | CFAP418 | Bardet-Biedl syndrome, type 21; Cone-rod dystrophy 16 and Retinitis pigmentosa 64; Ciliary dyskinesia, primary, 26 | < 1 in 500 | Reduced |
| 10 | CFAP43 | Spermatogenic failure, type 19 | N/A | N/A |
| 18 | CFAP53 | Heterotaxy, visceral, 6, autosomal recessive | N/A | N/A |
| 19 | CFD | Complement factor D deficiency | < 1 in 500 | Reduced |
| 1 | CFH | Complement factor H deficiency | < 1 in 500 | Reduced |
| 4 | CFI | Complement factor I deficiency | N/A | N/A |
| 14 | CFL2 | Nemaline myopathy, type 7, autosomal recessive | < 1 in 500 | Reduced |
| 7 | CFTR | Cystic fibrosis | 1 in 25 | 1 in 833 |
| 10 | CHAT | Myasthenic syndrome, congenital, type 6, presynaptic | 1 in 121 | 1 in 134 |
| 22 | CHKB | Muscular dystrophy, congenital, megaconial type | < 1 in 500 | Reduced |
| 16 | CHMP1A | Pontocerebellar hypoplasia, type 8 | < 1 in 500 | Reduced |
| 2 | CHRNA1 | Multiple pterygium syndrome, lethal type | N/A | N/A |
| 17 | CHRNB1 | ?Myasthenic syndrome, congenital, 2C, associated with acetylcholine receptor deficiency | N/A | N/A |
| 2 | CHRNA2 | Myasthenic syndrome, congenital, type 3B, fast-channel; Multiple pterygium syndrome, lethal type | N/A | N/A |
| 17 | CHRNE | Myasthenic syndrome, congenital, type 4B, fast-channel; Myasthenic syndrome, congenital, type 4C, associated with acetylcholine receptor deficiency | 1 in 244 | 1 in 2440 |
| 2 | CHRNA3 | Multiple pterygium syndrome (MPS), Escobar type; MPS, lethal type | 1 in 400 | 1 in 1,597 |
| 15 | CHST14 | Ehlers-Danlos syndrome, musculocontractural, type 1 | < 1 in 500 | Reduced |
| 10 | CHST3 | Spondyloepiphyseal dysplasia with congenital joint dislocations | < 1 in 500 | Reduced |
| 16 | CHST6 | Macular corneal dystrophy | 1 in 80 | 1 in 394 |
| 15 | CHSY1 | Temtamy preaxial brachydactyly syndrome | < 1 in 500 | Reduced |
| 10 | CHUK | Cocoon syndrome | N/A | N/A |
| 15 | CIB2 | Deafness, autosomal recessive, type 48; Usher syndrome, type 1J | < 1 in 500 | Reduced |
| 16 | CIITA | Bare lymphocyte syndrome, type 2, complementation group A | < 1 in 500 | Reduced |

| | | | | |
|----|---------|---------------------------------------------------------------------------------------------------------------------|------------|------------|
| 6 | CILK1 | Endocrine-cerebroosteadysplasia | < 1 in 500 | Reduced |
| 4 | CISD2 | Wolfram syndrome 2 | < 1 in 500 | Reduced |
| 12 | CIT | Microcephaly 17, primary, autosomal recessive | N/A | N/A |
| 2 | CKAP2L | Filippi syndrome | < 1 in 500 | Reduced |
| 11 | CLCF1 | Cold-induced sweating syndrome 2 | < 1 in 500 | Reduced |
| 7 | CLCN1 | Myotonia congenita, recessive | 1 in 159 | 1 in 319 |
| 3 | CLCN2 | Leukoencephalopathy with ataxia | N/A | N/A |
| 16 | CLCN7 | Osteopetrosis, autosomal recessive type 4 | < 1 in 500 | Reduced |
| 1 | CLCNKA | Barter syndrome, type 4B, digenic | N/A | N/A |
| 1 | CLCNKB | Barter syndrome, type 3; Barter syndrome, type 4B, digenic | N/A | N/A |
| 3 | CLDN1 | Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis | < 1 in 500 | Reduced |
| 13 | CLDN10 | HELIX syndrome | < 1 in 500 | Reduced |
| 21 | CLDN14 | Deafness type 29, autosomal recessive | < 1 in 500 | Reduced |
| 3 | CLDN16 | Hypomagnesemia, type 3, renal | N/A | N/A |
| 1 | CLDN19 | Rena hypomagnesemia type 5, with ocular involvement | < 1 in 500 | Reduced |
| 11 | CLMP | Congenital short bowel syndrome | < 1 in 500 | Reduced |
| 16 | CLN3 | Ceroid lipofuscinosis, neuronal, type 3 | 1 in 242 | 1 in 346 |
| 13 | CLN5 | Ceroid lipofuscinosis, neuronal, type 5 | 1 in 400 | 1 in 8000 |
| 15 | CLN6 | Ceroid lipofuscinosis, neuronal, type 6 | < 1 in 500 | Reduced |
| 8 | CLN8 | Ceroid lipofuscinosis, neuronal, type 8 | < 1 in 500 | Reduced |
| 11 | CLP1 | Pontocerebellar hypoplasia, type 10 | < 1 in 500 | Reduced |
| 11 | CLPB | 3-methylglutaconic aciduria, type 7, with cataracts, neurologic involvement and neutropenia | N/A | N/A |
| 19 | CLPP | Perrault syndrome 3 | N/A | N/A |
| 3 | CLRN1 | Usher syndrome, type 3A | 1 in 250 | 1 in 1667 |
| 4 | CNGA1 | Retinitis pigmentosa type 49 | 1 in 625 | 1 in 1,171 |
| 2 | CNGA3 | Achromatopsia, type 2 | N/A | N/A |
| 16 | CNGB1 | Retinitis pigmentosa type 45 | 1 in 200 | 1 in 4000 |
| 8 | CNGB3 | Achromatopsia, type 3 | 1 in 125 | 1 in 1250 |
| 10 | CNNM2 | Hypomagnesemia, seizures, and mental retardation | < 1 in 500 | Reduced |
| 2 | CNNM4 | Jalili syndrome | < 1 in 500 | Reduced |
| 6 | CNPY3 | Epileptic encephalopathy, early infantile, type 60 | < 1 in 500 | Reduced |
| 17 | CNTNAP1 | Lethal congenital contracture syndrome 7 | N/A | N/A |
| 7 | CNTNAP2 | Pitt-Hopkins like syndrome 1 | < 1 in 500 | Reduced |
| 1 | COA6 | Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4 | < 1 in 500 | Reduced |
| 14 | COA8 | Mitochondrial complex IV deficiency, nuclear type 17 | < 1 in 500 | Reduced |
| 17 | COASY | Neurodegeneration with brain iron accumulation 6 | N/A | N/A |
| 17 | COG1 | Congenital disorder of glycosylation, type IIg | < 1 in 500 | Reduced |
| 16 | COG4 | Congenital disorder of glycosylation, type 2J | N/A | N/A |
| 7 | COG5 | Congenital disorder of glycosylation, type 2I | N/A | N/A |
| 13 | COG6 | Congenital disorder of glycosylation, type 2L; Shaheen syndrome | N/A | N/A |
| 16 | COG7 | Congenital disorder of glycosylation, type 2E | < 1 in 500 | Reduced |
| 16 | COG8 | Congenital disorder of glycosylation, type 2H | N/A | N/A |
| 1 | COL11A1 | Fibrochondrogenesis type 1 | N/A | N/A |
| 6 | COL11A2 | Otospondylomegapiphyseal dysplasia, autosomal recessive | N/A | N/A |
| 10 | COL13A1 | Myasthenic syndrome, congenital, 19 | N/A | N/A |
| 10 | COL17A1 | Epidermolysis bullosa, junctional, non-Herlitz type | < 1 in 500 | Reduced |
| 21 | COL18A1 | Knobloch syndrome, type 1 | < 1 in 500 | Reduced |
| 7 | COL1A2 | Ehlers-Danlos syndrome, cardiac valvular type | N/A | N/A |
| 4 | COL25A1 | Fibrosis of extraocular muscles, congenital, type 5 | < 1 in 500 | Reduced |
| 9 | COL27A1 | Steel syndrome | 1 in 500 | 1 in 2500 |
| 2 | COL4A3 | Alport syndrome, autosomal recessive, type 2 | 1 in 300 | 1 in 1500 |
| 2 | COL4A4 | Alport syndrome, autosomal recessive, type 2 | 1 in 425 | 1 in 4250 |
| 21 | COL6A1 | Ullrich congenital muscular dystrophy, type 1 (Limb-girdle muscular dystrophy, type 22 [LGMD R22]) | N/A | N/A |
| 21 | COL6A2 | Ullrich congenital muscular dystrophy 1; Bethlem myopathy-1; Myosclerosis | N/A | N/A |
| 2 | COL6A3 | Bethlem myopathy 1; Ullrich congenital muscular dystrophy 1; Dystonia 27 | N/A | N/A |
| 3 | COL7A1 | Dystrophic epidermolysis bullosa (DEB), Hallopeau-Siemens (HS) type and non-HS type; DEB pruriginosa; DEB pretibial | 1 in 150 | 1 in 1000 |
| 6 | COL9A1 | Stickler syndrome, type 4 | N/A | N/A |
| 1 | COL9A2 | ?Stickler syndrome, type V | N/A | N/A |
| 8 | COLEC10 | 3MC syndrome 3 | < 1 in 500 | Reduced |
| 2 | COLEC11 | 3MC syndrome 2 | < 1 in 500 | Reduced |
| 3 | COLQ | Myasthenic syndrome, congenital, type 5 | 1 in 805 | 1 in 1,420 |
| 4 | COQ2 | Primary coenzyme Q10 deficiency, type 1 | < 1 in 500 | Reduced |
| 9 | COQ4 | Coenzyme Q10 deficiency, primary, type 7 | N/A | N/A |
| 14 | COQ6 | Coenzyme Q10 deficiency, primary, type 6 | N/A | N/A |
| 1 | COQ8A | Primary coenzyme Q10 deficiency, type 4 | < 1 in 500 | Reduced |
| 19 | COQ8B | Nephrotic syndrome, type 9 | N/A | N/A |
| 16 | COQ9 | Coenzyme Q10 deficiency, primary, type 5 | < 1 in 500 | Reduced |
| 16 | CORO1A | Immunodeficiency, type 8 | < 1 in 500 | Reduced |

| | | | | |
|----|---------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| 17 | COX10 | Mitochondrial complex IV deficiency, nuclear type 3 | < 1 in 500 | Reduced |
| 10 | COX15 | Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency, type 2; Leigh syndrome due to cytochrome c oxidase deficiency | 1 in 480 | 1 in 640 |
| 1 | COX20 | Mitochondrial complex IV deficiency, nuclear type 11 | < 1 in 500 | Reduced |
| 19 | COX6B1 | Mitochondrial complex IV deficiency, nuclear type 7 | < 1 in 500 | Reduced |
| 3 | CP | Aceruloplasminemia | N/A | N/A |
| 8 | CPA6 | Febrile seizures, familial, type 11 | N/A | N/A |
| 19 | CPAMD8 | Anterior segment dysgenesis, type 8 | N/A | N/A |
| 5 | CPLANE1 | Joubert syndrome 17 | N/A | N/A |
| 4 | CPLX1 | Epileptic encephalopathy, early infantile, 63 | < 1 in 500 | Reduced |
| 2 | CPS1 | Carbamoylphosphate synthetase 1 deficiency | 1 in 500 | 1 in 2500 |
| 11 | CPT1A | Carnitine palmitoyltransferase type 1A deficiency, hepatic | < 1 in 500 | Reduced |
| 1 | CPT2 | Carnitine palmitoyltransferase type 2 deficiency, lethal neonatal; Carnitine palmitoyltransferase type 2 deficiency, infantile | 1 in 100 | 1 in 667 |
| 1 | CR2 | Immunodeficiency, common variable, type 7 | N/A | N/A |
| 12 | CRADD | Mental retardation, autosomal recessive, type 34, with variant lissencephaly | < 1 in 500 | Reduced |
| 1 | CRB1 | Retinitis pigmentosa, type 12; Leber congenital amaurosis, type 8 | 1 in 158 | 1 in 316 |
| 9 | CRB2 | Ventriculomegaly with cystic kidney disease | N/A | N/A |
| 3 | CRBN | Mental retardation, autosomal recessive, type 2 | < 1 in 500 | Reduced |
| 2 | CRIPT | Short stature with microcephaly and distinctive facies | < 1 in 500 | Reduced |
| 19 | CRLF1 | Cold-induced sweating syndrome type 1 | < 1 in 500 | Reduced |
| 7 | CRPPA | Muscular dystrophy-dystroglycanopathy, type A7; Muscular dystrophy-dystroglycanopathy, type C7 | N/A | N/A |
| 3 | CRTAP | Osteogenesis imperfecta, type 7 | 1 in 1,416 | 1 in 3,539 |
| 21 | CRYAA | Cataract 9, multiple types | < 1 in 500 | Reduced |
| 11 | CRYAB | Myopathy, myofibrillar, fatal infantile hypertonic, alpha-B crystallin-related; Cataract 16, multiple types | < 1 in 500 | Reduced |
| 22 | CRYBB1 | Cataract 17 | < 1 in 500 | Reduced |
| 22 | CRYBB3 | Cataract 22 | < 1 in 500 | Reduced |
| 22 | CSF2RB | Surfactant metabolism dysfunction, pulmonary, type 5 | < 1 in 500 | Reduced |
| 1 | CSF3R | Neutropenia, severe congenital, type 7, autosomal recessive | N/A | N/A |
| 8 | CSPP1 | Joubert syndrome 21 | N/A | N/A |
| 3 | CSTA | Peeling skin syndrome, type 4 | < 1 in 500 | Reduced |
| 21 | CSTB | Epilepsy, progressive myoclonic type 1A (Unverricht and Lundborg) | < 1 in 500 | Reduced |
| 17 | CTC1 | Cerebroretinal microangiopathy with calcifications and cysts | N/A | N/A |
| 1 | CTH | Cystathioninuria | 1 in 80 | 1 in 7,870 |
| 17 | CTNS | Nephropathic cystinosis | 1 in 200 | 1 in 400 |
| 1 | CTPS1 | Immunodeficiency, type 24 | < 1 in 500 | Reduced |
| 20 | CTSA | Galactosialidosis | 1 in 64 | 1 in 118 |
| 11 | CTSC | Haim-Munk syndrome; Papillon-Lefevre syndrome | 1 in 500 | 1 in 2,496 |
| 11 | CTSD | Ceroid lipofuscinosis, neuronal, type 10 | < 1 in 500 | Reduced |
| 11 | CTSF | Ceroid lipofuscinosis, neuronal, type 13 (Kufs type) | N/A | N/A |
| 1 | CTSK | Pycnodysostosis | < 1 in 500 | Reduced |
| 10 | CUBN | Megaloblastic anemia 1 (Imerslund-Grasbeck syndrome) | N/A | N/A |
| 6 | CUL7 | 3M syndrome 1 | N/A | N/A |
| 5 | CWC27 | Retinitis pigmentosa with or without skeletal anomalies | < 1 in 500 | Reduced |
| 10 | CWF19L1 | Spinocerebellar ataxia, autosomal recessive, type 17 | N/A | N/A |
| 18 | CYB5A | 46,XY disorder of sex development due to isolated 17,20-lyase deficiency | < 1 in 500 | Reduced |
| 22 | CYB5R3 | Methemoglobinemia, type 1; Methemoglobinemia, type 2 | N/A | N/A |
| 16 | CYBA | Chronic granulomatous disease, type 4 | < 1 in 500 | Reduced |
| 8 | CYC1 | Mitochondrial complex III deficiency, nuclear type 6 | < 1 in 500 | Reduced |
| 15 | CYP11A1 | 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency | 1 in 500 | 1 in 7,143 |
| 8 | CYP11B1 | Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency | 1 in 300 | 1 in 2000 |
| 8 | CYP11B2 | Hypoadosteronism, congenital, due to CMO I deficiency | < 1 in 500 | Reduced |
| 10 | CYP17A1 | 17 alpha(o)-hydroxylase/17,20-lyase deficiency | < 1 in 500 | Reduced |
| 15 | CYP19A1 | Aromatase deficiency | < 1 in 500 | Reduced |
| 2 | CYP1B1 | Glaucoma, primary congenital, type 3A | 1 in 196 | 1 in 407 |
| 6 | CYP21A2 | Congenital adrenal hyperplasia due to 21-hydroxylase deficiency | 1 in 62 | 1 in 1240 |
| 20 | CYP24A1 | Hypercalcemia, infantile, type 1 | N/A | N/A |
| 2 | CYP26B1 | Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies | N/A | N/A |
| 10 | CYP26C1 | Focal facial dermal dysplasia 4 | < 1 in 500 | Reduced |
| 2 | CYP27A1 | Cerebrotendinous xanthomatosis | 1 in 275 | 1 in 5500 |
| 12 | CYP27B1 | Vitamin D-dependent rickets, type 1 | < 1 in 500 | Reduced |
| 11 | CYP2R1 | Rickets due to defect in vitamin D 25-hydroxylation | N/A | N/A |
| 4 | CYP2U1 | Spastic paraplegia, type 56, autosomal recessive | N/A | N/A |
| 19 | CYP4F22 | Ichthyosis, congenital, autosomal recessive, type 5 | N/A | N/A |
| 4 | CYP4V2 | Bietti crystalline corneoretinal dystrophy | 1 in 130 | 1 in 1300 |
| 8 | CYP7B1 | Spastic paraplegia, type 5A, autosomal recessive | < 1 in 500 | Reduced |
| 2 | D2HGDH | D-2-hydroxyglutaric aciduria | < 1 in 500 | Reduced |
| 3 | DAG1 | Muscular dystrophy-dystroglycanopathy type A9; Muscular dystrophy-dystroglycanopathy type C9 | < 1 in 500 | Reduced |
| 2 | DARS1 | Hypomyelination with brainstem and spinal cord involvement and leg spasticity | N/A | N/A |

| | | | | |
|----|----------|---------------------------------------------------------------------------------------|------------|-----------|
| 1 | DARS2 | Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation | N/A | N/A |
| 9 | DBH | Dopamine beta-hydroxylase deficiency | N/A | N/A |
| 1 | DBT | Maple syrup urine disease, type 2 | 1 in 410 | 1 in 2733 |
| 2 | DCAF17 | Woodhouse-Sakati syndrome | < 1 in 500 | Reduced |
| 18 | DCC | Gaze palsy, familial horizontal, with progressive scoliosis, type 2 | < 1 in 500 | Reduced |
| 6 | DCDC2 | Sclerosing cholangitis, neonatal; Nephronophthisis 19 | N/A | N/A |
| 11 | DCHS1 | Van Maldergem syndrome 1 | N/A | N/A |
| 10 | DCLRE1C | Omenn syndrome; Severe combined immunodeficiency, Athabaskan type | < 1 in 500 | Reduced |
| 11 | DCPS | Al-Raqad syndrome | N/A | N/A |
| 11 | DDB2 | Xeroderma pigmentosum, complementation group E | < 1 in 500 | Reduced |
| 7 | DDC | Aromatic L-amino acid decarboxylase deficiency | N/A | N/A |
| 14 | DDHD1 | Spastic paraplegia, type 28, autosomal recessive | N/A | N/A |
| 8 | DDHD2 | Spastic paraplegia, type 54, autosomal recessive | < 1 in 500 | Reduced |
| 1 | DDR2 | Spondylometaphyseal dysplasia, short limb-hand type | N/A | N/A |
| 20 | DDRGK1 | Spondyloepimetaphyseal dysplasia, Shohat type | < 1 in 500 | Reduced |
| 12 | DDX11 | Warsaw breakage syndrome | N/A | N/A |
| 1 | DDX59 | Orofaciodigital syndrome V | N/A | N/A |
| 11 | DENND5A | Epileptic encephalopathy, early infantile, 49 | < 1 in 500 | Reduced |
| 2 | DES | Myopathy, myofibrillar, type 1 | N/A | N/A |
| 8 | DGAT1 | ?Diarrhea 7, protein-losing enteropathy type | N/A | N/A |
| 17 | DGKE | Nephrotic syndrome, type 7 | < 1 in 500 | Reduced |
| 2 | DGUOK | DGUOK-related mitochondrial DNA depletion syndrome | < 1 in 500 | Reduced |
| 1 | DHCR24 | Desmosterolosis | < 1 in 500 | Reduced |
| 11 | DHCR7 | Smith-Lemli-Opitz syndrome | 1 in 100 | 1 in 1000 |
| 1 | DHDDS | Retinitis pigmentosa, type 59 | < 1 in 500 | Reduced |
| 5 | DHFR | Megaloblastic anemia due to dihydrofolate reductase deficiency | < 1 in 500 | Reduced |
| 12 | DHH | 46,XY complete gonadal dysgenesis | < 1 in 500 | Reduced |
| 16 | DHODH | Miller syndrome | N/A | N/A |
| 19 | DHPS | Neurodevelopmental disorder with seizures and speech and walking impairment | N/A | N/A |
| 10 | DHTKD1 | 2-aminoadipic 2-oxoadipic aciduria | N/A | N/A |
| 5 | DIAPH1 | Seizures, cortical blindness, microcephaly syndrome | < 1 in 500 | Reduced |
| 2 | DIS3L2 | Perlman syndrome | N/A | N/A |
| 11 | DLAT | Pyruvate dehydrogenase E2 deficiency | < 1 in 500 | Reduced |
| 7 | DLD | Dihydropyrimidinase deficiency | < 1 in 500 | Reduced |
| 19 | DLL3 | Spondylocostal dysostosis type 1 | N/A | N/A |
| 5 | DMGDH | Dimethylglycine dehydrogenase deficiency | N/A | N/A |
| 4 | DMP1 | Hypophosphatemic rickets, autosomal recessive | < 1 in 500 | Reduced |
| 15 | DMXL2 | Developmental and epileptic encephalopathy, type 81 | N/A | N/A |
| 16 | DNAAF1 | Ciliary dyskinesia, primary, type 13 | N/A | N/A |
| 8 | DNAAF11 | Ciliary dyskinesia, primary, type 19 | N/A | N/A |
| 14 | DNAAF2 | Ciliary dyskinesia, primary, type 10 | N/A | N/A |
| 19 | DNAAF3 | Ciliary dyskinesia, primary, type 2 | N/A | N/A |
| 15 | DNAAF4 | Ciliary dyskinesia, primary, type 25 | N/A | N/A |
| 7 | DNAAF5 | Ciliary dyskinesia, primary, type 18 | N/A | N/A |
| 3 | DNAH1 | Spermatogenic failure, type 18 | N/A | N/A |
| 7 | DNAH11 | Ciliary dyskinesia, primary, type 7, with or without situs inversus | N/A | N/A |
| 5 | DNAH5 | Ciliary dyskinesia, primary, type 3, with or without situs inversus | 1 in 130 | 1 in 520 |
| 17 | DNAH9 | Ciliary dyskinesia, primary, type 40 | N/A | N/A |
| 9 | DNAI1 | Ciliary dyskinesia, primary, type 1, with or without situs inversus | 1 in 323 | 1 in 1615 |
| 17 | DNAI2 | Ciliary dyskinesia, primary, type 9, with or without situs inversus | < 1 in 500 | Reduced |
| 11 | DNAJB13 | Ciliary dyskinesia, primary, type 34 | < 1 in 500 | Reduced |
| 2 | DNAJB2 | Spinal muscular atrophy, distal, autosomal recessive, type 5 | < 1 in 500 | Reduced |
| 10 | DNAJC12 | Hyperphenylalaninemia, mild, non-BH4-deficient | 1 in 500 | N/A |
| 3 | DNAJC19 | 3-methylglutaconic aciduria, type 5 | < 1 in 500 | Reduced |
| 5 | DNAJC21 | Bone marrow failure syndrome, type 3 | N/A | N/A |
| 1 | DNAJC6 | Parkinson disease, type 19A, juvenile-onset; Parkinson disease, type 19B, early-onset | < 1 in 500 | Reduced |
| 14 | DNAL1 | Ciliary dyskinesia, primary, type 16 | < 1 in 500 | Reduced |
| 3 | DNASE1L3 | Systemic lupus erythematosus 16 | < 1 in 500 | Reduced |
| 12 | DNM1L | Encephalopathy due to defective mitochondrial and peroxisomal fission, type 1 | < 1 in 500 | Reduced |
| 19 | DNM2 | Lethal congenital contracture syndrome, type 5 | N/A | N/A |
| 20 | DNMT3B | Immunodeficiency-centromeric instability-facial anomalies syndrome, type 1 | < 1 in 500 | Reduced |
| 5 | DOCK2 | Immunodeficiency, type 40 | < 1 in 500 | Reduced |
| 19 | DOCK6 | Adams-Oliver syndrome 2 | N/A | N/A |
| 1 | DOCK7 | Epileptic encephalopathy, early infantile, 23 | < 1 in 500 | Reduced |
| 9 | DOCK8 | Hyper-IgE recurrent infection syndrome, autosomal recessive | N/A | N/A |
| 4 | DOK7 | Fetal akinesia deformation sequence, type 3; Myasthenic syndrome, congenital, type 10 | 1 in 262 | 1 in 719 |
| 9 | DOLK | Congenital disorder of glycosylation, type 1M | < 1 in 500 | <1 in 563 |
| 21 | DONSON | Microcephaly, short stature, and limb abnormalities | N/A | N/A |

| | | | | |
|----|---------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| 11 | DPAGT1 | Congenital disorder of glycosylation, type 1J; Myasthenic syndrome, congenital, type 13 | < 1 in 500 | <1 in 808 |
| 17 | DPH1 | Developmental delay with short stature, dysmorphic features, and sparse hair | N/A | N/A |
| 20 | DPM1 | Congenital disorder of glycosylation, type 1E | < 1 in 500 | <1 in 1,750 |
| 9 | DPM2 | Congenital disorder of glycosylation, type 1u | < 1 in 500 | Reduced |
| 1 | DPM3 | Congenital disorder of glycosylation, type 1o | < 1 in 500 | Reduced |
| 12 | DPY19L2 | Spermatogenic failure, type 9 | N/A | N/A |
| 1 | DPYD | Dihydropyrimidine dehydrogenase deficiency | 1 in 558 | 1 in 55,701 |
| 8 | DPYS | Dihydropyrimidinuria | N/A | N/A |
| 1 | DRAM2 | Cone-rod dystrophy 21 | < 1 in 500 | Reduced |
| 2 | DRC1 | Ciliary dyskinesia, primary, type 21 | N/A | N/A |
| 18 | DSG1 | Erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper IgE | < 1 in 500 | Reduced |
| 18 | DSG4 | Hypotrichosis, type 6 | N/A | N/A |
| 6 | DSG | Cardiomyopathy, dilated, with woolly hair and keratoderma; Epidermolysis bullosa, lethal acantholytic | < 1 in 500 | Reduced |
| 6 | DST | Neuropathy, hereditary sensory and autonomic, type VI; Epidermolysis bullosa simplex 3, localized or generalized intermediate, with bp230 deficiency | N/A | N/A |
| 1 | DSTYK | Spastic paraplegia, type 23, autosomal recessive | < 1 in 500 | Reduced |
| 6 | DTNBP1 | Hermansky-Pudlak syndrome, type 7 | N/A | N/A |
| 15 | DUOX2 | Thyroid dysmorphogenesis, type 6 | 1 in 80 | 1 in 170 |
| 15 | DUOX2 | Thyroid dysmorphogenesis, type 5 | 1 in 80 | 1 in 144 |
| 18 | DYM | Smith-McCort dysplasia; Dyggve-Melchior-Clausen disease | N/A | N/A |
| 11 | DYNC2H1 | Short-rib thoracic dysplasia, type 3, with or without polydactyly | 1 in 50 | 1 in 500 |
| 7 | DYNC211 | Short-rib thoracic dysplasia 8 with or without polydactyly | N/A | N/A |
| 9 | DYNC212 | Short-rib thoracic dysplasia 11 with or without polydactyly | N/A | N/A |
| 2 | DYNC2L1 | Short-rib thoracic dysplasia 15 with polydactyly | N/A | N/A |
| 3 | DYNLT2B | Short-rib thoracic dysplasia 17 with or without polydactyly | < 1 in 500 | Reduced |
| 2 | DYSF | Miyoshi muscular dystrophy, type 1; Limb-girdle muscular dystrophy, type 2 (LGMD R2) | 1 in 300 | 1 in 3000 |
| 3 | DZIP1L | Polycystic kidney disease 5 | N/A | N/A |
| 16 | EARS2 | Combined oxidative phosphorylation deficiency 12 | N/A | N/A |
| 2 | ECEL1 | Arthrogryposis, distal, type 5D | N/A | N/A |
| 10 | ECHS1 | Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency | N/A | N/A |
| 1 | ECM1 | Urbach-Wiethe disease | N/A | N/A |
| 2 | EDAR | Ectodermal dysplasia 10B, hypohidrotic/hair/tooth type | 1 in 131 | 1 in 252 |
| 1 | EDARADD | Ectodermal dysplasia 11B, hypohidrotic/hair/tooth type | < 1 in 500 | Reduced |
| 6 | EDN1 | Auriculocondylar syndrome, type 3 | < 1 in 500 | Reduced |
| 20 | EDN3 | Waardenburg syndrome, type 4B | < 1 in 500 | Reduced |
| 13 | EDNRB | ABCD syndrome | < 1 in 500 | Reduced |
| 11 | EFEMP2 | Cutis laxa, autosomal recessive, type 1B | < 1 in 500 | Reduced |
| 15 | EFL1 | Shwachman-Diamond syndrome 2 | N/A | N/A |
| 7 | EGR | ?Inflammatory skin and bowel disease, neonatal, 2 | N/A | N/A |
| 10 | EGR2 | Dejerine-Sottas disease | < 1 in 500 | Reduced |
| 2 | EIF2AK3 | Wolcott-Rallison syndrome | < 1 in 500 | <1 in 2,500 |
| 15 | EIF2AK4 | Pulmonary venoocclusive disease 2 | N/A | N/A |
| 12 | EIF2B1 | Leukoencephalopathy with vanishing white matter (VWM) | < 1 in 500 | Reduced |
| 14 | EIF2B2 | Leukoencephalopathy with vanishing white matter (VWM) | < 1 in 500 | Reduced |
| 1 | EIF2B3 | Leukoencephalopathy with vanishing white matter (VWM) | < 1 in 500 | Reduced |
| 2 | EIF2B4 | Leukoencephalopathy with vanishing white matter (VWM) | < 1 in 500 | Reduced |
| 3 | EIF2B5 | Leukoencephalopathy with vanishing white matter (VWM) | 1 in 400 | 1 in 8000 |
| 17 | EIF4A3 | Robin sequence with cleft mandible and limb anomalies | < 1 in 500 | Reduced |
| 17 | ELAC2 | Combined oxidative phosphorylation deficiency 17 | N/A | N/A |
| 20 | ELMO2 | Vascular malformation, primary intraosseous | < 1 in 500 | Reduced |
| 6 | ELOVL4 | Ichthyosis, spastic quadriplegia, and mental retardation | < 1 in 500 | Reduced |
| 9 | ELP1 | Familial dysautonomia | 1 in 200 | 1 in 2000 |
| 18 | ELP2 | Mental retardation, autosomal recessive, type 58 | N/A | N/A |
| 1 | EMC1 | Cerebellar atrophy, visual impairment, and psychomotor retardation | N/A | N/A |
| 14 | EML1 | Band heterotopia | N/A | N/A |
| 16 | EMP2 | Nephrotic syndrome, type 10 | N/A | N/A |
| 4 | ENAM | Amelogenesis imperfecta, type 1C | N/A | N/A |
| 17 | ENO3 | ?Glycogen storage disease XIII | N/A | N/A |
| 6 | ENPP1 | Arterial calcification, generalized, of infancy, type 1 | 1 in 333 | 1 in 3330 |
| 10 | ENTPD1 | Spastic paraplegia, type 64, autosomal recessive | < 1 in 500 | Reduced |
| 3 | EOGT | Adams-Oliver syndrome 4 | < 1 in 500 | Reduced |
| 1 | EPB41 | Elliptyocytosis, type 1 | < 1 in 500 | Reduced |
| 15 | EPB42 | Spherocytosis, type 5 | N/A | N/A |
| 2 | EPCAM | EPCAM-related conditions | < 1 in 500 | Reduced |
| 18 | EPG5 | Vici syndrome | N/A | N/A |
| 6 | EPM2A | Epilepsy, progressive myoclonic, type 2A (Lafora) | N/A | N/A |
| 1 | EPRS1 | Leukodystrophy, hypomyelinating, type 15 | N/A | N/A |
| 11 | EPS8L2 | Deafness autosomal recessive, type 106 | N/A | N/A |
| 17 | ERAL1 | Perrault syndrome 6 | < 1 in 500 | Reduced |

| | | | | |
|----|---------|-----------------------------------------------------------------------------------------------------------------------|------------|-------------|
| 12 | ERBB3 | Lethal congenital contractural syndrome, type 2 | N/A | N/A |
| 19 | ERCC1 | Cerebrooculofacioskeletal syndrome, type 4 | N/A | N/A |
| 19 | ERCC2 | Trichothiodystrophy, type 1; Xeroderma pigmentosum, group D | 1 in 500 | 1 in 10000 |
| 2 | ERCC3 | Trichothiodystrophy, type 2 | 1 in 436 | 1 in 1,306 |
| 16 | ERCC4 | Fanconi anemia, complementation group Q | N/A | N/A |
| 13 | ERCC5 | Cerebrooculofacioskeletal syndrome 3; Xeroderma pigmentosum, group G;Xeroderma pigmentosum, group G/Cockayne syndrome | < 1 in 500 | Reduced |
| 10 | ERCC6 | Cockayne syndrome, type B; Cerebrooculofacioskeletal syndrome, type 1 | 1 in 300 | 1 in 2000 |
| 9 | ERCC6L2 | Bone marrow failure syndrome, type 2 | N/A | N/A |
| 5 | ERCC8 | Cockayne syndrome, type A | < 1 in 500 | Reduced |
| 10 | ERLIN1 | Spastic paraplegia, type 62, autosomal recessive | < 1 in 500 | Reduced |
| 8 | ERLIN2 | Spastic paraplegia, type 18, autosomal recessive | < 1 in 500 | Reduced |
| 8 | ESCO2 | Roberts syndrome | < 1 in 500 | Reduced |
| 1 | ESPN | Deafness, autosomal recessive, type 36 | N/A | N/A |
| 6 | ESR1 | Estrogen resistance | < 1 in 500 | Reduced |
| 14 | ESRRB | Deafness, autosomal recessive, type 35 | < 1 in 500 | Reduced |
| 15 | ETFA | Glutaric acidemia, type 2A | < 1 in 500 | Reduced |
| 19 | ETFB | Glutaric acidemia, type 2B | < 1 in 500 | Reduced |
| 4 | ETFDH | Glutaric acidemia, type 2C | 1 in 300 | 1 in 2000 |
| 19 | ETHE1 | Ethylmalonic encephalopathy | < 1 in 500 | Reduced |
| 4 | EVC | Ellis-van Creveld syndrome | 1 in 240 | 1 in 960 |
| 4 | EVC2 | Ellis-van Creveld syndrome | 1 in 300 | 1 in 2000 |
| 9 | EXOSC3 | Pontocerebellar hypoplasia, type 1B | 1 in 139 | 1 in 300 |
| 11 | EXPH5 | Epidermolysis bullosa, nonspecific, autosomal recessive | N/A | N/A |
| 8 | EXTL3 | Immunoskeletal dysplasia with neurodevelopmental abnormalities | N/A | N/A |
| 6 | EYS | Retinitis pigmentosa, type 25 | 1 in 100 | 1 in 1000 |
| 13 | F10 | Factor X deficiency | < 1 in 500 | Reduced |
| 4 | F11 | Factor XI deficiency | 1 in 200 | 1 in 2500 |
| 6 | F13A1 | Factor XIII A deficiency | N/A | N/A |
| 1 | F13B | Factor XIII B deficiency | < 1 in 500 | Reduced |
| 11 | F2 | Prothrombin deficiency | 1 in 300 | 1 in 1500 |
| 1 | F5 | Factor V deficiency | 1 in 500 | 1 in 10000 |
| 13 | F7 | Factor VII deficiency | N/A | N/A |
| 16 | FA2H | Spastic paraplegia, type 35, autosomal recessive | < 1 in 500 | Reduced |
| 11 | FADD | Infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations | < 1 in 500 | Reduced |
| 15 | FAH | Tyrosinemia, type 1 | 1 in 200 | 1 in 2000 |
| 2 | FAM161A | Retinitis pigmentosa, type 28 | 1 in 350 | 1 in 3500 |
| 17 | FAM20A | Amelogenesis imperfecta, type 1G (Enamel-renal syndrome) | < 1 in 500 | Reduced |
| 7 | FAM20C | Raine syndrome | < 1 in 500 | <1 in 1,000 |
| 15 | FAN1 | Interstitial nephritis, karyomegalic | N/A | N/A |
| 16 | FANCA | Fanconi anemia, complementation group A | 1 in 200 | 1 in 400 |
| 9 | FANCC | Fanconi anemia, complementation group C | 1 in 480 | 1 in 2400 |
| 3 | FANCD2 | Fanconi anemia, complementation group D2 | N/A | N/A |
| 6 | FANCE | Fanconi anemia, complementation group E | N/A | N/A |
| 11 | FANCF | Fanconi anemia, complementation group F | < 1 in 500 | Reduced |
| 9 | FANCG | Fanconi anemia, complementation group G | < 1 in 500 | Reduced |
| 15 | FANCI | Fanconi anemia, complementation group I | N/A | N/A |
| 2 | FANCL | Fanconi anemia, complementation group L | N/A | N/A |
| 14 | FANCM | Spermatogenic failure, type 28; ?Premature ovarian failure 15 | < 1 in 500 | Reduced |
| 11 | FAR1 | Peroxisomal fatty acyl-CoA reductase 1 disorder | < 1 in 500 | Reduced |
| 6 | FARS2 | Combined oxidative phosphorylation deficiency 14; Spastic paraplegia, type 77, autosomal recessive | N/A | N/A |
| 2 | FASTKD2 | Combined oxidative phosphorylation deficiency 44 | < 1 in 500 | Reduced |
| 4 | FAT4 | Hennekam lymphangiectasia-lymphedema syndrome 2 | N/A | N/A |
| 14 | FBLN5 | Cutis laxa, autosomal recessive, type 1A | N/A | N/A |
| 9 | FBP1 | Fructose-1,6-bisphosphatase deficiency | < 1 in 500 | Reduced |
| 6 | FBXL4 | Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type) | N/A | N/A |
| 22 | FBXO7 | Parkinson disease, type 15, autosomal recessive | N/A | N/A |
| 17 | FDXR | Auditory neuropathy and optic atrophy | N/A | N/A |
| 18 | FECH | Protoporphyrin, erythropoietic, autosomal recessive | N/A | N/A |
| 20 | FERMT1 | Kindler syndrome | N/A | N/A |
| 11 | FERMT3 | Leukocyte adhesion deficiency, type 3 | < 1 in 500 | Reduced |
| 7 | FEZF1 | Hypogonadotropic hypogonadism type 22, with or without anosmia | < 1 in 500 | Reduced |
| 4 | FGA | Afibrinogenemia, congenital | N/A | N/A |
| 4 | FGB | Congenital afibrinogenemia | < 1 in 500 | Reduced |
| 12 | FGD4 | Charcot-Marie-Tooth disease, type 4H | N/A | N/A |
| 12 | FGF23 | Tumoral calcinosis, hyperphosphatemic, familial, type 2 | < 1 in 500 | Reduced |
| 11 | FGF3 | Deafness, congenital with inner ear agenesis, microtia, and microdontia | < 1 in 500 | Reduced |
| 4 | FGG | Afibrinogenemia, congenital; Hypofibrinogenemia, congenital | < 1 in 500 | Reduced |
| 1 | FH | Fumarase deficiency | 1 in 500 | 1 in 3333 |

| | | | | |
|----|---------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| 11 | FIBP | Thauvin-Robinet-Faivre syndrome | < 1 in 500 | Reduced |
| 6 | FIG4 | Charcot-Marie-Tooth disease, type 4J; Yunis-Varon syndrome | < 1 in 500 | Reduced |
| 17 | FKBP10 | Bruck syndrome 1 | N/A | N/A |
| 7 | FKBP14 | Ehlers-Danlos syndrome, kyphoscoliotic type, 2 | N/A | N/A |
| 19 | FKRP | Muscular dystrophy-dystroglycanopathy, type 5A (Walker-Warburg syndrome); Type 5B; Type 5C (limb-girdle muscular dystrophy, type 9 [LGMDR9]) | 1 in 176 | 1 in 2514 |
| 9 | FKTN | Muscular dystrophy-dystroglycanopathy, type 4A (Walker-Warburg syndrome); Type 4B; Type 4C (limb-girdle muscular dystrophy, type 13 [LGMD R13]) | < 1 in 500 | Reduced |
| 1 | FLAD1 | Lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency | < 1 in 500 | Reduced |
| 1 | FLG | Ichthyosis vulgaris | N/A | N/A |
| 11 | FLI1 | Bleeding disorder, platelet-type, type 21 | < 1 in 500 | Reduced |
| 3 | FLNB | Spondylocarpotarsal synostosis syndrome | N/A | N/A |
| 1 | FLVCR1 | Posterior column ataxia-retinitis pigmentosa syndrome | N/A | N/A |
| 14 | FLVCR2 | Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome | N/A | N/A |
| 1 | FMN2 | Mental retardation, autosomal recessive, type 47 | N/A | N/A |
| 1 | FMO3 | Trimethylaminuria | 1 in 100 | 1 in 1,000 |
| 11 | FOLR1 | Neurodegeneration due to cerebral folate transport deficiency | < 1 in 500 | Reduced |
| 9 | FOXE1 | Bamforth-Lazarus syndrome | < 1 in 500 | Reduced |
| 1 | FOXE3 | Anterior segment dysgenesis, type 2, multiple subtypes | < 1 in 500 | Reduced |
| 17 | FOXN1 | T-cell immunodeficiency, congenital alopecia and nail dystrophy | < 1 in 500 | Reduced |
| 11 | FOXRED1 | Mitochondrial complex I deficiency, nuclear type 19 | 1 in 439 | 1 in 822 |
| 4 | FRAS1 | Fraser syndrome, type 1 | 1 in 300 | 1 in 576 |
| 9 | FREM1 | Manitoba oculotrichoanal syndrome | N/A | N/A |
| 13 | FREM2 | Fraser syndrome, type 2 | N/A | N/A |
| 9 | FRRS1L | Epileptic encephalopathy, early infantile, 37 | < 1 in 500 | Reduced |
| 11 | FSHB | Hypogonadotropic hypogonadism, type 24, without anosmia | < 1 in 500 | Reduced |
| 2 | FSHR | Ovarian dysgenesis 1;Ovarian hyperstimulation syndrome;Ovarian response to FSH stimulation | N/A | N/A |
| 21 | FTCD | Glutamate formiminotransferase deficiency | 1 in 355 | 1 in 591 |
| 19 | FTL | L-ferritin deficiency | < 1 in 500 | Reduced |
| 16 | FTO | Growth retardation, developmental delay, facial dysmorphism | < 1 in 500 | Reduced |
| 1 | FUCA1 | Fucosidosis | 1 in 1,149 | 1 in 4,880 |
| 14 | FUT8 | Congenital disorder of glycosylation with defective fucosylation, type 1 | < 1 in 500 | Reduced |
| 9 | FXN | Friedreich ataxia | 1 in 91 | 1 in 1,014 |
| 3 | FYCO1 | Cataract 18 | N/A | N/A |
| 8 | FZD6 | Nail disorder, nonsyndromic congenital, type 10 (claw-shaped nails) | < 1 in 500 | Reduced |
| 17 | G6PC1 | Glycogen storage disease, type 1A | 1 in 300 | 1 in 3000 |
| 17 | G6PC3 | Dursun syndrome | < 1 in 500 | <1 in 1,170 |
| 17 | GAA | Glycogen storage disease, type 2 | 1 in 100 | 1 in 500 |
| 14 | GALC | Krabbe disease | 1 in 120 | 1 in 218 |
| 1 | GALE | Galactose epimerase deficiency | < 1 in 500 | Reduced |
| 17 | GALK1 | Galactokinase deficiency with cataracts | 1 in 200 | 1 in 2500 |
| 16 | GALNS | Mucopolysaccharidosis, type 4A | 1 in 311 | 1 in 657 |
| 2 | GALNT3 | Tumoral calcinosis, hyperphosphatemic, familial, type 1 | N/A | N/A |
| 9 | GALT | Galactosemia | 1 in 109 | 1 in 727 |
| 19 | GAMT | Cerebral creatine deficiency syndrome, type 2 | 1 in 500 | 1 in 10000 |
| 16 | GAN | Giant axonal neuropathy, type 1 | < 1 in 500 | Reduced |
| 16 | GAS8 | Ciliary dyskinesia, primary, type 33 | < 1 in 500 | Reduced |
| 15 | GATM | Cerebral creatine deficiency syndrome, type 3 | < 1 in 500 | Reduced |
| 1 | GBA1 | Gaucher Disease, type I-III; GD IIIc; GD, perinatal lethal | 1 in 125 | 1 in 1563 |
| 9 | GBA2 | Spastic paraplegia, type 46, autosomal recessive | N/A | N/A |
| 3 | GBE1 | Glycogen storage disease, type 4 | 1 in 192 | 1 in 960 |
| 19 | GCDH | Glutaricaciduria, type 1 | 1 in 200 | 1 in 4000 |
| 14 | GCH1 | Hyperphenylalaninemia, BH4-deficient, type B | 1 in 250 | 1 in 436 |
| 7 | GCK | Permanent neonatal diabetes mellitus (PNDM) | < 1 in 500 | Reduced |
| 6 | GCM2 | Hypoparathyroidism, familial isolated (FIH) 2 | < 1 in 500 | Reduced |
| 6 | GCNT2 | Cataract 13, with adult i phenotype | N/A | N/A |
| 16 | GCSH | Multiple mitochondrial dysfunctions syndrome 7 | < 1 in 500 | Reduced |
| 8 | GDAP1 | Charcot-Marie-Tooth disease, recessive intermediate, type A | 1 in 130 | 1 in 298 |
| 19 | GDF1 | Right atrial isomerism (Ivemark syndrome) | N/A | N/A |
| 20 | GDF5 | Chondrodysplasia, Grebe type | < 1 in 500 | Reduced |
| 8 | GDF6 | Leber congenital amaurosis, type 17 | < 1 in 500 | Reduced |
| 16 | GFER | Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay | < 1 in 500 | Reduced |
| 3 | GFM1 | Combined oxidative phosphorylation deficiency, type 1 | 1 in 450 | 1 in 1500 |
| 2 | GFPT1 | Myasthenia, congenital, type 12, with tubular aggregates | < 1 in 500 | Reduced |
| 2 | GGCX | Vitamin K-dependent clotting factors, combined deficiency of, type 1 | < 1 in 500 | Reduced |
| 17 | GH1 | Growth hormone deficiency, isolated, type 1A; Kowarski syndrome | < 1 in 500 | Reduced |
| 5 | GHR | Laron dwarfism | N/A | N/A |
| 7 | GHRHR | Growth hormone deficiency, isolated, type 1B | 1 in 50 | 1 in 83 |
| 3 | GHSR | Growth hormone deficiency, isolated partial | < 1 in 500 | Reduced |

| | | | | |
|----|---------|----------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| 20 | GINS1 | Immunodeficiency, type 55 | N/A | N/A |
| 19 | GIPC3 | Deafness, autosomal recessive, type 15 | < 1 in 500 | Reduced |
| 6 | GJA1 | Cranio metaphyseal dysplasia, autosomal recessive | < 1 in 500 | Reduced |
| 13 | GJB2 | Deafness, autosomal recessive, type 1A; Deafness, digenic, GJB2/GJB6 | 1 in 40 | 1 in 500 |
| 13 | GJB6 | Deafness, autosomal recessive, type 1B; Deafness, digenic GJB2/GJB6 | 1 in 421 | 1 in 42,000 |
| 1 | GJC2 | Spastic paraplegia, type 44, autosomal recessive | < 1 in 500 | Reduced |
| 3 | GLB1 | GM1-gangliosidosis, types 1-3; Mucopolysaccharidosis, type 4B (Morquio) | 1 in 277 | 1 in 2770 |
| 9 | GLDC | Glycine encephalopathy | 1 in 180 | 1 in 720 |
| 15 | GLDN | Lethal congenital contracture syndrome 11 | N/A | N/A |
| 9 | GLE1 | Lethal congenital contracture syndrome, type 1; Congenital arthrogyrosis with anterior horn cell disease | 1 in 350 | 1 in 3500 |
| 16 | GLIS2 | Nephronophthisis, type 7 | N/A | N/A |
| 9 | GLIS3 | Diabetes mellitus, neonatal, with congenital hypothyroidism | N/A | N/A |
| 5 | GLRA1 | Hyperekplexia, type 1 | < 1 in 500 | Reduced |
| 4 | GLRB | Hyperekplexia, type 2 | < 1 in 500 | Reduced |
| 14 | GLRX5 | Anemia, sideroblastic, type 3, pyridoxine-refractory; Spasticity, childhood-onset, with hyperglycinemia | < 1 in 500 | Reduced |
| 1 | GLUL | Glutamine deficiency, congenital | < 1 in 500 | Reduced |
| 3 | GLYCK | D-glyceric aciduria | N/A | N/A |
| 5 | GM2A | GM2-gangliosidosis, AB variant | < 1 in 500 | Reduced |
| 2 | GMPPA | Alacrima, achalasia, and mental retardation syndrome | N/A | N/A |
| 3 | GMPPB | Muscular dystrophy-dystroglycanopathy 14 | N/A | N/A |
| 3 | GNAT1 | Night blindness, congenital stationary, type 1G | N/A | N/A |
| 1 | GNAT2 | Achromatopsia, type 4 | N/A | N/A |
| 15 | GNB5 | Intellectual developmental disorder with cardiac arrhythmia; Language delay and ADHD/cognitive impairment with or without cardiac arrhythmia | < 1 in 500 | Reduced |
| 9 | GNE | Inclusion body myopathy, type 2 (Nonaka myopathy) | 1 in 203 | 1 in 4060 |
| 6 | GNMT | Glycine N-methyltransferase deficiency | 1 in 500 | 1 in 24,951 |
| 1 | GNPAT | Rhizomelic chondrodysplasia punctata, type 2 | < 1 in 500 | Reduced |
| 12 | GNPTAB | Mucopolipidosis 2 alpha/beta; Mucopolipidosis 3 alpha/beta | 1 in 176 | 1 in 17,522 |
| 16 | GNPTG | Mucopolipidosis III gamma | < 1 in 500 | Reduced |
| 4 | GNRHR | Hypogonadotropic hypogonadism, type 7, without anosmia | 1 in 500 | 1 in 2,097 |
| 12 | GNS | Mucopolysaccharidosis, type 3D (Sanfilippo syndrome D) | < 1 in 500 | Reduced |
| 1 | GORAB | Geroderma osteodysplasticum | N/A | N/A |
| 17 | GOSR2 | Epilepsy, progressive myoclonic, type 6 | N/A | N/A |
| 16 | GOT2 | Epileptic encephalopathy, early infantile, 82 | < 1 in 500 | Reduced |
| 17 | GP1BA | Bernard-Soulier syndrome, type A1 | < 1 in 500 | Reduced |
| 22 | GP1BB | Bernard-Soulier syndrome, type B | 1 in 500 | 1 in 531 |
| 19 | GP6 | Bleeding disorder, platelet-type, type 11 | N/A | N/A |
| 3 | GP9 | Bernard-Soulier syndrome, type C | 1 in 451 | 1 in 4510 |
| 8 | GPAA1 | Glycosylphosphatidylinositol biosynthesis defect 15 | N/A | N/A |
| 13 | GPC6 | Omodysplasia, type 1 | < 1 in 500 | Reduced |
| 12 | GPD1 | Hypertriglyceridemia, transient infantile | < 1 in 500 | Reduced |
| 14 | GPHN | Molybdenum cofactor deficiency C | < 1 in 500 | Reduced |
| 19 | GPI | Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency | N/A | N/A |
| 8 | GPIHBP1 | Hyperlipoproteinemia, type 1D | < 1 in 500 | Reduced |
| 17 | GPR179 | Night blindness, congenital stationary (complete), type 1E, autosomal recessive | < 1 in 500 | Reduced |
| 14 | GPR68 | Amelogenesis imperfecta, type 2A6 (hypomaturation type) | < 1 in 500 | Reduced |
| 1 | GPSM2 | Chudley-McCullough syndrome | N/A | N/A |
| 16 | GPT2 | Mental retardation, autosomal recessive 49 | < 1 in 500 | Reduced |
| 19 | GPX4 | Spondylometaphyseal dysplasia, Sedaghatian type | < 1 in 500 | Reduced |
| 8 | GRHL2 | Ectodermal dysplasia/short stature syndrome | < 1 in 500 | Reduced |
| 9 | GRHPR | Hyperoxaluria, primary, type 2 | 1 in 433 | 1 in 21650 |
| 4 | GRID2 | Spinocerebellar ataxia, autosomal recessive, type 18 | < 1 in 500 | Reduced |
| 6 | GRIK2 | Mental retardation, autosomal recessive, type, 6 | < 1 in 500 | Reduced |
| 9 | GRIN1 | Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal recessive | < 1 in 500 | Reduced |
| 12 | GRIP1 | Fraser syndrome 3 | 1 in 224 | 1 in 2,236 |
| 13 | GRK1 | Oguchi disease-2 | N/A | N/A |
| 6 | GRM1 | Spinocerebellar ataxia, autosomal recessive, type 13 | < 1 in 500 | Reduced |
| 5 | GRM6 | Night blindness, congenital stationary (complete), type 1B, autosomal recessive | < 1 in 500 | Reduced |
| 17 | GRN | Ceroid lipofuscinosis, neuronal, type 11 | N/A | N/A |
| 4 | GRXCR1 | Deafness, autosomal recessive, type 25 | N/A | N/A |
| 14 | GSC | Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities | < 1 in 500 | Reduced |
| 20 | GSS | Glutathione synthetase deficiency | < 1 in 500 | Reduced |
| 6 | GTF2H5 | Trichothiodystrophy, type 3, photosensitive | < 1 in 500 | Reduced |
| 6 | GTPBP2 | Jaberi-Elahi syndrome | < 1 in 500 | Reduced |
| 19 | GTPBP3 | Combined oxidative phosphorylation deficiency 23 | < 1 in 500 | Reduced |
| 12 | GUCY2C | Meconium ileus | N/A | N/A |
| 17 | GUCY2D | Leber congenital amaurosis, type 1 | 1 in 248 | 1 in 305 |
| 4 | GUF1 | ?Epileptic encephalopathy, early infantile, 40 | N/A | N/A |
| 7 | GUSB | Mucopolysaccharidosis, type 7 | 1 in 552 | 1 in 1,6531 |

| | | | | |
|----|---------|-----------------------------------------------------------------------------------------------------------|------------|-------------|
| 3 | GYG1 | Polyglucosan body myopathy, type 2 | N/A | N/A |
| 19 | GYS1 | Glycogen storage disease, type 0, muscle | < 1 in 500 | Reduced |
| 12 | GYS2 | Glycogen storage disease, type 0, liver | N/A | N/A |
| 20 | GZF1 | Joint laxity, short stature, and myopia | < 1 in 500 | Reduced |
| 1 | H6PD | Cortisone reductase deficiency 1 | N/A | N/A |
| 2 | HAO | Vertebral, cardiac, renal, and limb defects syndrome 1 | < 1 in 500 | Reduced |
| 6 | HACE1 | Spastic paraplegia and psychomotor retardation with or without seizures | < 1 in 500 | Reduced |
| 4 | HADH | 3-hydroxyacyl-CoA dehydrogenase deficiency | 1 in 415 | 1 in 622 |
| 2 | HADHA | Long-chain 3-hydroxy-CoA dehydrogenase (LCHAD) deficiency; Mitochondrial trifunctional protein deficiency | 1 in 250 | 1 in 5000 |
| 2 | HADHB | Mitochondrial trifunctional protein deficiency | < 1 in 500 | Reduced |
| 19 | HAMP | Hemochromatosis, type 2B | < 1 in 500 | Reduced |
| 5 | HARS1 | Usher syndrome, type 3B | N/A | N/A |
| 1 | HAX1 | Neutropenia, severe congenital, type 3, autosomal recessive | 1 in 219 | 1 in 2190 |
| 16 | HBA1 | Alpha thalassemia | 1 in 30 | 1 in 200 |
| 16 | HBA2 | Alpha thalassemia | 1 in 30 | 1 in 200 |
| 11 | HBB | HBB-related hemoglobinopathies | 1 in 67 | 1 in 670 |
| 10 | HELLS | Immunodeficiency-centromeric instability-facial anomalies syndrome 4 | < 1 in 500 | Reduced |
| 11 | HEPACAM | Megalencephalic leukoencephalopathy with subcortical cysts 2A | N/A | N/A |
| 15 | HERC1 | Macrocephaly, dysmorphic faces, and psychomotor retardation | < 1 in 500 | Reduced |
| 15 | HERC2 | Mental retardation, autosomal recessive, type 38 | N/A | N/A |
| 17 | HES7 | Spondylocostal dysostosis, type 4, autosomal recessive | < 1 in 500 | Reduced |
| 3 | HESX1 | Growth hormone deficiency with pituitary anomalies | < 1 in 500 | Reduced |
| 15 | HEXA | Tay-Sachs disease | 1 in 250 | 1 in 1250 |
| 5 | HEXB | Sandhoff disease, infantile, juvenile, and adult forms | 1 in 202 | 1 in 1347 |
| 6 | HFE | Hemochromatosis, type 1 | 1 in 10 | 1 in 200 |
| 1 | HFM1 | Premature ovarian failure 9 | N/A | N/A |
| 3 | HGD | Alkaptonuria | 1 in 250 | 1 in 2500 |
| 7 | HGF | Deafness, autosomal recessive, type 39 | < 1 in 500 | Reduced |
| 8 | HGSNAT | Mucopolysaccharidosis type 3C (Sanfilippo syndrome C) | 1 in 345 | 1 in 4313 |
| 2 | HIBCH | 3-hydroxyisobutryl-CoA hydrolase deficiency | N/A | N/A |
| 11 | HIKESHI | Leukodystrophy, hypomyelinating, type 13 | < 1 in 500 | Reduced |
| 5 | HINT1 | Neuromyotonia and axonal neuropathy, autosomal recessive | N/A | N/A |
| 1 | HJV | Hemochromatosis, type 2A | < 1 in 500 | Reduced |
| 10 | HK1 | Charcot-Marie-Tooth disease, type 4G | N/A | N/A |
| 21 | HLCS | Holocarboxylase synthetase deficiency | 1 in 300 | 1 in 3000 |
| 1 | HMGCL | HMG-CoA lyase deficiency | < 1 in 500 | Reduced |
| 1 | HMGCS2 | HMG-CoA synthase-2 deficiency | N/A | N/A |
| 22 | HMOX1 | Heme oxygenase-1 deficiency | 1 in 500 | N/A |
| 4 | HMX1 | Oculoauricular syndrome | < 1 in 500 | Reduced |
| 2 | HNMT | Mental retardation, autosomal recessive, type 51 | < 1 in 500 | Reduced |
| 10 | HOGA1 | Hyperoxaluria, primary, type 3 | 1 in 169 | 1 in 3380 |
| 7 | HOXA1 | Athabaskan brainstem dysgenesis syndrome | < 1 in 500 | Reduced |
| 17 | HOXB1 | Facial paresis, hereditary congenital, 3 | < 1 in 500 | Reduced |
| 12 | HOXC13 | Ectodermal dysplasia 9, hair/nail type | N/A | N/A |
| 1 | HPCA | Dystonia 2, torsion, autosomal recessive | < 1 in 500 | Reduced |
| 12 | HPD | Tyrosinemia, type 3 | < 1 in 500 | Reduced |
| 4 | HPGD | Hypertrophic osteoarthropathy, primary, type 1 (pachydermoperiostosis) | N/A | N/A |
| 10 | HPS1 | Hermansky-Pudlak syndrome, type 1 | 1 in 493 | 1 in 4930 |
| 3 | HPS3 | Hermansky-Pudlak syndrome, type 3 | 1 in 300 | 1 in 375 |
| 22 | HPS4 | Hermansky-Pudlak syndrome, type 4 | N/A | N/A |
| 11 | HPS5 | Hermansky-Pudlak syndrome, type 5 | N/A | N/A |
| 10 | HPS6 | Hermansky-Pudlak syndrome, type 6 | N/A | N/A |
| 10 | HPSE2 | Urofacial syndrome, type 1 | N/A | N/A |
| 8 | HR | Alopecia universalis; Atrichia with papular lesions | N/A | N/A |
| 16 | HSD11B2 | Apparent mineralocorticoid excess | < 1 in 500 | Reduced |
| 9 | HSD17B3 | 46,XY disorder of sex development due to 17-beta-hydroxysteroid dehydrogenase 3 deficiency | < 1 in 500 | <1 in 2,750 |
| 5 | HSD17B4 | D-bifunctional protein deficiency | 1 in 534 | 1 in 13350 |
| 1 | HSD3B2 | Adrenal hyperplasia, congenital, due to 3-beta-hydroxysteroid dehydrogenase 2 deficiency | 1 in 862 | 1 in 8620 |
| 16 | HSD3B7 | Bile acid synthesis defect, congenital, type 1 | < 1 in 500 | Reduced |
| 5 | HSPA9 | Even-plus syndrome | < 1 in 500 | Reduced |
| 2 | HSPD1 | Leukodystrophy, hypomyelinating, type 4 | < 1 in 500 | Reduced |
| 1 | HSPG2 | Schwartz-Jampel syndrome, type 1; Dyssegmental dysplasia, Silverman-Handmaker type | < 1 in 500 | <1 in 1,625 |
| 10 | HTRA1 | CARASIL syndrome | N/A | N/A |
| 2 | HTRA2 | 3-methylglutaconic aciduria, type 8 | < 1 in 500 | Reduced |
| 3 | HYAL1 | ?Mucopolysaccharidosis, type 9 | < 1 in 500 | Reduced |
| 7 | HYCC1 | Leukodystrophy, hypomyelinating, type 5 | < 1 in 500 | Reduced |
| 16 | HYDIN | Ciliary dyskinesia, primary, type 5 | N/A | N/A |
| 11 | HYLS1 | Hydrolethals syndrome | 1 in 500 | 1 in 714 |

| | | | | |
|----|---------|---------------------------------------------------------------------------------------------|------------|-------------|
| 9 | IARS1 | Growth retardation, intellectual developmental disorder, hypotonia, and hepatopathy | N/A | N/A |
| 1 | IBA57 | Multiple mitochondrial dysfunctions syndrome 3 | < 1 in 500 | Reduced |
| 2 | ICOS | Immunodeficiency, common variable, 1 | < 1 in 500 | Reduced |
| 20 | IDH3B | Retinitis pigmentosa, type 46 | 1 in 500 | 1 in 999 |
| 4 | IDUA | Mucopolysaccharidosis type 1 | 1 in 153 | 1 in 2186 |
| 18 | IER3IP1 | Microcephaly, epilepsy, and diabetes syndrome | < 1 in 500 | Reduced |
| 6 | IFNGR1 | Immunodeficiency, type 27A, mycobacteriosis | < 1 in 500 | Reduced |
| 21 | IFNGR2 | Immunodeficiency, type 28, mycobacteriosis | < 1 in 500 | Reduced |
| 3 | IFT122 | Cranioectodermal dysplasia 1 | N/A | N/A |
| 16 | IFT140 | Retinitis pigmentosa, type 80; Short-rib thoracic dysplasia 9 with or without polydactyly | N/A | N/A |
| 2 | IFT172 | Short-rib thoracic dysplasia 10 with or without polydactyly | N/A | N/A |
| 14 | IFT43 | Short-rib thoracic dysplasia 18 with polydactyly | N/A | N/A |
| 20 | IFT52 | Short-rib thoracic dysplasia 16 with or without polydactyly | < 1 in 500 | Reduced |
| 3 | IFT80 | Short-rib thoracic dysplasia, type 2, with or without polydactyly | N/A | N/A |
| 12 | IFT81 | Short-rib thoracic dysplasia 19 with or without polydactyly | N/A | N/A |
| 12 | IGF1 | Growth retardation with deafness and mental retardation due to IGF1 deficiency | < 1 in 500 | Reduced |
| 15 | IGF1R | Insulin-like growth factor I, resistance to | < 1 in 500 | Reduced |
| 16 | IGFALS | Acid-labile subunit deficiency | N/A | N/A |
| 4 | IGFBP7 | Retinal arterial macroaneurysm with supravalvular pulmonic stenosis | < 1 in 500 | Reduced |
| 11 | IGHMBP2 | Charcot-Marie-Tooth disease, axonal, type 25 | < 1 in 500 | <1 in 4,000 |
| 22 | IGLL1 | Agammaglobulinemia 2 | < 1 in 500 | Reduced |
| 2 | IHH | Acrocapitofemoral dysplasia | < 1 in 500 | Reduced |
| 8 | IKBKB | Immunodeficiency, type 15 | < 1 in 500 | Reduced |
| 11 | IL10RA | Inflammatory bowel disease, type 28, early onset, autosomal recessive | < 1 in 500 | Reduced |
| 21 | IL10RB | Inflammatory bowel disease, type 25, early onset, autosomal recessive | < 1 in 500 | Reduced |
| 9 | IL11RA | Craniosynostosis and dental anomalies | N/A | N/A |
| 5 | IL12B | Immunodeficiency, type 29, mycobacteriosis | < 1 in 500 | Reduced |
| 19 | IL12RB1 | Immunodeficiency, type 30 | N/A | N/A |
| 22 | IL17RA | Immunodeficiency, type 51 | < 1 in 500 | Reduced |
| 3 | IL17RC | Candidiasis, familial, 9 | N/A | N/A |
| 2 | IL1RN | Sterile multifocal osteomyelitis with periostitis and pustulosis | < 1 in 500 | Reduced |
| 16 | IL21R | Immunodeficiency, type 56 | < 1 in 500 | Reduced |
| 10 | IL2RA | Immunodeficiency, type 41, with lymphoproliferation and autoimmunity | < 1 in 500 | Reduced |
| 2 | IL36RN | Psoriasis, type 14, pustular | < 1 in 500 | Reduced |
| 5 | IL7R | Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type | N/A | N/A |
| 3 | ILDR1 | Deafness, autosomal recessive, type 42 | N/A | N/A |
| 8 | IMPA1 | Mental retardation, autosomal recessive 59 | < 1 in 500 | Reduced |
| 3 | IMPG2 | Retinitis pigmentosa, type 56 | N/A | N/A |
| 9 | INPP5E | Joubert syndrome, type 1 | < 1 in 500 | Reduced |
| 17 | INPP5K | Muscular dystrophy, congenital, with cataracts and intellectual disability | N/A | N/A |
| 11 | INPPL1 | Opsismodysplasia | N/A | N/A |
| 11 | INS | Permanent neonatal diabetes mellitus (PNDM) | < 1 in 500 | Reduced |
| 19 | INSR | Diabetes mellitus, insulin-resistant, with acanthosis nigricans, type A | < 1 in 500 | Reduced |
| 7 | INTS1 | Neurodevelopmental disorder with cataracts, poor growth, and dysmorphic facies | N/A | N/A |
| 9 | INVS | Nephronophthisis, type 2, infantile | N/A | N/A |
| 3 | IQCB1 | Senior-Loken syndrome, type 5 | N/A | N/A |
| 7 | IQCE | Polydactyly, postaxial, type A7 | N/A | N/A |
| 12 | IRAK4 | Immunodeficiency, type 67 (IRAK4 deficiency) | N/A | N/A |
| 16 | IRF8 | Immunodeficiency, type 32B, monocyte and dendritic cell deficiency | < 1 in 500 | Reduced |
| 16 | IRX5 | Hamamy syndrome | < 1 in 500 | Reduced |
| 9 | ISCA1 | Multiple mitochondrial dysfunctions syndrome 5 | < 1 in 500 | Reduced |
| 14 | ISCA2 | Multiple mitochondrial dysfunctions syndrome 4 | < 1 in 500 | Reduced |
| 12 | ISCU | Myopathy with lactic acidosis, hereditary | < 1 in 500 | Reduced |
| 1 | ISG15 | Immunodeficiency, type 38 | < 1 in 500 | Reduced |
| 20 | ITCH | Autoimmune disease, multisystem, with facial dysmorphism | < 1 in 500 | Reduced |
| 17 | ITGA2B | Glanzmann thrombasthenia | N/A | N/A |
| 17 | ITGA3 | Interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital | N/A | N/A |
| 2 | ITGA6 | Epidermolysis bullosa, junctional, with pyloric stenosis | N/A | N/A |
| 12 | ITGA7 | Muscular dystrophy, congenital, due to ITGA7 deficiency | N/A | N/A |
| 10 | ITGA8 | Renal hypodysplasia/aplasia 1 | N/A | N/A |
| 21 | ITGB2 | Leukocyte adhesion deficiency | < 1 in 500 | Reduced |
| 17 | ITGB3 | Glanzmann thrombasthenia | N/A | N/A |
| 17 | ITGB4 | Epidermolysis bullosa, junctional, with pyloric atresia | < 1 in 500 | Reduced |
| 2 | ITGB6 | Amelogenesis imperfecta, type 1H | N/A | N/A |
| 5 | ITK | Lymphoproliferative syndrome 1 | < 1 in 500 | Reduced |
| 20 | ITPA | Epileptic encephalopathy, early infantile, type 35 | < 1 in 500 | Reduced |
| 3 | ITPR1 | Gillespie syndrome | N/A | N/A |
| 15 | IVD | Isovaleric acidemia | 1 in 115 | 1 in 1917 |

| | | | | |
|----|----------|-----------------------------------------------------------------------------------------------------------------|------------|------------|
| 6 | IYD | Thyroid dysmorphogenesis, type 4 | 1 in 159 | 1 in 633 |
| 3 | JAGN1 | Neutropenia, severe congenital, 6, autosomal recessive | < 1 in 500 | Reduced |
| 19 | JAK3 | Severe Combined Immunodeficiency, autosomal recessive, T-negative/B-positive type | 1 in 475 | 1 in 732 |
| 11 | JAM3 | Hemorrhagic destruction of the brain, subependymal calcification, and cataracts | < 1 in 500 | Reduced |
| 17 | JUP | Naxos disease | < 1 in 500 | Reduced |
| 19 | KANK2 | Nephrotic syndrome, type 16 | < 1 in 500 | Reduced |
| 16 | KARS1 | Deafness, autosomal recessive, type 89 | N/A | N/A |
| 16 | KATNB1 | Lissencephaly 6, with microcephaly | N/A | N/A |
| 16 | KATNIP | Joubert syndrome 26 | N/A | N/A |
| 21 | KCNE1 | Jervell and Lange-Nielsen syndrome 2 | < 1 in 500 | Reduced |
| 11 | KCNJ1 | Barter syndrome, type 2 | < 1 in 500 | Reduced |
| 1 | KCNJ10 | SESAME syndrome | N/A | N/A |
| 11 | KCNJ11 | Hyperinsulinemic hypoglycemia, type 2 (congenital hyperinsulinism); Permanent neonatal diabetes mellitus (PNDM) | 1 in 232 | 1 in 4640 |
| 2 | KCNJ13 | Leber congenital amaurosis, type 16 | < 1 in 500 | Reduced |
| 9 | KCNV2 | Retinal cone dystrophy, type 3B | < 1 in 500 | Reduced |
| 7 | KCTD7 | Epilepsy, progressive myoclonic, type 3, with or without intracellular inclusions | < 1 in 500 | Reduced |
| 18 | KDSR | Erythrokeratoderma variabilis et progressiva 4 | < 1 in 500 | Reduced |
| 12 | KERA | Cornea plana 2, autosomal recessive | N/A | N/A |
| 6 | KHDC3L | Hydatidiform mole, recurrent, type 2 | < 1 in 500 | Reduced |
| 14 | KIAA0586 | Short-rib thoracic dysplasia 14 with polydactyly | N/A | N/A |
| 17 | KIAA0753 | ?Orofaciodigital syndrome, type 15 | N/A | N/A |
| 7 | KIAA1549 | Retinitis pigmentosa, type 86 | N/A | N/A |
| 1 | KIF14 | Microcephaly 20, primary, autosomal recessive; ?Meckel syndrome 12 | N/A | N/A |
| 2 | KIF1A | Neuropathy, hereditary sensory, type 2C; Spastic paraplegia, type 30, autosomal recessive | N/A | N/A |
| 17 | KIF1C | Spastic ataxia 2, autosomal recessive | N/A | N/A |
| 15 | KIF7 | Acrocallosal syndrome; Joubert syndrome, type 12 | N/A | N/A |
| 10 | KIFBP | Goldberg-Shprintzen megacolon syndrome | < 1 in 500 | Reduced |
| 19 | KISS1R | Hypogonadotropic hypogonadism, type 8, with or without anosmia | N/A | N/A |
| 20 | KIZ | Retinitis pigmentosa 69 | N/A | N/A |
| 5 | KLHL3 | Pseudohypoadosteronism, type 2D | N/A | N/A |
| 3 | KLHL40 | Nemaline myopathy 8, autosomal recessive | N/A | N/A |
| 2 | KLHL41 | Nemaline myopathy 9 | N/A | N/A |
| 7 | KLHL7 | Cold-induced sweating syndrome 3 | < 1 in 500 | Reduced |
| 19 | KLK4 | Amelogenesis imperfecta, type 2A1 (hypomaturation type) | < 1 in 500 | Reduced |
| 4 | KLKB1 | Fletcher factor (prekallikrein) deficiency | N/A | N/A |
| 15 | KNL1 | Microcephaly 4, primary, autosomal recessive | < 1 in 500 | Reduced |
| 19 | KPTN | Mental retardation, autosomal recessive 41 | N/A | N/A |
| 22 | KREMEN1 | Ectodermal dysplasia 13, hair/tooth type | < 1 in 500 | Reduced |
| 17 | KRT10 | Epidermolytic hyperkeratosis | N/A | N/A |
| 17 | KRT14 | Epidermolysis bullosa simplex, autosomal recessive, type 1 | < 1 in 500 | Reduced |
| 17 | KRT25 | Woolly hair, autosomal recessive 3 | < 1 in 500 | Reduced |
| 12 | KRT5 | Epidermolysis bullosa simplex, autosomal recessive, type 1 | < 1 in 500 | Reduced |
| 12 | KRT85 | Ectodermal dysplasia 4, hair/nail type | N/A | N/A |
| 3 | KY | Myopathy, myofibrillar, type 7 | < 1 in 500 | Reduced |
| 2 | KYNU | Vertebral, cardiac, renal, and limb defects syndrome, type 2 | N/A | N/A |
| 14 | L2HGDH | L-2-hydroxyglutaric aciduria | < 1 in 500 | Reduced |
| 18 | LAMA1 | Poretti-Boltshauser syndrome | N/A | N/A |
| 6 | LAMA2 | LAMA2-related muscular dystrophy | 1 in 125 | 1 in 625 |
| 18 | LAMA3 | Junctional epidermolysis bullosa (JEB) Herlitz type; JEB non-Herlitz type | < 1 in 500 | Reduced |
| 7 | LAMB1 | Lissencephaly, type 5 | N/A | N/A |
| 3 | LAMB2 | Pierson syndrome; Nephrotic syndrome, type 5, with or without ocular abnormalities | N/A | N/A |
| 1 | LAMB3 | Junctional epidermolysis bullosa (JEB) Herlitz type; JEB non-Herlitz type | 1 in 222 | 1 in 11100 |
| 1 | LAMC2 | Junctional epidermolysis bullosa (JEB) Herlitz type; JEB non-Herlitz type | < 1 in 500 | Reduced |
| 9 | LAMC3 | Cortical malformations, occipital | N/A | N/A |
| 22 | LARGE1 | Muscular dystrophy-dystroglycanopathy, type 6A and 6B | 1 in 123 | 1 in 287 |
| 4 | LARP7 | Alazami syndrome | N/A | N/A |
| 5 | LARS1 | ?Infantile liver failure syndrome 1 (ILFS1) | N/A | N/A |
| 3 | LARS2 | Perrault syndrome, type 4 | N/A | N/A |
| 16 | LAT | Immunodeficiency, type 52 | < 1 in 500 | Reduced |
| 1 | LBR | Greenberg skeletal dysplasia | N/A | N/A |
| 6 | LCAS | Leber congenital amaurosis, type 5 | < 1 in 500 | Reduced |
| 16 | LCAT | Familial LCAT deficiency; Fish-eye disease | N/A | N/A |
| 1 | LCK | ?Immunodeficiency, type 22 | N/A | N/A |
| 2 | LCT | Lactase deficiency, congenital | N/A | N/A |
| 11 | LDHA | Glycogen storage disease type 11 | < 1 in 500 | Reduced |
| 19 | LDLR | Hypercholesterolemia, familial, type 1 | N/A | N/A |
| 1 | LDLRAP1 | Hypercholesterolemia, familial, autosomal recessive | < 1 in 500 | Reduced |
| 6 | LEMD2 | Cataract 46, juvenile-onset | < 1 in 500 | Reduced |

| | | | | |
|----|----------|---------------------------------------------------------------------------------------------------|------------|-------------|
| 7 | LEP | Obesity, morbid, due to leptin deficiency | < 1 in 500 | Reduced |
| 1 | LEPR | Obesity, morbid, due to leptin receptor deficiency | N/A | N/A |
| 19 | LGI4 | Arthrogyriosis multiplex congenita, neurogenic, with myelin defect | < 1 in 500 | Reduced |
| 19 | LHB | Hypogonadotropic hypogonadism, type 23, with or without anosmia | < 1 in 500 | Reduced |
| 2 | LHCGR | Leydig cell hypoplasia | < 1 in 500 | <1 in 1,060 |
| 6 | LHFPL5 | Deafness, autosomal recessive, type 67 | < 1 in 500 | Reduced |
| 9 | LHX3 | Pituitary hormone deficiency, combined, type 3 | 1 in 1,398 | 1 in 13980 |
| 4 | LIAS | Hyperglycinemia, lactic acidosis, and seizures | < 1 in 500 | Reduced |
| 5 | LIFR | Stuve-Wiedemann syndrome / Schwartz-Jampel type 2 syndrome | < 1 in 500 | Reduced |
| 13 | LIG4 | LIG4 syndrome | N/A | N/A |
| 19 | LIM2 | Cataract 19, multiple types | < 1 in 500 | Reduced |
| 15 | LINS1 | Mental retardation, autosomal recessive, type 27 | N/A | N/A |
| 10 | LIPA | Lysosomal acid lipase deficiency | 1 in 112 | 1 in 2240 |
| 19 | LIPE | Lipodystrophy, familial partial, type 6 | N/A | N/A |
| 3 | LIPH | Hypotrichosis, type 7 or woolly hair, autosomal recessive, type 2, with or without hypotrichosis | 1 in 500 | 1 in 2,995 |
| 10 | LIPN | Ichthyosis, congenital, autosomal recessive 8 | < 1 in 500 | Reduced |
| 2 | LIPT1 | Lipoyltransferase 1 deficiency | N/A | N/A |
| 11 | LIPT2 | Encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities | N/A | N/A |
| 18 | LMAN1 | Combined deficiency of factor V and factor VIII, type 1 | < 1 in 500 | Reduced |
| 6 | LMBRD1 | Methylmalonic aciduria and homocystinuria, cblF type | 1 in 414 | 1 in 552 |
| 16 | LMF1 | Lipase deficiency, combined | N/A | N/A |
| 3 | LMOD3 | Nemaline myopathy 10 | < 1 in 500 | Reduced |
| 19 | LONP1 | CODAS syndrome | N/A | N/A |
| 18 | LOXHD1 | Deafness, autosomal recessive, type 77 | 1 in 150 | 1 in 1500 |
| 13 | LPAR6 | Hypotrichosis, type 8 or woolly hair, autosomal recessive, type 1, with or without hypotrichosis | < 1 in 500 | Reduced |
| 2 | LPIN1 | Myoglobinuria, acute recurrent, autosomal recessive | N/A | N/A |
| 18 | LPIN2 | Majeed syndrome | N/A | N/A |
| 8 | LPL | Lipoprotein lipase deficiency | 1 in 374 | 1 in 3740 |
| 4 | LRAT | Leber congenital amaurosis type 14 | < 1 in 500 | Reduced |
| 4 | LRBA | Immunodeficiency, common variable, 8, with autoimmunity | N/A | N/A |
| 1 | LRIG2 | Urofacial syndrome 2 | N/A | N/A |
| 4 | LRIT3 | Night blindness, congenital stationary (complete), 1F, autosomal recessive | < 1 in 500 | Reduced |
| 10 | LRMDA | Albinism, oculocutaneous, type 7 | N/A | N/A |
| 2 | LRP2 | Donnai-Barrow syndrome | < 1 in 500 | Reduced |
| 11 | LRP4 | Cenani-Lenz syndactyly syndrome | N/A | N/A |
| 11 | LRP5 | Osteoporosis-pseudoglioma syndrome | < 1 in 500 | Reduced |
| 4 | LRPAP1 | Myopia, type 23, autosomal recessive | < 1 in 500 | Reduced |
| 2 | LRPPRC | Leigh syndrome, French-Canadian type | < 1 in 500 | Reduced |
| 9 | LRSAM1 | Charcot-Marie-Tooth disease, axonal, type 2P | < 1 in 500 | Reduced |
| 11 | LRTOMT | Deafness, autosomal recessive, type 63 | < 1 in 500 | Reduced |
| 21 | LSS | Alopecia-intellectual disability syndrome 4; Cataract 44; Hypotrichosis 14 | N/A | N/A |
| 14 | LTBP2 | Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma | N/A | N/A |
| 11 | LTBP3 | Dental anomalies and short stature | N/A | N/A |
| 19 | LTBP4 | Cutis laxa, autosomal recessive, type 1C | N/A | N/A |
| 5 | LYRM7 | Mitochondrial complex III deficiency, nuclear type 8 | < 1 in 500 | Reduced |
| 1 | LYST | Chediak-Higashi syndrome | < 1 in 500 | Reduced |
| 3 | LZTFL1 | Bardet-Biedl syndrome, type 17 | < 1 in 500 | Reduced |
| 22 | LZTR1 | Noonan syndrome, type 2 | N/A | N/A |
| 19 | MAG | Spastic paraplegia, type 75, autosomal recessive | < 1 in 500 | Reduced |
| 7 | MAGI2 | Nephrotic syndrome, type 15 | < 1 in 500 | Reduced |
| 6 | MAK | Retinitis pigmentosa type 62 | N/A | N/A |
| 18 | MALT1 | Immunodeficiency, type 12 | < 1 in 500 | Reduced |
| 9 | MAN1B1 | Mental retardation, autosomal recessive, type 15 | N/A | N/A |
| 19 | MAN2B1 | Alpha-mannosidosis | 1 in 274 | 1 in 5480 |
| 4 | MANBA | Mannosidosis, beta | < 1 in 500 | Reduced |
| 2 | MAP3K20 | Centronuclear myopathy, type 6, with fiber-type disproportion | N/A | N/A |
| 15 | MAPKBP1 | Nephronophthisis 20 | N/A | N/A |
| 17 | MAPT | Supranuclear palsy, progressive atypical (parkinsonism syndrome) | N/A | N/A |
| 12 | MARS1 | Interstitial lung and liver disease | N/A | N/A |
| 2 | MARS2 | Spastic ataxia, type 3, autosomal recessive | < 1 in 500 | Reduced |
| 5 | MARVELD2 | Deafness, autosomal recessive, type 49 | N/A | N/A |
| 3 | MASP1 | 3MC syndrome 1 | N/A | N/A |
| 10 | MAT1A | Methionine adenosyltransferase deficiency, autosomal recessive | < 1 in 500 | Reduced |
| 2 | MATN3 | ?Spondyloepimetaphyseal dysplasia | < 1 in 500 | Reduced |
| 19 | MBOAT7 | Mental retardation, autosomal recessive 57 | < 1 in 500 | Reduced |
| 18 | MC2R | Glucocorticoid deficiency, due to ACTH unresponsiveness | N/A | N/A |
| 3 | MCCC1 | 3-Methylcrotonyl-CoA carboxylase deficiency, type 1 | 1 in 353 | 1 in 7060 |
| 5 | MCCC2 | 3-Methylcrotonyl-CoA carboxylase deficiency, type 2 | 1 in 204 | 1 in 4080 |

| | | | | |
|----|---------|-------------------------------------------------------------------------------------------------------------|------------|-------------|
| 2 | MCEE | Methylmalonyl-CoA epimerase deficiency | 1 in 500 | 1 in 50,000 |
| 2 | MCFD2 | Combined deficiency of factor V and factor VIII, type 2 | N/A | N/A |
| 5 | MCIDAS | Ciliary dyskinesia, primary, type 42 | < 1 in 500 | Reduced |
| 21 | MCM3AP | Peripheral neuropathy, autosomal recessive, with or without impaired intellectual development | N/A | N/A |
| 8 | MCM4 | Immunodeficiency, type 54 | < 1 in 500 | Reduced |
| 6 | MCM9 | Ovarian dysgenesis 4 | N/A | N/A |
| 19 | MCOLN1 | Mucopolidosis type 4 | 1 in 1,166 | 1 in 4,850 |
| 8 | MCPH1 | Microcephaly type 1, primary, autosomal recessive | 1 in 500 | 1 in 8,333 |
| 7 | MDH2 | Epileptic encephalopathy, early infantile, 51 | < 1 in 500 | Reduced |
| 1 | MECR | Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities | < 1 in 500 | Reduced |
| 11 | MED17 | Microcephaly, postnatal progressive, with seizures and brain atrophy | < 1 in 500 | Reduced |
| 6 | MED23 | Mental retardation, autosomal recessive, type 18 | N/A | N/A |
| 19 | MED25 | Basel-Vanagait-Smirin-Yosef syndrome | < 1 in 500 | Reduced |
| 16 | MEFV | Familial Mediterranean fever | 1 in 40 | 1 in 133 |
| 5 | MEGF10 | Myopathy, areflexia, respiratory distress, and dysphagia, early-onset | N/A | N/A |
| 19 | MEGF8 | Carpenter syndrome, type 2 | N/A | N/A |
| 17 | MEOX1 | Klippel-Feil syndrome 2 | < 1 in 500 | Reduced |
| 2 | MERTK | Retinitis pigmentosa type 38 | 1 in 500 | 1 in 2500 |
| 15 | MESP2 | Spondylocostal dysostosis, type 2, autosomal recessive | 1 in 500 | 1 in 50000 |
| 17 | METTL23 | Mental retardation, autosomal recessive 44 | < 1 in 500 | Reduced |
| 2 | MFF | Encephalopathy due to defective mitochondrial and peroxisomal fission, type 2 | < 1 in 500 | Reduced |
| 1 | MFN2 | Charcot-Marie-Tooth disease, axonal, type 2A2B | N/A | N/A |
| 11 | MFRP | Microphthalmia, isolated type 5 | 1 in 250 | 1 in 1667 |
| 1 | MFSD2A | Microcephaly 15, primary, autosomal recessive | < 1 in 500 | Reduced |
| 4 | MFSD8 | Ceroid lipofuscinosis, neuronal, type 7 | 1 in 300 | 1 in 3000 |
| 14 | MGAT2 | Congenital disorder of glycosylation, type 2a | < 1 in 500 | Reduced |
| 20 | MGME1 | Mitochondrial DNA depletion syndrome 11 | < 1 in 500 | Reduced |
| 12 | MGP | Keutel syndrome | < 1 in 500 | Reduced |
| 10 | MICU1 | Myopathy with extrapyramidal signs | N/A | N/A |
| 13 | MIPPEP | Combined oxidative phosphorylation deficiency 31 | N/A | N/A |
| 3 | MITF | COMMAD syndrome | N/A | N/A |
| 20 | MKKS | Bardet-Biedl syndrome type 6 | < 1 in 500 | Reduced |
| 17 | MKS1 | Bardet-Biedl syndrome type 13; Meckel syndrome, type 1; Joubert syndrome, type 28 | 1 in 246 | 1 in 2460 |
| 22 | MLC1 | Megalencephalic leukoencephalopathy with subcortical cysts | < 1 in 500 | Reduced |
| 2 | MLPH | Griscelli syndrome, type 3 | < 1 in 500 | Reduced |
| 16 | MLYCD | Malonyl-CoA decarboxylase deficiency | 1 in 500 | 1 in 1,000 |
| 4 | MMAA | Methylmalonic aciduria, vitamin B12-responsive | 1 in 677 | 1 in 4513 |
| 12 | MMAB | Methylmalonic aciduria, vitamin B12-responsive, type cblB | < 1 in 500 | Reduced |
| 1 | MMACHC | Methylmalonic aciduria and homocystinuria, cblC type | 1 in 170 | 1 in 2429 |
| 2 | MMADHC | Homocystinuria, cblD type, variant 1 | < 1 in 500 | Reduced |
| 3 | MME | Charcot-Marie-Tooth disease, axonal, type 2T | N/A | N/A |
| 11 | MMP13 | Metaphyseal dysplasia, Spahr type | N/A | N/A |
| 16 | MMP2 | Multicentric osteolysis, nodulosis, and arthropathy (MONA) | < 1 in 500 | Reduced |
| 11 | MMP20 | Amelogenesis imperfecta, type 2A2 (hypomaturational type) | < 1 in 500 | Reduced |
| 10 | MMP21 | Heterotaxy, visceral, 7, autosomal | N/A | N/A |
| 6 | MMUT | Methylmalonic aciduria, mut(0) type | 1 in 135 | 1 in 3375 |
| 18 | MOCOS | Xanthinuria, type 2 | N/A | N/A |
| 6 | MOCS1 | Molybdenum cofactor deficiency A | 1 in 350 | 1 in 3500 |
| 5 | MOCS2 | Molybdenum cofactor deficiency B | 1 in 400 | 1 in 4000 |
| 2 | MOGS | Congenital disorder of glycosylation, type 2B | < 1 in 500 | <1 in 667 |
| 6 | MPC1 | Mitochondrial pyruvate carrier deficiency | < 1 in 500 | Reduced |
| 17 | MPDU1 | Congenital disorder of glycosylation, type 1F | < 1 in 500 | Reduced |
| 9 | MPDZ | Hydrocephalus, congenital, type 2, with or without brain or eye anomalies | N/A | N/A |
| 15 | MPI | Congenital disorder of glycosylation, type 1B | 1 in 473 | 1 in 11825 |
| 6 | MPIG6B | Thrombocytopenia, anemia, and myelofibrosis | N/A | N/A |
| 1 | MPL | Thrombocytopenia, congenital amegakaryocytic | 1 in 241 | 1 in 2410 |
| 7 | MPLKIP | Trichothiodystrophy, type 4, nonphotosensitive | < 1 in 500 | Reduced |
| 17 | MPO | Myeloperoxidase deficiency | N/A | N/A |
| 2 | MPV17 | Mitochondrial DNA depletion syndrome type 6 (hepatocerebral); Charcot-Marie-Tooth disease, axonal, type 2EE | 1 in 612 | 1 in 7650 |
| 1 | MPZ | Dejerine-Sottas disease | < 1 in 500 | Reduced |
| 21 | MRAP | Glucocorticoid deficiency, type 2 | < 1 in 500 | Reduced |
| 11 | MRE11 | Ataxia-telangiectasia-like disorder 1 | N/A | N/A |
| 10 | MRPS16 | Combined oxidative phosphorylation deficiency 2 | < 1 in 500 | Reduced |
| 3 | MRPS22 | Combined oxidative phosphorylation deficiency type 5 | N/A | N/A |
| 16 | MRPS34 | Combined oxidative phosphorylation deficiency 32 | N/A | N/A |
| 5 | MSH3 | Familial adenomatous polyposis, type 4 | N/A | N/A |
| 4 | MSMO1 | Microcephaly, congenital cataract, and psoriasiform dermatitis | < 1 in 500 | Reduced |
| 12 | MSRB3 | Deafness, autosomal recessive, type 74 | < 1 in 500 | Reduced |

| | | | | |
|----|---------|-----------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| 1 | MSTO1 | Myopathy, mitochondrial, and ataxia | N/A | N/A |
| 15 | MTFMT | Combined oxidative phosphorylation deficiency 15 | N/A | N/A |
| 14 | MTHFD1 | Combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia | N/A | N/A |
| 1 | MTHFR | Homocystinuria due to MTHFR deficiency | 1 in 1,119 | 1 in 11190 |
| 11 | MTMR2 | Charcot-Marie-Tooth disease, type 4B1 | 1 in 500 | 1 in 1,000 |
| 6 | MTO1 | Combined oxidative phosphorylation deficiency 10 | N/A | N/A |
| 1 | MTR | Homocystinuria-megaloblastic anemia, cblG complementation type | < 1 in 500 | <1 in 864 |
| 12 | MTRFR | Combined oxidative phosphorylation deficiency 7; Spastic paraplegia, type 55, autosomal recessive | < 1 in 500 | Reduced |
| 5 | MTRR | Homocystinuria-megaloblastic anemia, cbl E type | < 1 in 500 | Reduced |
| 4 | MTTP | Abetalipoproteinemia | < 1 in 500 | Reduced |
| 9 | MUSK | Fetal akinesia deformation sequence, type 1; Myasthenic syndrome, congenital, type 9, associated with acetylcholine receptor deficiency | N/A | N/A |
| 1 | MUTYH | Adenomas, multiple colorectal | N/A | N/A |
| 12 | MVK | Mevalonic aciduria | 1 in 286 | 1 in 2,261 |
| 12 | MYBPC1 | Lethal congenital contracture syndrome, type 4 | N/A | N/A |
| 3 | MYD88 | Immunodeficiency, type 68 | N/A | N/A |
| 17 | MYH2 | Proximal myopathy and ophthalmoplegia | N/A | N/A |
| 9 | MYMK | Carey-Fineman-Ziter syndrome | < 1 in 500 | Reduced |
| 17 | MYO15A | Deafness, autosomal recessive, type 3 | N/A | N/A |
| 22 | MYO18B | Klippel-Feil syndrome, type 4, autosomal recessive, with myopathy and facial dysmorphism | N/A | N/A |
| 15 | MYO1E | Glomerulosclerosis, focal segmental, 6 | < 1 in 500 | Reduced |
| 10 | MYO3A | Deafness, autosomal recessive, type 30 | < 1 in 500 | Reduced |
| 15 | MYO5A | GrisCELL syndrome, type 1 | N/A | N/A |
| 18 | MYO5B | Microvillus inclusion disease | N/A | N/A |
| 6 | MYO6 | Deafness, autosomal recessive, type 37 | < 1 in 500 | Reduced |
| 11 | MYO7A | Usher syndrome, type 1B; Deafness, autosomal recessive, type 2 | 1 in 129 | 1 in 2580 |
| 10 | MYPN | Nemaline myopathy, type 11, autosomal recessive | < 1 in 500 | Reduced |
| 2 | NADK2 | 2,4-dienoyl-CoA reductase deficiency | 1 in 500 | N/A |
| 22 | NAGA | Schindler disease, type I; Schindler disease, type III; Kanzaki disease | 1 in 500 | 1 in 5000 |
| 17 | NAGLU | Mucopolysaccharidosis, type 3B (Sanfilippo B) | 1 in 346 | 1 in 1384 |
| 17 | NAGS | N-acetylglutamate synthase deficiency | < 1 in 500 | Reduced |
| 13 | NALCN | Hypotonia, infantile, with psychomotor retardation and characteristic facies 1 | N/A | N/A |
| 9 | NANS | Spondyloepimetaphyseal dysplasia, Camera-Genevieve type | < 1 in 500 | Reduced |
| 11 | NARS2 | Combined oxidative phosphorylation deficiency 24 | N/A | N/A |
| 1 | NAXE | Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy | < 1 in 500 | Reduced |
| 2 | NBAS | Infantile liver failure syndrome, type 2; Short stature, optic nerve atrophy, and Pelger-Huet anomaly | N/A | N/A |
| 3 | NBEAL2 | Gray platelet syndrome | N/A | N/A |
| 8 | NBN | Nijmegen breakage syndrome | 1 in 525 | 1 in 17500 |
| 11 | NCAPD3 | Microcephaly 22, primary, autosomal recessive | N/A | N/A |
| 7 | NCF1 | Chronic granulomatous disease, type 1 | 1 in 343 | 1 in 1,027 |
| 1 | NCF2 | Chronic granulomatous disease, type 2 | < 1 in 500 | Reduced |
| 22 | NCF4 | Chronic granulomatous disease, type 3 | N/A | N/A |
| 16 | NDE1 | Lissencephaly, type 4 (with microcephaly) | < 1 in 500 | Reduced |
| 8 | NDRG1 | Charcot-Marie-Tooth disease, type 4D | < 1 in 500 | Reduced |
| 5 | NDST1 | Mental retardation, autosomal recessive, type 46 | < 1 in 500 | Reduced |
| 2 | NDUFA10 | Mitochondrial complex I deficiency, nuclear type 22 | < 1 in 500 | Reduced |
| 19 | NDUFA11 | Mitochondrial complex I deficiency, nuclear type 14 | < 1 in 500 | Reduced |
| 12 | NDUFA12 | ?Mitochondrial complex I deficiency, nuclear type 23 | < 1 in 500 | Reduced |
| 5 | NDUFA2 | Mitochondrial complex I deficiency, nuclear type 13 | < 1 in 500 | Reduced |
| 12 | NDUFA9 | Mitochondrial complex I deficiency, nuclear type 26 | < 1 in 500 | Reduced |
| 15 | NDUFAF1 | Mitochondrial complex I deficiency, nuclear type 11 | < 1 in 500 | Reduced |
| 5 | NDUFAF2 | Mitochondrial complex I deficiency, nuclear type 10 | < 1 in 500 | Reduced |
| 3 | NDUFAF3 | Mitochondrial complex I deficiency, nuclear type 18 | < 1 in 500 | Reduced |
| 20 | NDUFAF5 | Mitochondrial complex I deficiency, nuclear type 16 | 1 in 982 | 1 in 19640 |
| 8 | NDUFAF6 | Mitochondrial complex I deficiency, nuclear type 17 | N/A | N/A |
| 2 | NDUFB3 | Mitochondrial complex I deficiency, nuclear type 25 | N/A | N/A |
| 8 | NDUFB9 | Mitochondrial complex I deficiency, nuclear type 24 | N/A | N/A |
| 2 | NDUFS1 | Mitochondrial complex I deficiency, nuclear type 5 | N/A | N/A |
| 1 | NDUFS2 | Mitochondrial complex I deficiency, nuclear type 6 | < 1 in 500 | Reduced |
| 11 | NDUFS3 | Mitochondrial complex I deficiency, nuclear type 8 | < 1 in 500 | Reduced |
| 5 | NDUFS4 | Mitochondrial complex I deficiency, nuclear type 1 | < 1 in 500 | Reduced |
| 5 | NDUFS6 | Mitochondrial complex I deficiency, nuclear type 9 | < 1 in 500 | Reduced |
| 19 | NDUFS7 | Mitochondrial complex I deficiency, nuclear type 3 | < 1 in 500 | Reduced |
| 11 | NDUFS8 | Mitochondrial complex I deficiency, nuclear type 2 | < 1 in 500 | Reduced |
| 11 | NDUFV1 | Mitochondrial complex I deficiency, nuclear type 4 | 1 in 469 | 1 in 736 |
| 18 | NDUFV2 | Mitochondrial complex I deficiency, nuclear type 7 | < 1 in 500 | Reduced |
| 2 | NEB | Nemaline myopathy type 2 | 1 in 175 | 1 in 2188 |
| 11 | NECTIN1 | Cleft lip/palate-ectodermal dysplasia syndrome; Orofacial cleft 7 | < 1 in 500 | Reduced |
| 1 | NECTIN4 | Ectodermal dysplasia-syndactyly syndrome, type 1 | < 1 in 500 | Reduced |

| | | | | |
|----|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| 8 | NEFL | Charcot-Marie-Tooth disease, type 1F | < 1 in 500 | Reduced |
| 4 | NEK1 | Short-rib thoracic dysplasia, type 6, with or without polydactyly | N/A | N/A |
| 17 | NEK8 | Renal-hepatic-pancreatic dysplasia, type 2 | N/A | N/A |
| 14 | NEK9 | Lethal congenital contracture syndrome 10 | N/A | N/A |
| 6 | NEU1 | Sialidosis, type 1 and type 2 | < 1 in 500 | Reduced |
| 10 | NEUROG3 | Diarrhea 4, malabsorptive, congenital | < 1 in 500 | Reduced |
| 2 | NFU1 | Multiple mitochondrial dysfunctions syndrome 1 | < 1 in 500 | Reduced |
| 1 | NGF | Neuropathy, hereditary sensory and autonomic, type 5 | < 1 in 500 | Reduced |
| 3 | NGLY1 | Congenital disorder of deglycosylation | N/A | N/A |
| 2 | NHEJ1 | Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation | N/A | N/A |
| 6 | NHLRC1 | Epilepsy, progressive myoclonic, type 2B (Lafora) | < 1 in 500 | Reduced |
| 5 | NHP2 | Dyskeratosis congenita, autosomal recessive type 2 | 1 in 250 | 1 in 24,964 |
| 14 | NIN | Seckel syndrome, type 7 | N/A | N/A |
| 5 | NIPAL4 | Ichthyosis, congenital, autosomal recessive, type 6 | N/A | N/A |
| 8 | NKX2-6 | Conotruncal heart malformations | N/A | N/A |
| 4 | NKX3-2 | Spondylo-megaepiphyseal-metaphyseal dysplasia | < 1 in 500 | Reduced |
| 10 | NKX6-2 | Spastic ataxia 8, autosomal recessive, with hypomyelinating leukodystrophy | < 1 in 500 | Reduced |
| 17 | NLRP1 | Autoinflammation with arthritis and dyskeratosis | N/A | N/A |
| 19 | NLRP7 | Hydatidiform mole, recurrent, type 1 | 1 in 500 | 1 in 722 |
| 7 | NME8 | Ciliary dyskinesia, primary, type 6 | N/A | N/A |
| 1 | NMNAT1 | Leber congenital amaurosis 9; Spondyloepiphyseal dysplasia, sensorineural hearing loss, intellectual developmental disorder, and Leber congenital amaurosis | < 1 in 500 | Reduced |
| 5 | NNT | Glucocorticoid deficiency 4, with or without mineralocorticoid deficiency | < 1 in 500 | Reduced |
| 15 | NOP10 | Dyskeratosis congenita, autosomal recessive type 1 | 1 in 250 | 1 in 500 |
| 18 | NPC1 | Niemann-Pick disease, type C1 | 1 in 163 | 1 in 652 |
| 14 | NPC2 | Niemann-pick disease, type C2 | < 1 in 500 | Reduced |
| 2 | NPHP1 | Joubert syndrome type 4 | 1 in 418 | 1 in 825 |
| 3 | NPHP3 | Meckel syndrome type 7 | < 1 in 500 | Reduced |
| 1 | NPHP4 | Nephronophthisis type 4 | < 1 in 500 | Reduced |
| 19 | NPHS1 | Nephrotic syndrome, type 1 | 1 in 112 | 1 in 1400 |
| 1 | NPHS2 | Nephrotic syndrome, type 2 | 1 in 226 | 1 in 2260 |
| 9 | NPR2 | Acromesomelic dysplasia, Maroteaux type | N/A | N/A |
| 12 | NR1H4 | Cholestasis, progressive familial intrahepatic, type 5 | < 1 in 500 | Reduced |
| 15 | NR2E3 | Enhanced S-cone syndrome (Goldmann-Favre); Retinitis pigmentosa, type 37 | 1 in 278 | 1 in 5560 |
| 14 | NRL | Retinal degeneration, autosomal recessive, clumped pigment type | < 1 in 500 | Reduced |
| 2 | NRXN1 | Pitt-Hopkins-like syndrome, type 2 | < 1 in 500 | Reduced |
| 8 | NSMCE2 | Seckel syndrome, type 10 | < 1 in 500 | Reduced |
| 5 | NSUN2 | Mental retardation, autosomal recessive, type 5 | N/A | N/A |
| 10 | NT5C2 | Spastic paraplegia, type 45, autosomal recessive | < 1 in 500 | Reduced |
| 7 | NT5C3A | Anemia, hemolytic, due to UMPH1 deficiency | < 1 in 500 | Reduced |
| 6 | NTSE | Calcification of joints and arteries | N/A | N/A |
| 16 | NTHL1 | Familial adenomatous polyposis, type 3 | N/A | N/A |
| 1 | NTRK1 | Insensitivity to pain, congenital, with anhidrosis | 1 in 1,122 | 1 in 11220 |
| 14 | NUBPL | Mitochondrial complex I deficiency, nuclear type 21 | N/A | N/A |
| 12 | NUP107 | Nephrotic syndrome, type 11 | N/A | N/A |
| 19 | NUP62 | Striatonigral degeneration, infantile | < 1 in 500 | Reduced |
| 16 | NUP93 | Nephrotic syndrome, type 12 | N/A | N/A |
| 10 | OAT | Gyrate atrophy of choroid and retina | < 1 in 500 | Reduced |
| 2 | OBSL1 | 3M syndrome 2 | N/A | N/A |
| 15 | OCA2 | Oculocutaneous albinism type 2 | 1 in 101 | 1 in 204 |
| 5 | OCLN | Pseudo-TORCH syndrome, type 1 | < 1 in 500 | Reduced |
| 19 | ODAD1 | Ciliary dyskinesia, primary, type 20 | N/A | N/A |
| 10 | ODAD2 | Ciliary dyskinesia, primary, type 23 | N/A | N/A |
| 19 | ODAD3 | Ciliary dyskinesia, primary, type 30 | < 1 in 500 | Reduced |
| 3 | OPA1 | Behr syndrome | N/A | N/A |
| 19 | OPA3 | 3-methylglutaconic aciduria, type 3 | < 1 in 500 | Reduced |
| 10 | OPTN | Amyotrophic lateral sclerosis, type 12 | N/A | N/A |
| 12 | ORAI1 | Immunodeficiency, type 9 | < 1 in 500 | Reduced |
| 1 | ORC1 | Meier-Gorlin syndrome, type 1 | N/A | N/A |
| 2 | ORC4 | Meier-Gorlin syndrome, type 2 | N/A | N/A |
| 16 | ORC6 | Meier-Gorlin syndrome, type 3 | N/A | N/A |
| 14 | OSGEP | Galloway-Mowat syndrome 3 | N/A | N/A |
| 6 | OSTM1 | Osteopetrosis, autosomal recessive type 5 | < 1 in 500 | Reduced |
| 16 | OTOA | Deafness, autosomal recessive, type 22 | 1 in 500 | 1 in 1667 |
| 2 | OTOF | Deafness, autosomal recessive, type 9 | 1 in 228 | 1 in 22,701 |
| 11 | OTOG | Deafness, autosomal recessive, type 18B | N/A | N/A |
| 12 | OTOGL | Deafness, autosomal recessive, type 84B | N/A | N/A |
| 8 | OTUD6B | Intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies | < 1 in 500 | Reduced |
| 5 | OTULIN | Autoinflammation, panniculitis, and dermatosis syndrome | < 1 in 500 | Reduced |

| | | | | |
|----|--------|---------------------------------------------------------------------------------------------------------------------------|------------|------------|
| 5 | OXCT1 | Succinyl CoA:3-oxoacid CoA transferase deficiency | N/A | N/A |
| 3 | P2RY12 | Bleeding disorder, platelet-type, type 8 | < 1 in 500 | Reduced |
| 1 | P3H1 | Osteogenesis imperfecta, type 8 | 1 in 567 | 1 in 1,447 |
| 3 | P3H2 | Myopia, high, with cataract and vitreoretinal degeneration | N/A | N/A |
| 1 | PADI6 | Preimplantation embryonic lethality 2 | N/A | N/A |
| 12 | PAH | Phenylketonuria | 1 in 60 | 1 in 857 |
| 16 | PALB2 | PALB2-related conditions | N/A | N/A |
| 16 | PAM16 | Spondylometaphyseal dysplasia, Megarbane-Dagher-Melike type | < 1 in 500 | Reduced |
| 20 | PANK2 | Neurodegeneration with brain iron accumulation type 1 | 1 in 400 | 1 in 5000 |
| 10 | PAPSS2 | Brachyolmia, type 4, with mild epiphyseal and metaphyseal changes | N/A | N/A |
| 1 | PARK7 | Parkinson disease, type 7, autosomal recessive, early-onset | < 1 in 500 | Reduced |
| 16 | PARN | Dyskeratosis congenita, autosomal recessive 6 | N/A | N/A |
| 15 | PATL2 | Oocyte maturation defect 4 | N/A | N/A |
| 1 | PAX7 | Rhabdomyosarcoma 2, alveolar | < 1 in 500 | Reduced |
| 11 | PC | Pyruvate carboxylase deficiency | 1 in 251 | 1 in 3150 |
| 2 | PCARE | Retinitis pigmentosa, type 54 | N/A | N/A |
| 10 | PCBD1 | Hyperphenylalaninemia, BH4-deficient, type D | < 1 in 500 | Reduced |
| 13 | PCCA | Propionic acidemia | 1 in 636 | 1 in 2544 |
| 3 | PCCB | Propionic acidemia | 1 in 635 | 1 in 7938 |
| 5 | PCDH12 | Microcephaly, seizures, spasticity, and brain calcification | N/A | N/A |
| 10 | PCDH15 | Deafness, autosomal recessive, type 23; Usher syndrome, type 1D/F digenic | 1 in 497 | 1 in 1657 |
| 14 | PCK2 | PEPCK deficiency, mitochondrial | N/A | N/A |
| 21 | PCNT | Microcephalic osteodysplastic primordial dwarfism, type 2 | N/A | N/A |
| 5 | PCSK1 | Obesity with impaired prohormone processing | N/A | N/A |
| 3 | PCYT1A | Spondylometaphyseal dysplasia with cone-rod dystrophy | < 1 in 500 | Reduced |
| 6 | PDE10A | Dyskinesia, limb and orofacial, infantile-onset | N/A | N/A |
| 5 | PDE6A | Retinitis pigmentosa type 43 | 1 in 500 | 1 in 863 |
| 4 | PDE6B | Retinitis pigmentosa type 40 | 1 in 200 | 1 in 4000 |
| 10 | PDE6C | Cone dystrophy type 4 | N/A | N/A |
| 17 | PDE6G | Retinitis pigmentosa type 57 | < 1 in 500 | Reduced |
| 12 | PDE6H | Retinal cone dystrophy 3 and achromatopsia 6 | < 1 in 500 | Reduced |
| 3 | PDHB | Pyruvate dehydrogenase E1-beta deficiency | < 1 in 500 | Reduced |
| 11 | PDHX | Lacticacidemia due to PDX1 deficiency | < 1 in 500 | Reduced |
| 8 | PDP1 | Pyruvate dehydrogenase phosphatase deficiency | < 1 in 500 | Reduced |
| 10 | PDSS1 | Coenzyme Q10 deficiency, primary, type 2 | < 1 in 500 | Reduced |
| 6 | PDSS2 | Coenzyme Q10 deficiency, primary, type 3 | < 1 in 500 | Reduced |
| 13 | PDX1 | Pancreatic agenesis type 1 | < 1 in 500 | Reduced |
| 21 | PDXK | Neuropathy, hereditary motor and sensory, type VIC, with optic atrophy | < 1 in 500 | Reduced |
| 10 | PDZD7 | Deafness, autosomal recessive, type 57; Usher syndrome, type 2C, digenic | N/A | N/A |
| 19 | PEPD | Prolidase deficiency | N/A | N/A |
| 19 | PET100 | Mitochondrial complex IV deficiency, nuclear type 12 | < 1 in 500 | Reduced |
| 7 | PEX1 | Heimler syndrome 1; Peroxisome biogenesis disorder 1A (Zellweger); Peroxisome biogenesis disorder 1B (NALD/IRD) | 1 in 191 | 1 in 3820 |
| 1 | PEX10 | Peroxisome biogenesis disorder, type 6A (Zellweger syndrome); Peroxisome biogenesis disorder, type 6B | 1 in 1,287 | 1 in 16088 |
| 1 | PEX11B | ?Peroxisome biogenesis disorder 14B | N/A | N/A |
| 17 | PEX12 | Peroxisome biogenesis disorder type 3A (Zellweger) | < 1 in 500 | Reduced |
| 2 | PEX13 | Peroxisome biogenesis disorder, type 11A (Zellweger syndrome); Peroxisome biogenesis disorder, type 11B | < 1 in 500 | Reduced |
| 1 | PEX14 | Peroxisome biogenesis disorder, type 13A (Zellweger syndrome) | < 1 in 500 | Reduced |
| 11 | PEX16 | Peroxisome biogenesis disorder, type 8A (Zellweger syndrome); Peroxisome biogenesis disorder, type 8B | < 1 in 500 | Reduced |
| 1 | PEX19 | Peroxisome biogenesis disorder, type 12A (Zellweger syndrome) | < 1 in 500 | Reduced |
| 8 | PEX2 | Peroxisome biogenesis disorder type 5A (Zellweger) | < 1 in 500 | Reduced |
| 22 | PEX26 | Peroxisome biogenesis disorder type 7A (Zellweger) | < 1 in 500 | Reduced |
| 6 | PEX3 | Peroxisome biogenesis disorder, type 10A (Zellweger syndrome) | < 1 in 500 | Reduced |
| 12 | PEX5 | Peroxisome biogenesis disorder type 2A (Zellweger) | < 1 in 500 | Reduced |
| 6 | PEX6 | Peroxisome biogenesis disorder, type 4A (Zellweger syndrome); Peroxisome biogenesis disorder, type 4B; Heimler syndrome 2 | 1 in 83 | 1 in 277 |
| 6 | PEX7 | Rhizomelic chondrodysplasia punctata, type 1 | 1 in 371 | 1 in 7420 |
| 12 | PFKM | Glycogen storage disease, type 7 | < 1 in 500 | Reduced |
| 7 | PGAM2 | Glycogen storage disease X | < 1 in 500 | Reduced |
| 2 | PGAP1 | Mental retardation, autosomal recessive 42 | N/A | N/A |
| 11 | PGAP2 | Hyperphosphatasia with mental retardation syndrome 3 | N/A | N/A |
| 17 | PGAP3 | Hyperphosphatasia with mental retardation syndrome 4 | N/A | N/A |
| 1 | PGM1 | Congenital disorder of glycosylation, type 1t | N/A | N/A |
| 6 | PGM3 | Immunodeficiency, type 23 | N/A | N/A |
| 1 | PHGDH | Neu-Laxova syndrome, type 1; Phosphoglycerate dehydrogenase deficiency | 1 in 631 | 1 in 4207 |
| 16 | PHKB | Glycogen storage disease, type 9B | N/A | N/A |
| 16 | PHKG2 | Glycogen storage disease type 9c | N/A | N/A |
| 11 | PHOX2A | Fibrosis of extraocular muscles, congenital, 2 | < 1 in 500 | Reduced |
| 10 | PHYH | Refsum disease | < 1 in 500 | Reduced |

| | | | | |
|----|---------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| 22 | PI4KA | Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | N/A | N/A |
| 13 | PIBF1 | Joubert syndrome 33 | N/A | N/A |
| 16 | PIEZO1 | Lymphedema, hereditary, type 3 | N/A | N/A |
| 18 | PIEZO2 | Arthrogryposis, distal, with impaired proprioception and touch | N/A | N/A |
| 1 | PIGC | Glycosylphosphatidylinositol biosynthesis defect 16 | < 1 in 500 | Reduced |
| 4 | PIGG | Mental retardation, autosomal recessive 53 | N/A | N/A |
| 17 | PIGL | Zurich neuroectodermal syndrome | N/A | N/A |
| 1 | PIGM | Glycosylphosphatidylinositol deficiency | < 1 in 500 | Reduced |
| 18 | PIGN | Multiple congenital anomalies-hypotonia-seizures syndrome, type 1 | N/A | N/A |
| 9 | PIGO | Hyperphosphatasia with mental retardation syndrome 2 | N/A | N/A |
| 20 | PIGT | Multiple congenital anomalies-hypotonia-seizures syndrome 3 | N/A | N/A |
| 1 | PIGV | Hyperphosphatasia with mental retardation syndrome 1 | N/A | N/A |
| 17 | PIGW | Glycosylphosphatidylinositol biosynthesis defect 11 | N/A | N/A |
| 4 | PIGY | Hyperphosphatasia with mental retardation syndrome 6 | < 1 in 500 | Reduced |
| 1 | PINK1 | Parkinson disease, type 6, early onset | N/A | N/A |
| 19 | PIP5K1C | Lethal congenital contractural syndrome, type 3 | < 1 in 500 | Reduced |
| 2 | PJVK | Deafness, autosomal recessive, type 59 | N/A | N/A |
| 7 | PKD1L1 | Heterotaxy, visceral, 8, autosomal | N/A | N/A |
| 6 | PKHD1 | Polycystic kidney disease type 4 | 1 in 66 | 1 in 264 |
| 1 | PKLR | Pyruvate kinase deficiency | 1 in 160 | 1 in 3200 |
| 1 | PKP1 | Ectodermal dysplasia/skin fragility syndrome | < 1 in 500 | Reduced |
| 22 | PLA2G6 | Infantile neuroaxonal dystrophy type 1 | 1 in 343 | 1 in 856 |
| 9 | PLAA | Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies | < 1 in 500 | Reduced |
| 20 | PLCB1 | Epileptic encephalopathy, early infantile, type 12 | < 1 in 500 | Reduced |
| 20 | PLCB4 | Auriculocondylar syndrome, type 2 | < 1 in 500 | Reduced |
| 3 | PLCD1 | Nail disorder, nonsyndromic congenital, type 3 (leukonychia) | N/A | N/A |
| 10 | PLCE1 | Nephrotic syndrome, type 3 | < 1 in 500 | Reduced |
| 3 | PLD1 | Cardiac valvular defect, developmental | N/A | N/A |
| 8 | PLEC | Epidermolysis bullosa simplex with muscular dystrophy | N/A | N/A |
| 1 | PLEKHG5 | Charcot-Marie-Tooth disease, recessive intermediate, type C | N/A | N/A |
| 6 | PLG | Plasminogen deficiency, type 1 | < 1 in 500 | Reduced |
| 4 | PLK4 | Microcephaly and chorioretinopathy, autosomal recessive, 2 | < 1 in 500 | Reduced |
| 1 | PLOD1 | Ehlers-Danlos syndrome, kyphoscoliotic type, 1 | 1 in 159 | 1 in 299 |
| 3 | PLOD2 | Bruck syndrome 2 | N/A | N/A |
| 7 | PLOD3 | Lysyl hydroxylase 3 deficiency | N/A | N/A |
| 8 | PLPBP | Epilepsy, early-onset, vitamin B6-dependent | < 1 in 500 | Reduced |
| 16 | PMM2 | Congenital disorder of glycosylation, type 1A | 1 in 71 | 1 in 3550 |
| 17 | PMP22 | Dejerine-Sottas disease | < 1 in 500 | Reduced |
| 9 | PMPCA | Spinocerebellar ataxia, autosomal recessive, type 2 | N/A | N/A |
| 7 | PMPCB | Multiple mitochondrial dysfunctions syndrome 6 | N/A | N/A |
| 19 | PNKP | Microcephaly, seizures, and developmental delay; Ataxia-oculomotor apraxia 4; ?Charcot-Marie-Tooth disease, type 2B2 | N/A | N/A |
| 14 | PNP | Immunodeficiency due to purine nucleoside phosphorylase deficiency | < 1 in 500 | Reduced |
| 6 | PNPLA1 | Ichthyosis, congenital, autosomal recessive, type 10 | N/A | N/A |
| 11 | PNPLA2 | Neutral lipid storage disease with myopathy | N/A | N/A |
| 19 | PNPLA6 | Boucher-Neuhauser syndrome; Oliver-McFarlane syndrome; Spastic paraplegia, type 39, autosomal recessive | N/A | N/A |
| 17 | PNPO | Pyridoxamine 5'-phosphate oxidase deficiency | 1 in 1,107 | 1 in 3,983 |
| 2 | PNPT1 | Combined oxidative phosphorylation deficiency 13 | N/A | N/A |
| 3 | POC1A | Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis | < 1 in 500 | Reduced |
| 12 | POC1B | Cone-rod dystrophy 20 | < 1 in 500 | Reduced |
| 12 | POLE | FILS syndrome | N/A | N/A |
| 15 | POLG | POLG-related disorders | 1 in 194 | 1 in 340 |
| 6 | POLH | Xeroderma pigmentosum, variant type | N/A | N/A |
| 6 | POLR1C | Leukodystrophy, hypomyelinating, type 11; Treacher Collins syndrome 3 | 1 in 1,021 | 1 in 1,659 |
| 13 | POLR1D | Treacher Collins syndrome, type 2 | < 1 in 500 | Reduced |
| 10 | POLR3A | Leukodystrophy, hypomyelinating, type 7 | N/A | N/A |
| 12 | POLR3B | Leukodystrophy, hypomyelinating, type 8 | N/A | N/A |
| 2 | POMC | Obesity, adrenal insufficiency, and red hair due to POMC deficiency | < 1 in 500 | Reduced |
| 1 | POMGNT1 | Muscular dystrophy-dystroglycanopathy, type 3A (Walker-Warburg syndrome); Type 3B; Type 3C (limb-girdle muscular dystrophy, type 15 [LGMDR15]) | 1 in 315 | 1 in 31500 |
| 3 | POMGNT2 | Muscular dystrophy-dystroglycanopathy, type 8A (Walker-Warburg syndrome); Type 8C (limb-girdle muscular dystrophy, type 24 [LGMD R24]) | < 1 in 500 | Reduced |
| 8 | POMK | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12 | < 1 in 500 | Reduced |
| 13 | POMP | Keratosis linearis with ichthyosis congenita and sclerosing keratoderma | < 1 in 500 | Reduced |
| 9 | POMT1 | Muscular dystrophy-dystroglycanopathy, type 1A (Walker-Warburg syndrome); Type 1B; Type 1C (limb-girdle muscular dystrophy, type 11 [LGMD R11]) | 1 in 372 | 1 in 1,708 |
| 14 | POMT2 | Muscular dystrophy-dystroglycanopathy, type 2A (Walker-Warburg syndrome); Type 2B; Type 2C (limb-girdle muscular dystrophy, type 14 [LGMD R14]) | < 1 in 500 | Reduced |
| 8 | POP1 | Anauxetic dysplasia, type 2 | N/A | N/A |
| 7 | POR | Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis | 1 in 268 | 1 in 1,069 |
| 3 | POU1F1 | Pituitary hormone deficiency, combined, type 1 | 1 in 32 | 1 in 126 |

| | | | | |
|----|----------|------------------------------------------------------------------------------------------------------------------------|------------|------------|
| 4 | PPA2 | Sudden cardiac failure, infantile | N/A | N/A |
| 15 | PPIB | Osteogenesis imperfecta, type 9 | N/A | N/A |
| 4 | PPM1K | ?Maple syrup urine disease, mild variant | 1 in 200 | 1 in 4000 |
| 1 | PPP1R15B | Microcephaly, short stature, and impaired glucose metabolism 2 | < 1 in 500 | Reduced |
| 1 | PPT1 | Ceroid lipofuscinosis, neuronal, type 1 | 1 in 488 | 1 in 4880 |
| 17 | PRCD | Retinitis pigmentosa, type 36 | N/A | N/A |
| 9 | PRDM12 | Neuropathy, hereditary sensory and autonomic, type VIII | N/A | N/A |
| 4 | PRDM5 | Brittle cornea syndrome, type 2 | N/A | N/A |
| 1 | PRDX1 | Methylmalonic aciduria and homocystinuria, cblC type, digenic | < 1 in 500 | Reduced |
| 2 | PREPL | Myasthenic syndrome, congenital, type 22 | N/A | N/A |
| 10 | PRF1 | Hemophagocytic lymphohistiocytosis, familial, type 2 | 1 in 308 | 1 in 538 |
| 1 | PRG4 | Camptodactyly-arthropathy-coxa vara-pericarditis syndrome | N/A | N/A |
| 12 | PRICKLE1 | Epilepsy, progressive myoclonic, type 1B | < 1 in 500 | Reduced |
| 3 | PRKCD | Autoimmune lymphoproliferative syndrome, type 3 | < 1 in 500 | Reduced |
| 6 | PRKN | Parkinson disease, type 2, juvenile | N/A | N/A |
| 2 | PRKRA | Dystonia, type 16 | < 1 in 500 | Reduced |
| 16 | PRMT7 | Short stature, brachydactyly, intellectual developmental disability, and seizures | N/A | N/A |
| 2 | PROC | Thrombophilia due to protein C deficiency, autosomal recessive | N/A | N/A |
| 22 | PRODH | Hyperprolinemia, type 1 | N/A | N/A |
| 4 | PROM1 | Retinitis pigmentosa, type 41 | 1 in 323 | 1 in 6460 |
| 5 | PROP1 | Pituitary hormone deficiency, combined, type 2 | 1 in 84 | 1 in 4200 |
| 3 | PROS1 | Thrombophilia due to protein S deficiency, autosomal recessive | N/A | N/A |
| 6 | PRPH2 | Leber congenital amaurosis 18; Retinitis punctata albescens | N/A | N/A |
| 1 | PRRX1 | Agnathia-otocephaly complex | < 1 in 500 | Reduced |
| 4 | PRSS12 | Mental retardation, autosomal recessive, type 1 | N/A | N/A |
| 2 | PRSS56 | Microphthalmia, isolated, type 6 | N/A | N/A |
| 1 | PRUNE1 | Neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies | < 1 in 500 | Reduced |
| 19 | PRX | Charcot-Marie-Tooth disease, type 4F | N/A | N/A |
| 10 | PSAP | Combined SAP deficiency | < 1 in 500 | Reduced |
| 9 | PSAT1 | Neu-Laxova syndrome, type 2 | N/A | N/A |
| 6 | PSMB8 | Autoinflammation, lipodystrophy, and dermatosis syndrome | < 1 in 500 | Reduced |
| 17 | PSMC3IP | Ovarian dysgenesis 3 | < 1 in 500 | Reduced |
| 7 | PSPH | Phosphoserine phosphatase deficiency | < 1 in 500 | Reduced |
| 10 | PTF1A | Pancreatic agenesis 2 | < 1 in 500 | Reduced |
| 11 | PTH | Hypoparathyroidism, familial isolated, type 1 | < 1 in 500 | Reduced |
| 3 | PTH1R | Chondrodysplasia, Blomstrand type; Eiken syndrome | < 1 in 500 | Reduced |
| 3 | PTPN23 | Neurodevelopmental disorder and structural brain anomalies with or without seizures and spasticity | N/A | N/A |
| 1 | PTPRC | Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive | < 1 in 500 | Reduced |
| 12 | PTPRO | Nephrotic syndrome, type 6 | < 1 in 500 | Reduced |
| 12 | PTPRQ | Deafness, autosomal recessive, type 84A | N/A | N/A |
| 17 | PTRH2 | Infantile-onset multisystem neurologic, endocrine, and pancreatic disease | < 1 in 500 | Reduced |
| 11 | PTS | Hyperphenylalaninemia, BH4-deficient, type A | 1 in 478 | 1 in 1593 |
| 12 | PUS1 | Myopathy, lactic acidosis, and sideroblastic anemia, type 1 | < 1 in 500 | Reduced |
| 2 | PXDN | Anterior segment dysgenesis, type 7, with sclerocornea | < 1 in 500 | Reduced |
| 17 | PYCR1 | Cutis laxa, autosomal recessive, type 2B | N/A | N/A |
| 1 | PYCR2 | Leukodystrophy, hypomyelinating, type 10 | < 1 in 500 | Reduced |
| 14 | PYGL | Glycogen storage disease, type 6 | N/A | N/A |
| 11 | PYGM | McArdle disease | 1 in 206 | 1 in 2060 |
| 12 | PYROXD1 | Myopathy, myofibrillar, type 8 | N/A | N/A |
| 3 | QARS1 | Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy | N/A | N/A |
| 4 | QDPR | Hyperphenylalaninemia, BH4-deficient, type C | < 1 in 500 | Reduced |
| 10 | RAB18 | Warburg micro syndrome, type 3 | < 1 in 500 | Reduced |
| 6 | RAB23 | Carpenter syndrome | < 1 in 500 | Reduced |
| 15 | RAB27A | Griscelli syndrome, type 2 | N/A | N/A |
| 4 | RAB28 | Cone-rod dystrophy 18 | < 1 in 500 | Reduced |
| 4 | RAB33B | Smith-McCort dysplasia 2 | < 1 in 500 | Reduced |
| 2 | RAB3GAP1 | Warburg micro syndrome, type 1 | N/A | N/A |
| 1 | RAB3GAP2 | Martsolf syndrome 1; Warburg micro syndrome 2 | N/A | N/A |
| 5 | RAD50 | Nijmegen breakage syndrome-like disorder | N/A | N/A |
| 17 | RAD51C | RAD51C-related conditions | N/A | N/A |
| 11 | RAG1 | Omenn syndrome; Severe combined immunodeficiency, B cell-negative | 1 in 344 | 1 in 614 |
| 11 | RAG2 | Omenn syndrome; Severe combined immunodeficiency, B cell-negative | 1 in 1,925 | 1 in 19250 |
| 11 | RAPSN | Fetal akinesia deformation sequence, type 2; Myasthenic syndrome, congenital, type 11, associated with AChR deficiency | 1 in 165 | 1 in 1650 |
| 3 | RARB | Microphthalmia, syndromic 12 | < 1 in 500 | Reduced |
| 5 | RARS1 | Leukodystrophy, hypomyelinating, type 9 | N/A | N/A |
| 6 | RARS2 | Pontocerebellar hypoplasia, type 6 | 1 in 269 | 1 in 3363 |
| 15 | RASGRP1 | Immunodeficiency, type 64 | < 1 in 500 | Reduced |
| 18 | RAX | Isolated microphthalmia, type 3 | 1 in 159 | 1 in 475 |

| | | | | |
|----|-----------|-------------------------------------------------------------------------------------------------------------------------|------------|------------|
| 18 | RBBP8 | Jawad syndrome; Seckel syndrome, type 2 | N/A | N/A |
| 20 | RBCK1 | Polyglucosan body myopathy 1 with or without immunodeficiency | < 1 in 500 | Reduced |
| 1 | RBM8A | Thrombocytopenia-absent radius syndrome | N/A | N/A |
| 10 | RBP3 | ?Retinitis pigmentosa 66 | N/A | N/A |
| 10 | RBP4 | Retinal dystrophy, iris coloboma, and comedogenic acne syndrome | < 1 in 500 | Reduced |
| 13 | RCBTB1 | Retinal dystrophy with or without extraocular anomalies | N/A | N/A |
| 1 | RD3 | Leber congenital amaurosis, type 12 | < 1 in 500 | Reduced |
| 14 | RDH12 | Leber congenital amaurosis, type 13 | 1 in 456 | 1 in 4560 |
| 12 | RDH5 | Fundus albipunctatus | N/A | N/A |
| 11 | RDX | Deafness, autosomal recessive, type 24 | < 1 in 500 | Reduced |
| 8 | RECQL4 | Baller-Gerold syndrome; RAPADILINO syndrome; Rothmund-Thomson syndrome | N/A | N/A |
| 19 | REEP6 | Retinitis pigmentosa 77 | < 1 in 500 | Reduced |
| 7 | RELN | Lissencephaly 2 (Norman-Roberts type) | N/A | N/A |
| 1 | REN | Renal tubular dysgenesis | < 1 in 500 | Reduced |
| 5 | RETREG1 | Neuropathy, hereditary sensory and autonomic, type 2B | < 1 in 500 | Reduced |
| 3 | RFT1 | Congenital disorder of glycosylation, type In | N/A | N/A |
| 1 | RFX5 | Bare lymphocyte syndrome, type 2 | < 1 in 500 | Reduced |
| 6 | RFX6 | Mitchell-Riley syndrome | < 1 in 500 | Reduced |
| 19 | RFXANK | Bare lymphocyte syndrome, type 2, complementation group B | < 1 in 500 | Reduced |
| 13 | RFXAP | Bare lymphocyte syndrome, type 2 | < 1 in 500 | Reduced |
| 3 | RHO | Retinitis pigmentosa, type 4; Retinitis punctata albescens | 1 in 416 | 1 in 8320 |
| 20 | RIN2 | Macs syndrome | < 1 in 500 | Reduced |
| 21 | RIPK4 | Popliteal pterygium syndrome, Bartsocas-Papas type | < 1 in 500 | Reduced |
| 6 | RIPOR2 | Deafness, autosomal recessive, type 104 | N/A | N/A |
| 15 | RLBP1 | Bothnia retinal dystrophy; Fundus albipunctatus | < 1 in 500 | Reduced |
| 6 | RMND1 | Combined oxidative phosphorylation deficiency 11 | N/A | N/A |
| 9 | RMRP | Anauxetic dysplasia, type 1 | 1 in 500 | 1 in 6250 |
| 2 | RNASEH1 | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2 | < 1 in 500 | Reduced |
| 19 | RNASEH2A | Aicardi-Goutieres syndrome, type 4 | < 1 in 500 | Reduced |
| 13 | RNASEH2B | Aicardi-Goutieres syndrome, type 2 | 1 in 440 | 1 in 7,333 |
| 11 | RNASEH2C | Aicardi-Goutieres syndrome, type 3 | < 1 in 500 | Reduced |
| 6 | RNASET2 | Leukoencephalopathy, cystic, without megalencephaly | < 1 in 500 | Reduced |
| 3 | RNF168 | RIDDLE syndrome | N/A | N/A |
| 7 | RNF216 | Gordon Holmes syndrome | < 1 in 500 | Reduced |
| 11 | ROBO3 | Gaze palsy, familial horizontal, with progressive scoliosis, type 1 | N/A | N/A |
| 16 | ROGDI | Kohlschutter-Tonz syndrome | < 1 in 500 | Reduced |
| 11 | ROM1 | Retinitis pigmentosa, type 7, digenic | < 1 in 500 | Reduced |
| 9 | ROR2 | Robinow syndrome, autosomal recessive | < 1 in 500 | Reduced |
| 1 | RORC | Immunodeficiency, type 42 | < 1 in 500 | Reduced |
| 8 | RP1 | Retinitis pigmentosa, type 1 | N/A | N/A |
| 1 | RPE65 | RPE65-related Leber congenital amaurosis/early-onset severe retinal dystrophy | 1 in 366 | 1 in 4575 |
| 14 | RPGRIPI1 | Leber congenital amaurosis, type 6 | N/A | N/A |
| 16 | RPGRIPI1L | Joubert syndrome, type 7; Meckel syndrome, type 5; COACH syndrome | 1 in 319 | 1 in 860 |
| 8 | RRM2B | Mitochondrial DNA depletion syndrome, type 8A (encephalomyopathic type with renal tubulopathy) and type 8B (MNGIE type) | N/A | N/A |
| 21 | RSPH1 | Ciliary dyskinesia, primary, type 24 | N/A | N/A |
| 6 | RSPH3 | Ciliary dyskinesia, primary, type 32 | < 1 in 500 | Reduced |
| 6 | RSPH4A | Ciliary dyskinesia, primary, type 11 | N/A | N/A |
| 6 | RSPH9 | Ciliary dyskinesia, primary, type 12 | N/A | N/A |
| 20 | RSPO4 | Anonychia congenita | < 1 in 500 | Reduced |
| 16 | RSPRY1 | Spondyloepimetaphyseal dysplasia, Faden-Alkuraya type | < 1 in 500 | Reduced |
| 20 | RTEL1 | Dyskeratosis congenita, autosomal recessive type 5 | < 1 in 500 | Reduced |
| 6 | RTN4IP1 | Optic atrophy 10 with or without ataxia, mental retardation, and seizures | N/A | N/A |
| 18 | RTTN | Microcephaly, short stature, and polymicrogyria with seizures | N/A | N/A |
| 9 | RUSC2 | Mental retardation, autosomal recessive 61 | < 1 in 500 | Reduced |
| 12 | RXYLT1 | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10 | < 1 in 500 | Reduced |
| 19 | RYR1 | Minicore myopathy with external ophthalmoplegia | < 1 in 500 | Reduced |
| 19 | S1PR2 | Deafness, autosomal recessive, type 68 | < 1 in 500 | Reduced |
| 13 | SACS | Spastic ataxia, Charlevoix-Saguenay, type | 1 in 100 | 1 in 1000 |
| 2 | SAG | Oguchi disease, type 1 | < 1 in 500 | Reduced |
| 7 | SAMD9 | Tumoral calcinosis, familial, normophosphatemic | N/A | N/A |
| 20 | SAMHD1 | Aicardi-Goutieres syndrome, type 5 | 1 in 610 | 1 in 2033 |
| 5 | SAR1B | Chylomicron retention disease | < 1 in 500 | Reduced |
| 19 | SARS2 | Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis | N/A | N/A |
| 7 | SBDS | Shwachman-Diamond syndrome | 1 in 224 | 1 in 804 |
| 22 | SBF1 | Charcot-Marie-Tooth disease, type 4B3 | N/A | N/A |
| 11 | SBF2 | Charcot-Marie-Tooth disease, type 4B2 | N/A | N/A |
| 11 | SC5D | Lathosterolosis | < 1 in 500 | Reduced |
| 4 | SCARB2 | Epilepsy, progressive myoclonic, type 4, with or without renal failure | < 1 in 500 | Reduced |

| | | | | |
|----|----------|-------------------------------------------------------------------------------------------------------|------------|------------|
| 22 | SCARF2 | Van den Ende-Gupta syndrome | < 1 in 500 | Reduced |
| 19 | SCN1B | Epileptic encephalopathy, early infantile, type 52 | < 1 in 500 | Reduced |
| 17 | SCN4A | Myasthenic syndrome, congenital, type 16 | N/A | N/A |
| 2 | SCN9A | Indifference to pain and autosomal recessive hereditary sensory neuropathy type 2D | N/A | N/A |
| 12 | SCNN1A | Pseudohypoaldosteronism, type 1 | N/A | N/A |
| 16 | SCNN1B | Pseudohypoaldosteronism, type 1 | < 1 in 500 | Reduced |
| 16 | SCNN1G | Pseudohypoaldosteronism, type 1 | < 1 in 500 | Reduced |
| 17 | SCO1 | Mitochondrial complex IV deficiency, nuclear type 4 | < 1 in 500 | Reduced |
| 22 | SCO2 | Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency, type 1 | 1 in 500 | 1 in 8,333 |
| 11 | SCYL1 | Spinocerebellar ataxia, autosomal recessive, type 21 | N/A | N/A |
| 1 | SDCCAG8 | Bardet-Biedl syndrome, type 16 | N/A | N/A |
| 5 | SDHA | Mitochondrial respiratory chain complex II deficiency; Leigh syndrome | N/A | N/A |
| 19 | SDHAF1 | Mitochondrial complex II deficiency | < 1 in 500 | Reduced |
| 12 | SDR9C7 | Ichthyosis, congenital, autosomal recessive 13 | N/A | N/A |
| 14 | SEC23A | Craniofacioscapular dysplasia | N/A | N/A |
| 20 | SEC23B | Dyserythropoietic anemia, congenital, type 2 | N/A | N/A |
| 4 | SEC24D | Cole-Carpenter syndrome 2 | N/A | N/A |
| 9 | SECISBP2 | Thyroid hormone metabolism, abnormal | N/A | N/A |
| 1 | SELENON | Muscular dystrophy, rigid spine, type 1 | N/A | N/A |
| 1 | SEMA4A | Cone-rod dystrophy, type 10; Retinitis pigmentosa, type 35 | N/A | N/A |
| 4 | SEPSECS | Pontocerebellar hypoplasia, type 2D | < 1 in 500 | Reduced |
| 6 | SERAC1 | 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome (MEGDEL) | N/A | N/A |
| 14 | SERPINA1 | Alpha-1 antitrypsin deficiency | 1 in 24 | 1 in 2400 |
| 18 | SERPINB7 | Palmoplantar keratoderma, Nagashima type | < 1 in 500 | Reduced |
| 18 | SERPINB8 | Peeling skin syndrome 5 | < 1 in 500 | Reduced |
| 1 | SERPINC1 | Thrombophilia due to antithrombin III deficiency | N/A | N/A |
| 7 | SERPINE1 | Plasminogen activator inhibitor-1 deficiency | < 1 in 500 | Reduced |
| 17 | SERPINF1 | Osteogenesis imperfecta, type 6 | < 1 in 500 | Reduced |
| 17 | SERPINF2 | Alpha-2-plasmin inhibitor deficiency | < 1 in 500 | Reduced |
| 11 | SERPING1 | Angioedema, hereditary, types 1 and 2 | < 1 in 500 | Reduced |
| 11 | SERPINH1 | Osteogenesis imperfecta, type 10 | N/A | N/A |
| 9 | SETX | Spinocerebellar ataxia, autosomal recessive, type 1 | 1 in 500 | 1 in 2273 |
| 7 | SFRP4 | Pyle disease | < 1 in 500 | Reduced |
| 2 | SFTPB | Surfactant metabolism dysfunction, pulmonary, type 1 | N/A | N/A |
| 10 | SFXN4 | Combined oxidative phosphorylation deficiency 18 | < 1 in 500 | Reduced |
| 17 | SGCA | Limb-girdle muscular dystrophy, type 3 (LGMD R3) | 1 in 288 | 1 in 1920 |
| 4 | SGCB | Limb-girdle muscular dystrophy, type 4 (LGMD R4) | 1 in 628 | 1 in 2093 |
| 5 | SGCD | Limb-girdle muscular dystrophy, type 6 (LGMD R6) | < 1 in 500 | Reduced |
| 13 | SGCG | Limb-girdle muscular dystrophy, type 5 (LGMD R5) | 1 in 1,132 | 1 in 5,468 |
| 10 | SGPL1 | Nephrotic syndrome, type 14 | < 1 in 500 | Reduced |
| 17 | SGSH | Mucopolysaccharidosis, type 3A (Sanfilippo A) | 1 in 253 | 1 in 5060 |
| 5 | SH3PXD2B | Frank-ter Haar syndrome | < 1 in 500 | Reduced |
| 5 | SH3TC2 | Charcot-Marie-Tooth disease, type 4C | 1 in 130 | 1 in 1300 |
| 3 | SI | Sucrase-isomaltase deficiency, congenital | N/A | N/A |
| 5 | SIL1 | Marinesco-Sjogren syndrome | < 1 in 500 | Reduced |
| 14 | SIX6 | Optic disc anomalies with retinal and/or macular dystrophy | < 1 in 500 | Reduced |
| 6 | SKIC2 | Trichohepatoenteric syndrome, type 2 (diarrhea, syndromic) | N/A | N/A |
| 5 | SKIC3 | Trichohepatoenteric syndrome, type 1 (diarrhea, syndromic) | 1 in 634 | 1 in 951 |
| 13 | SLC10A2 | Bile acid malabsorption, primary | N/A | N/A |
| 12 | SLC11A2 | Anemia, hypochromic microcytic, with iron overload 1 | < 1 in 500 | Reduced |
| 15 | SLC12A1 | Bartter syndrome, type 1 | < 1 in 500 | Reduced |
| 16 | SLC12A3 | Gitelman syndrome | 1 in 100 | 1 in 1250 |
| 20 | SLC12A5 | Epileptic encephalopathy, early infantile, 34 | < 1 in 500 | Reduced |
| 15 | SLC12A6 | Agnesis of the corpus callosum with peripheral neuropathy | < 1 in 500 | Reduced |
| 17 | SLC13A5 | Epileptic encephalopathy, early infantile, 25 | < 1 in 500 | Reduced |
| 1 | SLC16A1 | Monocarboxylate transporter 1 deficiency | < 1 in 500 | Reduced |
| 6 | SLC17A5 | Salla disease | 1 in 328 | 1 in 2187 |
| 10 | SLC18A3 | Myasthenic syndrome, congenital, 21, presynaptic | < 1 in 500 | Reduced |
| 1 | SLC19A2 | Thiamine-responsive megaloblastic anemia syndrome | 1 in 500 | 1 in 888 |
| 2 | SLC19A3 | Thiamine metabolism dysfunction syndrome, type 2 (biotin- or thiamine-responsive encephalopathy type) | 1 in 232 | 1 in 1,785 |
| 9 | SLC1A1 | Dicarboxylic aminoaciduria | < 1 in 500 | Reduced |
| 2 | SLC1A4 | Spastic tetraplegia, thin corpus callosum, and progressive microcephaly | < 1 in 500 | Reduced |
| 11 | SLC22A12 | Hypouricemia, renal | N/A | N/A |
| 5 | SLC22A5 | Carnitine deficiency, systemic primary | 1 in 251 | 1 in 717 |
| 15 | SLC24A1 | Night blindness, congenital stationary (complete), type 1D, autosomal recessive | < 1 in 500 | Reduced |
| 14 | SLC24A4 | Amelogenesis imperfecta, type IIA5 | < 1 in 500 | Reduced |
| 15 | SLC24A5 | Albinism, oculocutaneous, type 6 | N/A | N/A |
| 22 | SLC25A1 | Combined D-2- and L-2-hydroxyglutaric aciduria | N/A | N/A |

| | | | | |
|----|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| 2 | SLC25A12 | Epileptic encephalopathy, early infantile, type 39 | < 1 in 500 | Reduced |
| 7 | SLC25A13 | Citrullinemia, type 2, neonatal-onset; Citrullinemia, type 2, adult-onset | 1 in 619 | 1 in 2063 |
| 13 | SLC25A15 | Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome | < 1 in 500 | Reduced |
| 17 | SLC25A19 | Microcephaly, Amish type; Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type) | < 1 in 500 | Reduced |
| 3 | SLC25A20 | Carnitine-acylcarnitine translocase deficiency | < 1 in 500 | Reduced |
| 11 | SLC25A22 | Epileptic encephalopathy, early infantile, type 3 | < 1 in 500 | Reduced |
| 3 | SLC25A26 | Combined oxidative phosphorylation deficiency 28 | < 1 in 500 | Reduced |
| 12 | SLC25A3 | Mitochondrial phosphate carrier deficiency | < 1 in 500 | Reduced |
| 3 | SLC25A38 | Anemia, sideroblastic, type 2, pyridoxine-refractory | N/A | N/A |
| 4 | SLC25A4 | Mitochondrial DNA depletion syndrome, type 12B (cardiomyopathic type) AR | < 1 in 500 | Reduced |
| 5 | SLC25A46 | Neuropathy, hereditary motor and sensory, type VIB | N/A | N/A |
| 5 | SLC26A2 | Achondrogenesis Ib; Atelosteogenesis, type II; De la Chapelle dysplasia; Diastrophic dysplasia; Diastrophic dysplasia, broad bone-platyspondylic variant; Epiphyseal dysplasia, multiple, 4 | 1 in 129 | 1 in 4300 |
| 7 | SLC26A3 | Diarrhea 1, secretory chloride, congenital | < 1 in 500 | Reduced |
| 7 | SLC26A4 | Deafness, autosomal recessive, type 4; Pendred syndrome | 1 in 88 | 1 in 587 |
| 7 | SLC26A5 | ?Deafness, autosomal recessive, type 61 | N/A | N/A |
| 9 | SLC27A4 | Ichthyosis prematurity syndrome | N/A | N/A |
| 10 | SLC29A3 | Histiocytosis-lymphadenopathy plus syndrome | < 1 in 500 | Reduced |
| 1 | SLC2A1 | GLUT1 deficiency syndrome 1, infantile onset, severe | < 1 in 500 | Reduced |
| 20 | SLC2A10 | Arterial tortuosity syndrome | N/A | N/A |
| 3 | SLC2A2 | Fanconi-Bickel syndrome | < 1 in 500 | Reduced |
| 4 | SLC2A9 | Hypouricemia, renal, type 2 | N/A | N/A |
| 1 | SLC30A10 | Hyper manganeseemia with dystonia, type 1 | < 1 in 500 | Reduced |
| 3 | SLC33A1 | Congenital cataracts, hearing loss, and neurodegeneration | < 1 in 500 | Reduced |
| 5 | SLC34A1 | Hypercalcemia, infantile, type 2 | N/A | N/A |
| 4 | SLC34A2 | Pulmonary alveolar microlithiasis | N/A | N/A |
| 9 | SLC34A3 | Hypophosphatemic rickets with hypercalciuria | N/A | N/A |
| 6 | SLC35A1 | Congenital disorder of glycosylation, type 2F | < 1 in 500 | <1 in 1,500 |
| 1 | SLC35A3 | Arthrogryposis, impaired intellectual development, and seizures | < 1 in 500 | Reduced |
| 11 | SLC35C1 | Congenital disorder of glycosylation, type 2C | < 1 in 500 | Reduced |
| 1 | SLC35D1 | Schneckenbecken dysplasia | < 1 in 500 | Reduced |
| 11 | SLC37A4 | Glycogen storage disease, type 1B | 1 in 500 | 1 in 7143 |
| 16 | SLC38A8 | Foveal hypoplasia 2, with or without optic nerve misrouting and/or anterior segment dysgenesis | N/A | N/A |
| 11 | SLC39A13 | Ehlers-Danlos syndrome, spondylodysplastic type, 3 | < 1 in 500 | Reduced |
| 8 | SLC39A14 | Hyper manganeseemia with dystonia 2 | < 1 in 500 | Reduced |
| 8 | SLC39A4 | Acrodermatitis enteropathica | 1 in 316 | 1 in 1580 |
| 4 | SLC39A8 | Congenital disorder of glycosylation, type II n | < 1 in 500 | Reduced |
| 2 | SLC3A1 | Cystinuria | 1 in 42 | 1 in 84 |
| 1 | SLC45A1 | Intellectual developmental disorder with neuropsychiatric features | N/A | N/A |
| 5 | SLC45A2 | Albinism, oculocutaneous, type 4 | < 1 in 500 | <1 in 1,600 |
| 17 | SLC46A1 | Folate malabsorption, hereditary | < 1 in 500 | Reduced |
| 17 | SLC4A1 | Distal renal tubular acidosis | N/A | N/A |
| 20 | SLC4A11 | Corneal endothelial dystrophy, autosomal recessive | 1 in 295 | 1 in 1475 |
| 4 | SLC4A4 | Renal tubular acidosis, proximal, with ocular abnormalities | < 1 in 500 | Reduced |
| 8 | SLC52A2 | Brown-Vialetto-Van Laere syndrome, type 2 | < 1 in 500 | Reduced |
| 20 | SLC52A3 | Brown-Vialetto-Van Laere syndrome, type 1 | < 1 in 500 | Reduced |
| 22 | SLC5A1 | Glucose/galactose malabsorption | N/A | N/A |
| 16 | SLC5A2 | Renal glucosuria | N/A | N/A |
| 19 | SLC5A5 | Thyroid dysmorphogenesis, type 1 | 1 in 72 | 1 in 96 |
| 2 | SLC5A7 | Myasthenic syndrome, congenital, type 20, presynaptic | < 1 in 500 | Reduced |
| 1 | SLC6A17 | Mental retardation, autosomal recessive 48 | < 1 in 500 | Reduced |
| 5 | SLC6A19 | Hartnup disorder | 1 in 87 | 1 in 124 |
| 5 | SLC6A3 | Parkinsonism-dystonia, infantile | < 1 in 500 | Reduced |
| 11 | SLC6A5 | Hyperekplexia, type 3 | N/A | N/A |
| 1 | SLC6A9 | Glycine encephalopathy with normal serum glycine | < 1 in 500 | Reduced |
| 3 | SLC7A14 | Retinitis pigmentosa 68 | N/A | N/A |
| 14 | SLC7A7 | Lysinuric protein intolerance | < 1 in 500 | Reduced |
| 19 | SLC7A9 | Cystinuria | 1 in 42 | 1 in 48 |
| 5 | SLC9A3 | Diarrhea 8, secretory sodium, congenital | < 1 in 500 | Reduced |
| 3 | SLC02A1 | Hypertrophic osteoarthropathy, primary, autosomal recessive, type 2 | N/A | N/A |
| 13 | SLITRK6 | Deafness and myopia | < 1 in 500 | Reduced |
| 8 | SLURP1 | Meleda disease | < 1 in 500 | Reduced |
| 16 | SLX4 | Fanconi anemia, complementation group P | N/A | N/A |
| 2 | SMARCAL1 | Schimke immunosseous dysplasia | 1 in 451 | 1 in 3007 |
| 17 | SMARCD2 | Specific granule deficiency 2 | < 1 in 500 | Reduced |
| 19 | SMG9 | Heart and brain malformation syndrome | < 1 in 500 | Reduced |
| 5 | SMN1 | Spinal muscular atrophy | 1 in 36 | 1 in 360 |
| 14 | SMOC1 | Microphthalmia, with limb anomalies | < 1 in 500 | Reduced |
| 6 | SMOC2 | Dentin dysplasia, type 1, with microdontia and misshapen teeth | < 1 in 500 | Reduced |

| | | | | |
|----|---------|--------------------------------------------------------------------------------------------------------------------|------------|------------|
| 11 | SMPD1 | Niemann-Pick disease, type A; Niemann-Pick disease, type B | 1 in 350 | 1 in 3500 |
| 22 | SNAP29 | Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome | < 1 in 500 | Reduced |
| 7 | SNX10 | Osteopetrosis, autosomal recessive, type 8 | < 1 in 500 | Reduced |
| 6 | SNX14 | Spinocerebellar ataxia, autosomal recessive, type 20 | N/A | N/A |
| 6 | SOBP | Mental retardation, anterior maxillary protrusion, and strabismus | < 1 in 500 | Reduced |
| 21 | SOD1 | Spastic tetraplegia and axial hypotonia, progressive; Amyotrophic lateral sclerosis, type 1 | < 1 in 500 | Reduced |
| 9 | SOHLH1 | Ovarian dysgenesis 5 | < 1 in 500 | Reduced |
| 17 | SOST | Sclerosteosis, type 1; Van Buchem disease | < 1 in 500 | Reduced |
| 20 | SOX18 | Hypotrichosis-lymphedema-telangiectasia syndrome | < 1 in 500 | Reduced |
| 2 | SP110 | Hepatic venoocclusive disease with immunodeficiency | N/A | N/A |
| 12 | SP7 | Osteogenesis imperfecta, type XII | < 1 in 500 | Reduced |
| 8 | SPAG1 | Ciliary dyskinesia, primary, type 28 | N/A | N/A |
| 5 | SPARC | Osteogenesis imperfecta, type XVII | < 1 in 500 | Reduced |
| 13 | SPART | Spastic paraplegia, type 20, autosomal recessive | < 1 in 500 | Reduced |
| 4 | SPATA5 | Epilepsy, hearing loss, and mental retardation syndrome | N/A | N/A |
| 14 | SPATA7 | Leber congenital amaurosis, type 3 | < 1 in 500 | Reduced |
| 2 | SPEG | Centronuclear myopathy, type 5 | N/A | N/A |
| 15 | SPG11 | Amyotrophic lateral sclerosis 5, juvenile; Charcot-Marie-Tooth disease, axonal, type 2X; Spastic paraplegia 11 | 1 in 192 | 1 in 467 |
| 15 | SPG21 | Mast syndrome | < 1 in 500 | Reduced |
| 16 | SPG7 | Spastic paraplegia, type 7, autosomal recessive | 1 in 80 | 1 in 183 |
| 5 | SPINK1 | Tropical calcific pancreatitis | < 1 in 500 | Reduced |
| 5 | SPINK5 | Netherton syndrome | N/A | N/A |
| 19 | SPINT2 | Diarrhea 3, secretory sodium, congenital, syndromic | < 1 in 500 | Reduced |
| 2 | SPR | Dystonia, dopa-responsive, due to sepiapterin reductase deficiency | < 1 in 500 | Reduced |
| 1 | SPRTN | Ruijs-Aalfs syndrome | < 1 in 500 | Reduced |
| 1 | SPTA1 | Pyropoikilocytosis; Spherocytosis, type 3 | N/A | N/A |
| 11 | SPTBN2 | Spinocerebellar ataxia, autosomal recessive, type 14 | N/A | N/A |
| 19 | SPTBN4 | Neurodevelopmental disorder with hypotonia, neuropathy, and deafness | N/A | N/A |
| 5 | SQSTM1 | Neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset | N/A | N/A |
| 2 | SRD5A2 | 46,XY disorder of sex development due to 5-alpha-reductase 2 deficiency (pseudovaginal perineoscrotal hypospadias) | 1 in 400 | 1 in 4000 |
| 4 | SRD5A3 | Congenital disorder of glycosylation, type 1Q; Kahrizi syndrome | N/A | N/A |
| 11 | ST14 | Ichthyosis, congenital, autosomal recessive, type 11 | < 1 in 500 | Reduced |
| 1 | ST3GAL3 | Mental retardation, autosomal recessive 12 | < 1 in 500 | Reduced |
| 2 | ST3GAL5 | Salt and pepper developmental regression syndrome | < 1 in 500 | Reduced |
| 12 | STAC3 | Native American myopathy | < 1 in 500 | Reduced |
| 7 | STAG3 | Premature ovarian failure, type 8; Spermatogenic failure 61 | N/A | N/A |
| 2 | STAMBP | Microcephaly-capillary malformation syndrome | < 1 in 500 | Reduced |
| 8 | STAR | Lipoid adrenal hyperplasia | 1 in 1,147 | 1 in 14338 |
| 2 | STAT1 | Immunodeficiency, type 31B, mycobacterial and viral infections | < 1 in 500 | Reduced |
| 12 | STAT2 | Immunodeficiency, type 44 | < 1 in 500 | Reduced |
| 17 | STAT5B | Laron syndrome with immunodeficiency | < 1 in 500 | Reduced |
| 1 | STIL | Microcephaly, type 7, primary, autosomal recessive | N/A | N/A |
| 11 | STIM1 | Immunodeficiency, type 10 | < 1 in 500 | Reduced |
| 20 | STK4 | T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations | N/A | N/A |
| 15 | STRA6 | Microphthalmia, isolated, with coloboma, type 8 | N/A | N/A |
| 17 | STRADA | Polyhydramnios, megalencephaly, and symptomatic epilepsy | N/A | N/A |
| 15 | STRC | Deafness, autosomal recessive, type 16 | 1 in 68 | 1 in 80 |
| 16 | STUB1 | Spinocerebellar ataxia, autosomal recessive, type 16 | < 1 in 500 | Reduced |
| 6 | STX11 | Hemophagocytic lymphohistiocytosis, familial, type 4 | < 1 in 500 | Reduced |
| 19 | STXBP2 | Hemophagocytic lymphohistiocytosis, familial, type 5 | N/A | N/A |
| 13 | SUCLA2 | Mitochondrial DNA depletion syndrome, type 5 (encephalomyopathic with or without methylmalonic aciduria) | < 1 in 500 | Reduced |
| 2 | SUCLG1 | Mitochondrial DNA depletion syndrome, type 9 (encephalomyopathic, type with methylmalonic aciduria) | N/A | N/A |
| 10 | SUFU | Joubert syndrome, type 32 | < 1 in 500 | Reduced |
| 7 | SUGCT | Glutaric aciduria, type 3 | N/A | N/A |
| 19 | SULT2B1 | Ichthyosis, congenital, autosomal recessive, type 14 | < 1 in 500 | Reduced |
| 3 | SUMF1 | Multiple sulfatase deficiency | < 1 in 500 | Reduced |
| 20 | SUN5 | Spermatogenic failure, type 16 | < 1 in 500 | Reduced |
| 12 | SUOX | Sulfite oxidase deficiency | < 1 in 500 | Reduced |
| 9 | SURF1 | Mitochondrial complex IV deficiency, nuclear type 1; Charcot-Marie-Tooth disease, type 4K | 1 in 191 | 1 in 329 |
| 6 | SYNE1 | Spinocerebellar ataxia, autosomal recessive, type 8 | N/A | N/A |
| 19 | SYNE4 | Deafness, autosomal recessive, type 76 | N/A | N/A |
| 21 | SYNJ1 | Epileptic encephalopathy, early infantile, 53 | < 1 in 500 | Reduced |
| 1 | SYT14 | ?Spinocerebellar ataxia, autosomal recessive, type 11 | N/A | N/A |
| 1 | SZT2 | Epileptic encephalopathy, early infantile, 18 | N/A | N/A |
| 12 | TAC3 | Hypogonadotropic hypogonadism, type 10, with or without anosmia | N/A | N/A |
| 17 | TACO1 | Mitochondrial complex IV deficiency, nuclear type 8 | < 1 in 500 | Reduced |
| 4 | TACR3 | Hypogonadotropic hypogonadism, type 11, with or without anosmia | N/A | N/A |
| 1 | TACSTD2 | Corneal dystrophy, gelatinous drop-like | < 1 in 500 | Reduced |

| | | | | |
|----|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| 1 | TAF13 | Mental retardation, autosomal recessive 60 | < 1 in 500 | Reduced |
| 8 | TAF2 | Mental retardation, autosomal recessive 40 | < 1 in 500 | Reduced |
| 7 | TAF6 | Alazami-Yuan syndrome | < 1 in 500 | Reduced |
| 11 | TALDO1 | Transaldolase deficiency | < 1 in 500 | Reduced |
| 22 | TANGO2 | Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration | N/A | N/A |
| 6 | TAP1 | Bare lymphocyte syndrome, type 1 | < 1 in 500 | Reduced |
| 6 | TAP2 | Bare lymphocyte syndrome, type 1, due to TAP2 deficiency | < 1 in 500 | Reduced |
| 6 | TAPBP | Bare lymphocyte syndrome, type 1 | N/A | N/A |
| 4 | TAPT1 | Osteochondrodysplasia, complex lethal, Symoens-Barnes-Gistelincx type | < 1 in 500 | Reduced |
| 16 | TAT | Tyrosinemia, type 2 | < 1 in 500 | Reduced |
| 20 | TBC1D20 | Warburg micro syndrome 4 | < 1 in 500 | Reduced |
| 3 | TBC1D23 | Pontocerebellar hypoplasia, type 11 | < 1 in 500 | Reduced |
| 16 | TBC1D24 | DOORS (deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures) syndrome; Epileptic encephalopathy, early infantile, type 16; Deafness, autosomal recessive, type 86 | N/A | N/A |
| 6 | TBC1D7 | Macrocephaly/megalencephaly syndrome, autosomal recessive | < 1 in 500 | Reduced |
| 17 | TBCD | Encephalopathy, progressive, early-onset, with brain atrophy and thin corpus callosum | N/A | N/A |
| 1 | TBCE | Encephalopathy, progressive, with amyotrophy and optic atrophy; Hypoparathyroidism-retardation-dysmorphism syndrome; Kenny-Caffey syndrome, type 1 | N/A | N/A |
| 4 | TBCK | Hypotonia, infantile, with psychomotor retardation and characteristic facies 3 | N/A | N/A |
| 1 | TBX15 | Cousin syndrome | < 1 in 500 | Reduced |
| 1 | TBX19 | Congenital isolated adrenocorticotrophic hormone deficiency | < 1 in 500 | Reduced |
| 7 | TBXAS1 | Ghosal syndrome | N/A | N/A |
| 17 | TCAP | Limb-girdle muscular dystrophy, type 7 (LGMD R7) | < 1 in 500 | Reduced |
| 11 | TCIRG1 | Osteopetrosis, autosomal recessive, type 1 | 1 in 399 | 1 in 7980 |
| 22 | TCN2 | Transcobalamin II deficiency | N/A | N/A |
| 12 | TCTN1 | Joubert syndrome, type 13 | N/A | N/A |
| 12 | TCTN2 | Joubert syndrome, type 24; ?Meckel syndrome, type 8 | N/A | N/A |
| 10 | TCTN3 | Joubert syndrome 18; Orofaciodigital syndrome IV | N/A | N/A |
| 14 | TDP1 | ?Spinocerebellar ataxia, autosomal recessive with axonal neuropathy | N/A | N/A |
| 6 | TDP2 | Spinocerebellar ataxia, autosomal recessive, type 23 | < 1 in 500 | Reduced |
| 9 | TDRD7 | Cataract 36 | < 1 in 500 | Reduced |
| 14 | TECPR2 | Spastic paraplegia, type 49, autosomal recessive | 1 in 1,946 | 1 in 12973 |
| 19 | TECR | Mental retardation, autosomal recessive, type 14 | < 1 in 500 | Reduced |
| 4 | TECRL | Ventricular tachycardia, catecholaminergic polymorphic, 3 | < 1 in 500 | Reduced |
| 11 | TECTA | Deafness, autosomal recessive, type 21 | N/A | N/A |
| 16 | TELO2 | You-Hoover-Fong syndrome | N/A | N/A |
| 4 | TENM3 | Microphthalmia, isolated, with coloboma 9 | N/A | N/A |
| 5 | TERT | Dyskeratosis congenita, autosomal recessive, type 4 | < 1 in 500 | Reduced |
| 8 | TEX15 | Spermatogenic failure, type 25 | N/A | N/A |
| 3 | TF | Atransferrinemia | 1 in 500 | 1 in 7,143 |
| 7 | TFR2 | Hemochromatosis, type 3 | < 1 in 500 | Reduced |
| 3 | TFRC | Immunodeficiency, type 46 | < 1 in 500 | Reduced |
| 8 | TG | Thyroid dysmorphogenesis, type 3 | 1 in 159 | 1 in 268 |
| 13 | TGDS | Catel-Manzke syndrome | N/A | N/A |
| 14 | TGM1 | Ichthyosis, congenital, autosomal recessive, type 1 | 1 in 186 | 1 in 1860 |
| 15 | TGM5 | Peeling skin syndrome, type 2 | N/A | N/A |
| 11 | TH | Segawa syndrome, recessive | < 1 in 500 | Reduced |
| 16 | THOC6 | Beaulieu-Boycott-Innes syndrome | N/A | N/A |
| 3 | THRB | Thyroid hormone resistance, autosomal recessive | < 1 in 500 | Reduced |
| 19 | TIMM50 | 3-methylglutaconic aciduria, type 9 | < 1 in 500 | Reduced |
| 3 | TIMMDC1 | Mitochondrial complex I deficiency, nuclear type 31 | N/A | N/A |
| 9 | TJP2 | Cholestasis, progressive familial intrahepatic 4; Hypercholanemia, familial 1 | N/A | N/A |
| 16 | TK2 | Mitochondrial DNA depletion syndrome , type 2 (myopathic type) | 1 in 500 | 1 in 16667 |
| 3 | TKT | Short stature, developmental delay, and congenital heart defects | < 1 in 500 | Reduced |
| 19 | TLE6 | Preimplantation embryonic lethality | N/A | N/A |
| 9 | TMC1 | Deafness, autosomal recessive, type 7 | N/A | N/A |
| 17 | TMC6 | Epidermodysplasia verruciformis | < 1 in 500 | Reduced |
| 17 | TMC8 | Epidermodysplasia verruciformis | < 1 in 500 | Reduced |
| 1 | TMCO1 | Craniofacial dysmorphism, skeletal anomalies, and mental retardation syndrome | < 1 in 500 | Reduced |
| 17 | TMEM107 | Meckel syndrome, type 13; Orofaciodigital syndrome, type 16 | N/A | N/A |
| 11 | TMEM126A | Optic atrophy 7 | < 1 in 500 | Reduced |
| 11 | TMEM126B | Mitochondrial complex I deficiency, nuclear type 29 | < 1 in 500 | Reduced |
| 11 | TMEM138 | Joubert syndrome 16 | < 1 in 500 | Reduced |
| 4 | TMEM165 | Congenital disorder of glycosylation, type 2K | < 1 in 500 | Reduced |
| 17 | TMEM199 | Congenital disorder of glycosylation, type 2P | < 1 in 500 | Reduced |
| 11 | TMEM216 | Joubert syndrome, type 2; Meckel syndrome, type 2 | < 1 in 500 | Reduced |
| 16 | TMEM231 | Joubert syndrome, type 20; Meckel syndrome, type 11 | N/A | N/A |
| 2 | TMEM237 | Joubert syndrome, type 14 | N/A | N/A |
| 14 | TMEM260 | Structural heart defects and renal anomalies syndrome | N/A | N/A |

| | | | | |
|----|-----------|-------------------------------------------------------------------------------------------------------------------|------------|------------|
| 8 | TMEM67 | Meckel syndrome 3; COACH syndrome 1; Joubert syndrome 6; Nephronophthisis 11 | 1 in 147 | 1 in 2,940 |
| 8 | TMEM70 | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2 | < 1 in 500 | Reduced |
| 3 | TMIE | Deafness, autosomal recessive, type 6 | < 1 in 500 | Reduced |
| 21 | TMPRSS15 | Enterokinase deficiency | N/A | N/A |
| 21 | TMPRSS3 | Deafness, autosomal recessive, type 8/10 | N/A | N/A |
| 22 | TMPRSS6 | Iron-refractory iron deficiency anemia | N/A | N/A |
| 12 | TMTC3 | Lissencephaly 8 | N/A | N/A |
| 18 | TNFRSF11A | Osteopetrosis, autosomal recessive, type 7 | < 1 in 500 | Reduced |
| 8 | TNFRSF11B | Paget disease of bone, type 5, juvenile-onset | < 1 in 500 | Reduced |
| 17 | TNFRSF13B | Immunodeficiency, common variable, type 2 | N/A | N/A |
| 13 | TNFSF11 | Osteopetrosis, autosomal recessive, type 2 | < 1 in 500 | Reduced |
| 3 | TNIK | Mental retardation, autosomal recessive 54 | < 1 in 500 | Reduced |
| 19 | TNNT1 | Nemaline myopathy, type 5, Amish type | < 1 in 500 | Reduced |
| 6 | TNXB | Ehlers-Danlos syndrome, classic-like | 1 in 335 | 1 in 1675 |
| 1 | TOE1 | Pontocerebellar hypoplasia, type 7 | N/A | N/A |
| 17 | TOP3A | Microcephaly, growth restriction, and increased sister chromatid exchange 2 | N/A | N/A |
| 20 | TP53RK | Galloway-Mowat syndrome 4 | < 1 in 500 | Reduced |
| 12 | TP11 | Hemolytic anemia due to triosephosphate isomerase deficiency | < 1 in 500 | Reduced |
| 7 | TPK1 | Episodic encephalopathy due to thiamine pyrophosphokinase deficiency | N/A | N/A |
| 1 | TPM3 | Nemaline myopathy, type 1; Congenital fiber-type disproportion myopathy | < 1 in 500 | Reduced |
| 2 | TPO | Thyroid dysmorphogenesis, type 2A | 1 in 72 | 1 in 84 |
| 11 | TPP1 | Ceroid lipofuscinosis, neuronal, type 2; Spinocerebellar ataxia, autosomal recessive, type 7 | 1 in 266 | 1 in 1773 |
| 9 | TPRN | Deafness, autosomal recessive, type 79 | N/A | N/A |
| 2 | TRAF3IP1 | Senior-Loken syndrome, type 9 | N/A | N/A |
| 3 | TRAIIP | Seckel syndrome, type 9 | < 1 in 500 | Reduced |
| 4 | TRAPPC11 | Limb-girdle muscular dystrophy, type 18 (LGMD R18) | N/A | N/A |
| 2 | TRAPPC12 | Encephalopathy, progressive, early-onset, with brain atrophy and spasticity | < 1 in 500 | Reduced |
| 14 | TRAPPC6B | Neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy | < 1 in 500 | Reduced |
| 8 | TRAPPC9 | Mental retardation, autosomal recessive, type 13 | N/A | N/A |
| 6 | TRDN | Ventricular tachycardia, catecholaminergic polymorphic, type 5, with or without muscle weakness | 1 in 51 | 1 in 71 |
| 6 | TREM2 | Nasu-Hakola disease | < 1 in 500 | Reduced |
| 3 | TREX1 | Aicardi-Goutieres syndrome, type 1 | 1 in 98 | 1 in 186 |
| 8 | TRHR | Hypothyroidism, congenital, nongoitrous, type 7 | N/A | N/A |
| 4 | TRIM2 | Charcot-Marie-Tooth disease, type 2R | < 1 in 500 | Reduced |
| 9 | TRIM32 | Limb-girdle muscular dystrophy, type 8 (LGMD R8) | 1 in 226 | 1 in 376 |
| 17 | TRIM37 | Mulibrey nanism | < 1 in 500 | Reduced |
| 22 | TRIOBP | Deafness, autosomal recessive, type 28 | 1 in 445 | 1 in 8900 |
| 14 | TRIP11 | Achondrogenesis, type 1A | N/A | N/A |
| 5 | TRIP13 | Mosaic variegated aneuploidy syndrome 3 | < 1 in 500 | Reduced |
| 15 | TRIP4 | Spinal muscular atrophy with congenital bone fractures 1 | < 1 in 500 | Reduced |
| 1 | TRIT1 | Combined oxidative phosphorylation deficiency 35 | N/A | N/A |
| 4 | TRMT10A | Microcephaly, short stature, and impaired glucose metabolism 1 | < 1 in 500 | Reduced |
| 3 | TRMT10C | Combined oxidative phosphorylation deficiency 30 | < 1 in 500 | Reduced |
| 14 | TRMT5 | Combined oxidative phosphorylation deficiency 26 | N/A | N/A |
| 22 | TRMU | Liver failure, transient infantile | < 1 in 500 | Reduced |
| 3 | TRNT1 | Retinitis pigmentosa and erythrocytic microcytosis | N/A | N/A |
| 15 | TRPM1 | Night blindness, congenital stationary (complete), type 1C, autosomal recessive | N/A | N/A |
| 9 | TRPM6 | Familial hypomagnesemia with secondary hypocalcemia | N/A | N/A |
| 7 | TRPV6 | Hyperparathyroidism, transient neonatal | < 1 in 500 | Reduced |
| 1 | TSEN15 | Pontocerebellar hypoplasia, type 2F | < 1 in 500 | Reduced |
| 3 | TSEN2 | Pontocerebellar hypoplasia, type 2B | N/A | N/A |
| 19 | TSEN34 | Pontocerebellar hypoplasia type 2C | N/A | N/A |
| 17 | TSEN54 | Pontocerebellar hypoplasia, type 2A; Pontocerebellar hypoplasia, type 4 | 1 in 223 | 1 in 3,997 |
| 12 | TSMF | Combined oxidative phosphorylation deficiency, type 3 | < 1 in 500 | Reduced |
| 1 | TSHB | Hypothyroidism, congenital, nongoitrous, type 4 | 1 in 62 | 1 in 306 |
| 14 | TSHR | Hypothyroidism, congenital, nongoitrous, type 1 | 1 in 62 | 1 in 189 |
| 17 | TTC19 | Mitochondrial complex III deficiency, nuclear type 2 | N/A | N/A |
| 2 | TTC21B | Short-rib thoracic dysplasia, type 4, with or without polydactyly | N/A | N/A |
| 2 | TTC7A | Gastrointestinal defects and immunodeficiency syndrome | N/A | N/A |
| 14 | TTC8 | Bardet-Biedl syndrome, type 8 | N/A | N/A |
| 8 | TTI2 | Mental retardation, autosomal recessive, type 39 | N/A | N/A |
| 14 | TTLL5 | Cone-rod dystrophy 19 | N/A | N/A |
| 2 | TTN | Limb-girdle muscular dystrophy type 10 (LGMDR10); Early-onset myopathy with fatal cardiomyopathy (Salih myopathy) | < 1 in 500 | Reduced |
| 8 | TTPA | Ataxia with isolated vitamin E deficiency | < 1 in 500 | Reduced |
| 22 | TUBA8 | Cortical dysplasia, complex, with other brain malformations, type 8 | N/A | N/A |
| 15 | TUBGCP4 | Microcephaly and chorioretinopathy, autosomal recessive, type 3 | N/A | N/A |
| 22 | TUBGCP6 | Microcephaly and chorioretinopathy, autosomal recessive, type 1 | N/A | N/A |
| 16 | TUFM | Combined oxidative phosphorylation deficiency 4 | < 1 in 500 | Reduced |

| | | | | |
|----|---------|-------------------------------------------------------------------------------------------------------------------|------------|-------------|
| 6 | TULP1 | Retinitis pigmentosa 14; Leber congenital amaurosis 15 | N/A | N/A |
| 8 | TUSC3 | Mental retardation, autosomal recessive, type 7 | N/A | N/A |
| 2 | TWIST2 | Focal facial dermal dysplasia, type 3 (Setleis type) | < 1 in 500 | Reduced |
| 10 | TWINK | Mitochondrial DNA depletion syndrome, type 7 (hepatocerebral type); Perrault syndrome type 5 | < 1 in 500 | Reduced |
| 18 | TXNL4A | Burn-McKeown syndrome | N/A | N/A |
| 19 | TYK2 | Immunodeficiency, type 35 | < 1 in 500 | Reduced |
| 22 | TYMP | Mitochondrial DNA depletion syndrome, type 1 (MNGIE type) | 1 in 425 | 1 in 10625 |
| 11 | TYR | Oculocutaneous albinism (OCA) type 1A; OCA type 1B | 1 in 92 | 1 in 1840 |
| 19 | TYROBP | Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, type 1 (Nasu-Hakola disease) | < 1 in 500 | Reduced |
| 9 | TYRP1 | Albinism, oculocutaneous, type 3 | < 1 in 500 | <1 in 1,400 |
| 3 | UBA5 | Epileptic encephalopathy, early infantile, 44 | N/A | N/A |
| 1 | UBE2T | Fanconi anemia, complementation group T | < 1 in 500 | Reduced |
| 15 | UBE3A | Angelman syndrome | 1 in 62 | N/A |
| 12 | UBE3B | Kaufman oculocerebrofacial syndrome | N/A | N/A |
| 15 | UBR1 | Johanson-Blizzard syndrome | N/A | N/A |
| 4 | UCHL1 | Spastic paraplegia, type 79, autosomal recessive | < 1 in 500 | Reduced |
| 13 | UFM1 | Leukodystrophy, hypomyelinating, type 14 | < 1 in 500 | Reduced |
| 2 | UGT1A1 | Crigler-Najjar syndrome, type 1; Crigler-Najjar syndrome, type 2 | 1 in 500 | 1 in 5,496 |
| 3 | UMPS | Orotic aciduria | < 1 in 500 | Reduced |
| 17 | UNC13D | Hemophagocytic lymphohistiocytosis, familial, type 3 | 1 in 108 | 1 in 202 |
| 2 | UNC80 | Hypotonia, infantile, with psychomotor retardation and characteristic facies, type 2 | N/A | N/A |
| 12 | UNG | Immunodeficiency with hyper IgM, type 5 | < 1 in 500 | Reduced |
| 22 | UPB1 | Beta-ureidopropionase deficiency | < 1 in 500 | Reduced |
| 8 | UQCRB | Mitochondrial complex III deficiency, nuclear, type 3 | < 1 in 500 | Reduced |
| 16 | UQCRC2 | Mitochondrial complex III deficiency, nuclear type 5 | < 1 in 500 | Reduced |
| 5 | UQCRCQ | Mitochondrial complex III deficiency, nuclear, type 4 | < 1 in 500 | Reduced |
| 1 | UROD | Porphyria cutanea tarda | N/A | N/A |
| 10 | UROS | Porphyria, congenital erythropoietic | N/A | N/A |
| 16 | USB1 | Poikiloderma with neutropenia | N/A | N/A |
| 11 | USH1C | Usher syndrome, type 1C; Deafness, autosomal recessive, type 18A | 1 in 257 | 1 in 3671 |
| 17 | USH1G | Usher syndrome, type 1G | < 1 in 500 | Reduced |
| 1 | USH2A | Usher syndrome, type 2A; Retinitis pigmentosa 39 | 1 in 70 | 1 in 467 |
| 22 | USP18 | Pseudo-TORCH syndrome 2 | < 1 in 500 | Reduced |
| 4 | UVSSA | UV-sensitive syndrome, type 3 | < 1 in 500 | Reduced |
| 16 | VAC14 | Striatonigral degeneration, childhood-onset | N/A | N/A |
| 6 | VAR51 | Neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy | N/A | N/A |
| 6 | VAR52 | Combined oxidative phosphorylation deficiency 20 | N/A | N/A |
| 12 | VDR | Rickets, vitamin D-resistant, type 2A | N/A | N/A |
| 14 | VIPAS39 | Arthrogyposis, renal dysfunction and cholestasis, type 2 | < 1 in 500 | Reduced |
| 16 | VKORC1 | Vitamin K-dependent clotting factors, combined deficiency of, type 2 | < 1 in 500 | Reduced |
| 9 | VLDLR | Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion, type 1 | < 1 in 500 | Reduced |
| 9 | VPS13A | Choreoacanthocytosis | 1 in 341 | 1 in 974 |
| 8 | VPS13B | Cohen syndrome | 1 in 224 | 1 in 747 |
| 15 | VPS13C | Parkinson disease 23, autosomal recessive, early onset | N/A | N/A |
| 15 | VPS33B | Arthrogyposis, renal dysfunction and cholestasis, type 1 | N/A | N/A |
| 8 | VPS37A | Spastic paraplegia, type 53, autosomal recessive | < 1 in 500 | Reduced |
| 1 | VPS45 | Neutropenia, severe congenital, type 5 | < 1 in 500 | Reduced |
| 17 | VPS53 | Pontocerebellar hypoplasia, type 2E | 1 in 1,506 | N/A |
| 14 | VRK1 | Pontocerebellar hypoplasia, type 1A | < 1 in 500 | Reduced |
| 14 | VSX2 | Microphthalmia with coloboma 3; Isolated microphthalmia 2 | 1 in 1,337 | 1 in 8913 |
| 12 | VWF | von Willibrand disease, type 3 | N/A | N/A |
| 1 | WARS2 | Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures | < 1 in 500 | Reduced |
| 12 | WASHC4 | ?Mental retardation, autosomal recessive, type 43 | N/A | N/A |
| 8 | WASHC5 | Ritscher-Schinzel syndrome, type 1 | N/A | N/A |
| 4 | WDR19 | Nephronophthisis, type 13; Senior-Loken syndrome, type 8 | N/A | N/A |
| 2 | WDR35 | Cranioectodermal dysplasia 2 | N/A | N/A |
| 17 | WDR45B | Neurodevelopmental disorder with spastic quadriplegia and brain abnormalities with or without seizures | < 1 in 500 | Reduced |
| 19 | WDR62 | Microcephaly, type 2, primary, autosomal recessive, with or without cortical malformations | N/A | N/A |
| 15 | WDR72 | Amelogenesis imperfecta, type 2A3 (hypomaturation type) | N/A | N/A |
| 15 | WDR73 | Galloway-Mowat syndrome 1 | N/A | N/A |
| 17 | WDR81 | Cerebellar ataxia, mental retardation, and dysequilibrium syndrome, type 2 | N/A | N/A |
| 7 | WEE2 | Oocyte maturation defect 5 | N/A | N/A |
| 4 | WFS1 | Wolfram syndrome, type 1 | 1 in 370 | 1 in 3700 |
| 9 | WHRN | Usher syndrome, type 2D; Deafness, autosomal recessive, type 31 | 1 in 93 | 1 in 127 |
| 2 | WIPF1 | ?Wiskott-Aldrich syndrome 2 | < 1 in 500 | Reduced |
| 12 | WNK1 | Neuropathy, hereditary sensory and autonomic, type 2 | N/A | N/A |
| 12 | WNT1 | Osteogenesis imperfecta, type XV | < 1 in 500 | Reduced |
| 2 | WNT10A | WNT10A-related conditions | 1 in 238 | 1 in 2975 |

| | | | | |
|----|----------|----------------------------------------------------------------------------------------------------------|------------|----------|
| 12 | WNT10B | Split-hand/foot malformation, type 6 | < 1 in 500 | Reduced |
| 17 | WNT3 | ?Tetra-amelia syndrome | N/A | N/A |
| 3 | WNT7A | Fuhrmann syndrome | < 1 in 500 | Reduced |
| 17 | WRAP53 | Dyskeratosis congenita, autosomal recessive, type 3 | N/A | N/A |
| 8 | WRN | Werner syndrome | 1 in 474 | 1 in 681 |
| 16 | WVVOX | Epileptic encephalopathy, early infantile, type 28; Spinocerebellar ataxia, autosomal recessive, type 12 | N/A | N/A |
| 2 | XDH | Xanthinuria, type 1 | N/A | N/A |
| 9 | XPA | Xeroderma pigmentosum, group A | < 1 in 500 | Reduced |
| 3 | XPC | Xeroderma pigmentosum, group C | < 1 in 500 | Reduced |
| 22 | XPNPEP3 | Nephronophthisis-like nephropathy, type 1 | N/A | N/A |
| 5 | XRCC4 | Short stature, microcephaly, and endocrine dysfunction | N/A | N/A |
| 16 | XYLT1 | Desbuquois dysplasia, type 2 | N/A | N/A |
| 17 | XYLT2 | Spondyloocular syndrome | N/A | N/A |
| 12 | YARS2 | Myopathy, lactic acidosis, and sideroblastic anemia, type 2 | N/A | N/A |
| 1 | YY1AP1 | Grange syndrome | N/A | N/A |
| 2 | ZAP70 | Autoimmune disease, multisystem, infantile-onset, type 2; Immunodeficiency, type 48 | N/A | N/A |
| 11 | ZBTB16 | Skeletal defects, genital hypoplasia, and mental retardation | N/A | N/A |
| 6 | ZBTB24 | Immunodeficiency-centromeric instability-facial anomalies syndrome, type 2 | N/A | N/A |
| 14 | ZC3H14 | Mental retardation, autosomal recessive, type 56 | < 1 in 500 | Reduced |
| 14 | ZFYVE26 | Spastic paraplegia, type 15, autosomal recessive | < 1 in 500 | Reduced |
| 1 | ZMPSTE24 | Mandibuloacral dysplasia with, type B lipodystrophy | N/A | N/A |
| 3 | ZMYND10 | Ciliary dyskinesia, primary, type 22 | N/A | N/A |
| 11 | ZNF408 | Retinitis pigmentosa, type 72 | N/A | N/A |
| 16 | ZNF423 | Joubert syndrome, type 19 | N/A | N/A |
| 16 | ZNF469 | Brittle cornea syndrome, type 1 | N/A | N/A |
| 17 | ZNHIT3 | PEHO syndrome | < 1 in 500 | Reduced |
| 11 | ZP1 | Oocyte maturation defect, type 1 | N/A | N/A |

N/A: no data prevalence unknown